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PREFACE 
The 90-kDa heat shock protein (Hsp90) is a highly conserved and ubiquitous 
molecular chaperone that plays a pivotal role in the functional regulation of various 
signaling proteins, including protein kinases and steroid hormone receptors, in the 
eukaryotic cells. Whereas the mechanistic details of Hsp90 function remain to be fully 
unveiled, the correct folding and acquisition of the ultimate biological activities of its 
client proteins rely on their physical interactions with Hsp90. Moreover, rather than 
working alone, Hsp90 forms dynamic heterocomplexes (referred to as the Hsp90 
machinery) with a group of cofactors or co-chaperones in vivo, which acts to assist as 
well as regulate its chaperone activity in a controlled and ordered fashion. Here, two of 
these Hsp90 co-chaperones, pSOcdc37 and protein phosphatase S (PPS), were analyzed in 
this study. Their different roles in regulating the biogenesis of the previously described 
Hsp90 client, the heme-regulated eIF2a kinase (HRI), were investigated. These studies 
not only enriched our limited understanding in the functional aspects of both pSOcdc37 and 
PPS, but also suggested a model in which the overall chaperone activity of Hsp90 
machinery, towards its substrates, is coordinated by the opposing effects of these two 
different Hsp90 cohorts in vivo. Furthermore, in an attempt to better understand these 
two Hsp90 cohorts, the domain structure of pSOcdc37 and potential post-translational 
phosphorylation sites of PPS were studied, respectively. Whereas many questions still 
remain to be answered, these studies shed new light on our current understanding of the 
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Hsp90 chaperone machinery and unveiled several novel directions for future 
investigations. 
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The principle of protein folding has been the subject of intensive studies over the 
past several decades. Consequently, remarkable progresses have been made in our 
understanding of the basic principle of such a fundamental and complex biological 
process that all cellular proteins need to undergo to achieve their native and functional 
tertiary structures. It is clear that rather than randomly sampling all possible 
conformations, proteins fold into their native structures through one or more specific 
pathway(s) in which the conformational space available to the proteins is efficiently 
restricted (60, 61). The major driving force for the rapid protein folding process appears 
to be the removal of hydrophobic side chains of amino acids away from the aqueous 
solution to form the hydrophobic core of the folded proteins (60). According to the 
widely-accepted Anfinsen theory, all the information necessary to specify the tertiary 
structure of a protein is contained in its primary amino acid sequence (3). Such a 
hypothesis was based on the observation that many small denatured proteins are able to 
fold back to their native conformations spontaneously in vitro. As a result, it had been 
assumed that all cellular proteins fold in the same unassisted fashion in vivo as well. 
However, failure of large multi-domain proteins to refold spontaneously in vitro argued 
strongly against such a simple view (111). Furthermore, even for small single-domain 
proteins, spontaneous folding in vitro could only occur under ideal conditions such as 
high dilution and low temperature (82). Such an ideal in vitro environment differs 
profoundly from that inside a living cell which is extremely crowded and dynamic with 
the effective protein concentration estimated to be as high as 300 mg/ml (271). One 
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could easily predict that proteins, especially nascent or denatured ones with hydrophobic 
regions exposed, are prone to form aggregations in such a folding unfriendly environment. 
Nonetheless, studies over the past decade have progressiv,ely unveiled the mechanism 
utilized by the living cells to ensure the correct arid efficient folding of many cellular 
proteins, referred to as assisted protein folding. The secret lies in a number of conserved 
protein families named molecular chaperones, which as their name implies guide proteins 
to their correct conformations, but do not remain associated with the final products 
(reviewed in 24, 82, 96, 200, 202). 
Molecular chaperones are ubiquitous cellular proteins many of which are 
abundantly expressed under both physiological and stressed conditions. They are also 
often called heat shock proteins (Hsps) based on the fact that their expression level 
becomes elevated in response to heat shock and other cellular stresses. Unlike folding 
catalysts, such as protein disulfide isomerases and peptidyl-prolyl isomerases (PPiase), 
molecular chaperones do not contain steric information specifying correct folding. 
Instead, they act by preventing incorrect interactions within or between non-native 
polypeptides, minimizing the number of non-productive folding pathways, thus generally 
increasing the yield but not the rate of folding reactions. Based primarily on the size and 
functional mechanism, molecular chaperones can be divided into several distinct families, 
namely Hsp104/Hsp101, Hsp90, Hsp70, Hsp60/GroEL (chaperonin), and small Hsps 
(sHsps). Regardless of the differences, the chaperoning activities of most of them are 
regulated by the dynamic cycles of nucleotide binding, hydrolysis and release except 
sHsps (reviewed in 24, 82, 96). 
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Hsp60/GroEL: 
As probably the best characterized example of the molecular chaperones, 
chaperonins exhibit distinct structural and functional features compared to other members 
of the chaperone family. They are large cylindrical oligomeric protein complexes 
consisting of two stacked rings of 7 to 9 identical or homologous subunits each 
depending on the specific sources (reviewed in 25, 82, 96). They can be further classified 
into two different groups based on the presence or absence of a small cofactor named 
GroES/Hsp 10. In group I chaperonins such as the bacterial GroEL and the Hsp60 
complexes from eukaryotic mitochondria and chloroplasts, GroES/HsplO forms a ring-
shaped lid structure which is essential for the nucleotide-regulated protein folding process 
of GroEL (73). Such a lid structure appears to be absent in group II chaperonins such as 
the eukaryotic TRiC (!ailless complex polypeptide-I [ICP-1] ring £Omplex) (100, 134) 
although recent evidence suggests that a different hetero-oligomeric protein called 
prefoldin or GimC (genes involved in microtubule biogenesis £Omplex) may be the 
functional equivalent of GroES/HsplO (85, 219, 250). Regardless of these subtle 
differences in subunit composition and structural architecture, both groups of chaperonins 
share the same functional mechanism which involves assisted protein folding in the large 
central cavity formed by the ring-shaped multiple subunits. It is thought that chaperonins 
function primarily by sequestering their unfolded polypeptide substrates inside the central 
cavity which mimics an "Anfinsen cage", provides infinite dilution and allows the 
substrates to fold according to their thermodynamic potentials (68). Extensive studies on 
the GroEUGroES complex revealed complicated yet controlled conformational changes 
of its different subunits during the ATP-driven reaction cycle of the assisted protein 
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folding process (96, 148). Such studies also suggested the reiterative binding and release 
of protein substrates by the chaperonins prior to the acquisition of their final native 
conformations. In addition to its function of preventing unproductive protein aggregation 
within the central cage, recent evidence suggests another possible mechanism of the 
GroEUGroES complex in which it unfolds the trapped intermediates and thus increases 
the folding rate of some proteins (218). 
Hsp90: 
Representing 1-2% of the total cytosolic proteins, hsp90 is among the most 
abundant proteins in eukaryotic cells. Its homologues have been found in the 
endoplasmic reticulum and mitochondria, namely grp94 (.21-kDa glucose-regulated 
nrotein) (231) and TRAP-1/hsp75 (type-1 tumor necrosis factor receptor-i!ssociated 
nrotein), respectively (72, 230). In addition, its counterpart also exists in prokaryotic 
cells, termed HtpG (high temperature protein G) (7). The eukaryotic cytoplasmic hsp90 
has two isoforms, hsp90-a and hsp90-~, which are 76% identical and the consequences 
of a gene duplication about 500 million years ago. While no major differences have been 
found between these two isoforms regarding their molecular characteristics and functions, 
they appear to be differentially expressed with hsp90-a being more inducible by heat 
shock and other stress conditions than hsp90-~, which is also sometimes referred to as 
hsc-90 (the constitutively expressed cognate protein of hsp90) (127, 159). 
Biochemical and electron microscopic studies indicate that hsp90 contains two 
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both length and composition among species and homologues (110, 125, 163, 208). 
Recently, the three-dimensional structures of the isolated N-terrninal domains of human 
and yeast Hsp90s, which were nearly identical, were solved by X-ray crystallography. 
Remarkably, both contain an unconventional nucleotide binding site which is recognized 
by ATP, ADP and the Hsp90-specific anti-tumor drug geldanamycin (183, 234). Such an 
unusual nucleotide-binding site has also been found in DNA gyrase B, MutL and 
Histidine kinases, and referred to as the Bergerat fold (11, 67). Unlike the conventional 
nucleotide binding fold, it is a a/~ bilayer sandwich consisting of four-stranded 
antiparallel ~-sheet flanked on one side by nine a-helices with the nucleotide bound 
between the a-helices and ~-sheet. In contrast to the extended conformation of the 
nucleotides bound to Hsp70 and GroEL, those bound to the N-terminal domain of Hsp90 
are rather compact and kinked and closely mimicked by geldanamycin (Figure 1) (183, 
234 ). Tertiary structure of the C-terminal part of Hsp90 has not been reported so far. 
However, functional studies have mapped the docking site for the tetratricopeptide repeat 
(TPR) domain to its extreme C-terminal 12-kDa fragment (39, 263). TPR domains 
consist of tandem degenerate repeats of 34 amino acids each of which adopts a basic 
structure of two anti-parallel a-helices connected by a short tum (53). TPR domains 
exist in several Hsp90 cohorts, such as p60/Hop, protein phosphatase 5 and 
imrnunophilins, and mediate their mutually exclusive interactions with Hsp90 (39). The 
C-terrninal 12-kDa fragment also contains the dimerization site of Hsp90 (156, 162). 
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Figure 1. (a) and (b) Structure of the N-terminal domain of ATP-bound yeast Hsp90 in 
two different orientations. (c-e) Conformations of ATP bound to Hsc70, GroEL and 
Hsp90. (t) Conformation of geldanamycin (GA), a fungal benzoquinone ansamycin, 
bound to Hsp90 ( adapted from ref 23 ). 
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Interestingly, a second ATP-binding site which can be occupied by novobiocin, a 
coumarin-type antibiotic that antagonizes Hsp90 function both in vitro and in vivo, has 
recently been mapped to the C-terminal region of Hsp90 (140) (discussed below). 
The charged linker region appears to be unessential for Hsp90 function since it is 
entirely absent from the prokaryotic HtpG and mammalian mitochondrial TRAP-l/Hsp75 
and totally dispensable for the viability and signal transduction functions in yeast (136). 
However, it contains two major in vivo phosphorylation sites of Hsp90 (65, 133) as well 
as a potential nuclear localization signal (152), indicating its possible involvement in the 
functional regulation and nucleo-cytoplasmic translocation of eukaryotic Hsp90. Recent 
evidence implicates that the charged region also mediates the functional communication 
between the N- and C-terminal domains of Hsp90. It appears to act as a molecular switch 
between the two domains of Hsp90 in a nucleotide-dependent fashion. According to the 
model recently proposed by Soti et al, in the nucleotide-free conformation of Hsp90 the 
charged region binds to the C-terminal domain whose ATP-binding ability is 
concomitantly hindered. The first ATP molecule binds to the N-terminal domain, 
establishing contacts with the charged region and thus relieving its steric hindrance on the 
C-terminal domain, which is then able to bind the second ATP molecule (232). Since 
ATP binding and hydrolysis are directly coupled to the chaperone activity of Hsp90 
(discussed below), this charged region is thus an important element for in vivo function of 
eukaryotic Hsp90. Such a model also predicts large conformational changes of Hsp90 
accompanying ATP binding, which has been firmly proven by different approaches 
including circular dichroism spectrum, tryptophan fluorescence and susceptibility to 
trypsinolysis (46). 
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Electron microscopy and antibody binding studies suggest that Hsp90 forms a 
dimer which exhibits an elongated structure. The two monomers are connected at the C-
terminal ends whereas their N-terminal ends point to opposite directions. Interestingly, 
upon ATP binding or heat shock, the linear conformation of the Hsp90 dimer changes 
into an 0-ring-shaped structure in which the N-terminal domains of the two monomers 
come in contact with each other (142). The existence of a second dimerization site within 
the N-terminal domain of Hsp90, in addition to the major site in the C-terminal domain, 
was also supported by the finding that the isolated N-terminal fragments of yeast Hsp90 
formed dimers in the crystal structure (184). Recently, the conditional and transient 
dimerization of the N-terminal domain has been coupled to the ATPase cycle of Hsp90 
which is believed to drive the molecular "clamp" of the dimer to open or close as a result 
of ATP binding and hydrolysis, respectively (182). The similar "clamp" mechanism is 
also used by DNA gyrase B (120) and MutL (6) both of which share the unusual Bergerat 
ATP-binding fold with Hsp90. ATPase cycle-regulated opening and closing of the clamp 
allow these two enzymes to bind and release their DNA substrates accordingly. Although 
the true functional significance of such a molecular clamp of Hsp90 is currently unclear, 
its regulated closure and opening may be directly involved in the efficient binding and 
releasing of the client proteins, which mechanistically resembles its structural relatives 
(regarding the ATP-binding domain), DNA gyrase B and MutL. 
Although it is now firmly established that Hsp90 is an ATP-dependent protein, 
such an issue has been quite controversial over the past years. The experimental 
difficulty in solving this question has been mostly due to the weak inherent ATPase 
activity of Hsp90 (165, 172) which is usually assessed in a high background of noise 
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from contaminating ATP-binding and hydrolyzing proteins. Recently with a combination 
of structural, genetic and more stringent biochemical studies it finally became clear that 
Hsp90 is indeed an "active" molecular chaperone which binds and hydrolyzes ATP, and 
most importantly such an ATPase activity is essential for its in vivo function ( 165, 172). 
Hsp90 mutants with compromised activities of ATP binding and hydrolysis (within its N-
terminal domain) failed to maintain the viability of yeast cells. Functional regulation of 
Hsp90 by nucleotides is accompanied by and perhaps a result of its concomitant 
conformational changes induced by nucleotide binding. According to a simple two-state 
model, occupation by ATP or its hydrolysis product ADP determines two distinct 
conformations of Hsp90. In the ATP-bound state, Hsp90 is in a "closed" or "slow 
on/slow off' form which interacts with the substrates tightly. ADP, on the other hand, 
changes Hsp90 to an "open" or "fast on/fast off' conformation which displays weaker 
affinity for the substrates (237). Conformational differences between these two 
alternating states are also reflected by the preferential binding of its cohorts p23 (91, 117, 
237) and p60/Hop (114) to the ATP-bound and ADP-bound forms of Hsp90, respectively. 
Evidence suggests that nucleotide-free Hsp90 exists in a conformation similar to the 
ADP-bound form, as judged by the criteria mentioned above (237). The Hsp90 specific 
inhibitor geldanamycin occupies the N-terminal nucleotide binding pocket of Hsp90, 
locks it in an ADP-like conformation and destabilizes its normal interaction with the 
substrates (91,208,234,257). The transition metal oxyanion molybdate, on the other 
hand, binds to the same nucleotide site and maintains Hsp90 in an ATP-bound state even 
after ATP hydrolysis, thus stabilizing its interactions with its substrates (90, 99). 
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Like Hsp70, the inherent ATPase activity of Hsp90 is also regulated by its 
interaction with the cohorts. Both p60/Hop and p50cdc37 have been postulated to inhibit 
the ATPase activity of yeast Hsp90 (185,220). The inhibitory effect of p60/Hop, 
however, is not caused by the simple occupation of the TPR-binding site in the C-
terminal domain of Hsp90 per se since binding of another TPR-containing cohort Cpr6 to 
the same site has no effect. Instead, it appears to involve direct interaction of p60/Hop 
with the N-terminal ATP-binding domain of Hsp90 which causes blockage of nucleotide 
binding (185). Alternatively, since both p60/Hop and p50cdc37 bind to the Hsp90 dimer as 
dimers themselves, they may exert their inhibitory effects by restricting the 
conformational flexibility of the Hsp90 dimer which is directly coupled to its ATPase 
cycle (185,220). Interestingly, the intrinsic ATPase activity of human Hsp90 is much 
weaker and seems to be regulated in a somewhat different way than the yeast protein. A 
recent study reported a 200-fold stimulation of the ATPase activity of human Hsp90 by a 
client protein, the ligand-binding domain of the glucocorticoid receptor. Whereas 
p60/Hop inhibits and the immunophilin FKBP59 further enhances the substrate-
stimulated ATPase activity of human Hsp90 respectively, they have no effect on its basal 
ATPase activity. p23, however, inhibits both the basal and substrate-stimulated ATPase 
activity of human Hsp90 (150). 
To make the ATPase cycle of Hsp90 even more complex, a second nucleotide-
binding site has recently been identified in its C-terminal region. The investigation 
started with the finding that novobiocin, a coumarin-type antibiotic which binds adjacent 
to the ATP-binding site of bacterial DNA gyrase B and interferes with nucleotide binding 
(147), also interacts with Hsp90 and causes depletion of Hsp90-dependent kinases in vivo 
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(141). Its binding to Hsp90 is readily competed by ATP and such a binding site is 
mapped to the C-terminal 190 amino acids of Hsp90 which overlaps with the 
dimerization and TPR-binding sites (140). The two nucleotide binding sites, although 
separated, seem to function in a cooperative fashion in light of the fact that within the 
context of the full length Hsp90, occupation of the N-terminal nucleotide pocket is 
necessary to open up the C-terminal site which is otherwise blocked by the charged 
region (232). The biological significance of this second nucleotide binding site is also 
underscored by the observation that novobiocin inhibits the interaction of Hsp90 with two 
of its co-chaperones p23 and Hsp70.(indirectly bridged by p60/Hop), which are essential 
components of the Hsp90 chaperone machinery (140). Nonetheless, it is far from clear 
exactly how these two nucleotide binding sites cooperate to regulate the structure and 
function of Hsp90. 
In vitro folding assays using artificial substrates, such as citrate synthase and 
rhodanese, have shown that Hsp90 is able to suppress the aggregation of nonnative 
proteins (112, 258, 264). However, its natural clients in vivo seem to be limited to a 
subset of protein families most of which are involved in cellular signal transduction such 
as members of the steroid hormone receptors and protein kinases (Table 1) (reviewed in 
23, 200). In most cases, the interaction with Hsp90 serves to maintain the client protein 
in an "inactive" but "activatable" state which is structurally unstable without the 
chaperone protection. Although this may explain the essentialness of Hsp90 in 
eukaryotic cells, its high abundance even under unstressed conditions suggests more 
general functions for this seemingly specialized chaperone. Nonetheless, although Hsp90 
is believed to participate in the after-stress recovery of various damaged cellular proteins 
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along with other molecular chaperones (47), under physiological conditions it does not 
seem to be important for the general folding of newly synthesized proteins ( 161). In a 
recent report Rutherford et al hypothesized that Hsp90 plays a pivotal role in evolution 
by functioning as a "buffer" for protein conformational diversity in the cell. They have 
found that by inactivating Hsp90 function through conditional mutations or geldanamycin 
treatment in Drosophila melanogaster multiple phenotypic variations were observed due 
to the unveiling of the preexisting mutations in various regulatory pathways, which are 
normally kept quiet by the functional Hsp90 (205). Such a buffering capacity of Hsp90 is 
also conserved in plant kingdom as similar approaches in Arabidopsis unveiled a wide 
array of genetic variations as well (188). Therefore, Hsp90 may serve to preserve protein 
function in the face of genetic variations by maintaining mutant proteins in their wild-
type conformations. 
Attempts have been made to map the client binding site on Hsp90. Using 
different in vitro substrates, two chaperone sites have been identified in Hsp90 that differ 
in both substrate specificity and ATP dependence (209,264). They are located in the 25-
kDa N-terminal nucleotide-binding domain and the 12-kDa C-terminal fragment, 
respectively. The C-terminal site binds to structured substrates in an ATP-independent 
fashion whereas the N-terminal site recognizes preferentially unfolded (poly)peptides in 
an ATP-dependent and geldanamycin-sensitive manner (209). Because the 12-kDa C-
terminal fragment also possesses the binding site for the TPR-containing cohorts of 
Hsp90 (39, 263), chaperone activity at this site may be potentially regulated by these 
cohorts. More recently, a third substrate binding site has been suggested to reside in the 
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Table 1. Examples of identified Hsp90 substrates (adapted from (200). 
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for these studies are all artificial substrates, the authenticity of these results needs to be 
further confirmed by future studies using natural substrates of Hsp90. Reciprocally, as to 
the substrate specificity of Hsp90, it appears that rather than being defined by consensus 
sequence or motifs as in the case for Hsp70, it may be determined instead by some yet 
unknown conformational states or folding characteristics that are common to all the 
substrates of Hsp90 (23). However, despite the uncertainty, the interaction of Hsp90 with 
its classical substrates protein kinases and steroid hormone receptors have been localized 
to the kinase domain (223,233,236) and ligand binding domain (52), respectively. 
In vivo function of Hsp90 is assisted as well as regulated by a host of partner 
proteins known as cohorts or co-chaperones. Many of them are heat shock proteins and 
possess chaperone activities themselves (reviewed in 23, 26, 173, 180, 200, 262) (Table 
2). Data accumulated from extensive studies on steroid hormone receptors suggest that 
these cohorts interact with Hsp90 in an ordered and dynamic fashion which defines a 
cyclic chaperone pathway comprising of distinct heterocomplexes that assist the folding 
and activation of client proteins sequentially (Figure 2) (178,200,208,226). According 
to this model, client proteins enter the cycle by associating with the Hsp70 system first. 
Such a binding reaction involves ATP hydrolysis and is facilitated by sequential actions 
of the Hsp70 cofactors Hsp40/DnaJ and p48/Hip. Hsp40/DnaJ stimulates ATP 
hydrolysis by Hsp70 whereas p48/Hip stabilizes the resultant ADP-bound conformation 
of Hsp70 which binds the nonnative clients with higher affinity (reviewed in 83). 
Subsequent binding of p60/Hop to this complex leads to the formation of the early 
complex of the folding pathway. Because the multi-TPR-containing protein p60/Hop is 
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Figure 2. Chaperone cycle for the activation of steroid hormone receptors (SHRs) by 
Hsp90 machinery (200, 208). Note that it is still an evolving model some steps of which 
are not well understood and being constantly modified. See text for detailed explanation 
for each step. 
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contact with the early complex which thus gives rise to the intermediate complex 
containing Hsp90, Hsp70, p60/Hop and p48/Hip. This intermediate complex presumably 
contains Hsp90 in its nucleotide-free or ADP-bound conformation which exhibits a fast-
on/fast-off and weaker affinity for the clients. In vitro studies have shown that this 
intermediate complex is sufficient to convert the steroid hormone receptors from the non 
p23 and one of the TPR-containing immunophilins. In this late complex, Hsp90 is 
believed to be in its ATP-bound conformation which is preferentially recognized by p23. 
Geldanamycin, by binding to the ATP pocket of Hsp90 with much greater affinity (200) 
blocks p23 binding and the functional assembly of the late complex, therefore inhibiting 
the proper folding and activation of the Hsp90 substrates. Early data have suggested that 
p23 functions to stabilize the interaction between Hsp90 and its substrates (62), however, 
an additional or alternative role has been proposed recently where it acts as a substrate 
release factor for Hsp90 (79, 81,261). In this role, p23 supposedly couples the 
conformational change of Hsp90 induced by ATP hydrolysis to the efficient substrate 
release. This function is consistent with its late appearance in the chaperone pathway 
where the client proteins are about to dissociate from the Hsp90 heterocomplex. 
Depending on their folding states, clients are either released in their stable and competent 
conformations or reenter the chaperone pathway for further rounds of folding. 
Hsp70: 
70-kDa heat shock prbteins (Hsp70s) are a highly conserved family of chaperones 
that are distributed ubiquitously in both prokaryotic and eukaryotic organisms (reviewed 
in 82). Hsp70 consists of two structurally and functionally distinct domains, the 44-kDa 
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N-terminal ATP binding domain (76) and the 18-kDa C-terminal peptide binding domain 
(269). Like Hsp90, Hsp70 function is also regulated by nucleotide binding and 
hydrolysis. However, in contrast to Hsp90, the ATP-bound form of Hsp70 represents the 
"open" and "fast on/fast off' conformation whereas the ADP-bound form exhibits the 
"closed" and "slow on/slow off' conformation (reviewed in 25, 96). Using approaches 
such as phage display and synthetic peptide libraries, Hsp70 has been shown to recognize 
linear polypeptide sequences enriched in hydrophobic amino acids (14, 78,203). This 
less selective substrate specificity of Hsp70, in contrast to Hsp90, is consistent with its 
involvement in general protein folding events. Crystallization experiment shows that 
peptides are bound in an extended conformation to a cleft in the peptide binding domain 
of Hsp70 (269). 
Several cohort proteins regulate the in vivo function of Hsp70 at different stages 
of its ATPase cycle. In both prokaryotes and eukaryotes, conversion of Hsp70 from the 
ATP-bound form to the ADP-bound form is facilitated by the Hsp40/DnaJ protein which 
stimulates ATP hydrolysis by Hsp70 (149, 155, 270). Hsp40/DnaJ proteins possess 
chaperone activity themselves as demonstrated by their abilities to bind unfolded proteins 
and prevent their aggregation in vitro (130,238). The conserved J-domain of this protein 
family binds directly to the ATPase domain of Hsp70 (174, 187). In prokaryotes, 
conversion of DnaK (Hsp70 homolog) from the ADP-bound state to the ATP-bound state 
is assisted by GrpE, a 23-kDa protein that acts as a nucleotide exchange factor (95). 
While a conserved GrpE homolog has not been identified in eukaryotic cytoplasm, a 
functional analog called Bag-I has been proposed to carry out such an activity (102, 240). 
X-ray crystallography studies indicate that, though structurally unrelated, both proteins 
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bind to the conserved ATPase domain of DnaK and Hsp70, respectively, and induce 
similar conformational changes within DnaK and Hsp70 that stimulate nucleotide 
exchange_(229). Interestingly, in mammalian cells, a 48-k:Da Hsp70-interacting 12rotein 
(Hip) functions to stabilize the ADP-bound state of Hsp70 (103). Therefore, by 
switching Hsp70 between its different nucleotide-bound states, these cohorts coordinately 
regulate the functional interaction of Hsp70 with its clients, helping to fold them correctly. 
p60/Hop: 
Originally identified as a 60-k:Da protein associated with the progesterone 
receptor (227, 228), p60 was later found to be homologous to the yeast stress-related 
protein STil (164) and a previously characterized TPR-containing human protein that 
was upregulated in virally transformed cells (106). More than two thirds of p60 is 
comprised of TPR motifs which are arranged into three tandem TPR domains. 
Mutagenesis (38) and structural studies (210) revealed that the first TPR domain binds 
Hsp70 and the central TPR domain interacts with Hsp90. Binding is primarily mediated 
by electrostatic interactions of the TPR domains with the EEVD motif located at the C-
terminus of both Hsp90 and Hsp70, whereas specificities are defined by selective 
hydrophobic contacts with the upstream residues of each protein. Being able to bind 
Hsp90 and Hsp70 simultaneously, p60 provides a physical link between these two 
essential chaperones which do not seem to possess direct binding sites for each other (49). 
It is thus also called Hop (Hsp Qrganizer protein) and believed to be an essential 
component of the Hsp90 chaperone machinery at the early stages of the assisted protein 
folding pathway (38, 63). Such an important function, however, does not seem to arise 
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entirely from its ability to passively bridge between Hsp90 and Hsp70. Recent evidence 
indicates that it negatively regulates the intrinsic ATPase activity of yeast Hsp90, which 
is possibly due to its inhibition of ATP binding to the N-terminal nucleotide binding 
pocket of Hsp90 (185). It agrees with the fact that p60/Hop preferentially binds to the 
ADP-bound but not ATP-bound form of Hsp90 (38). In addition, p60/Hop has also been 
shown to stimulate the ATPase activity of Hsp70 (92), suggesting that it functions to 
modulate or coordinate the ATP cycle of these proteins while bridging them in a single 
complex. Nonetheless, unlike other cohorts of Hsp90 such as p23 and immunophilins, 
p60/Hop has not been found to possess any passive chaperoning activity in vitro (17, 80). 
p23 is a highly acidic phosphoprotein that was originally identified as a 23-kDa 
component of the native steroid hormone receptor heterocomplex (115, 117). It binds 
selectively to the ATP-bound conformation of Hsp90 (237) although its exact binding 
site(s) on Hsp90 has (have) not been fully determined yet. Several lines of evidence 
suggest that rather than recognizing one single region of Hsp90, binding of p23 involves 
two or more noncontiguous regions of Hsp90 and requires the dimeric structure of Hsp90 
(28, 39, 90). p23 possesses passive chaperoning activity as demonstrated by its ability to 
prevent protein aggregation in vitro (17, 80). Nonetheless, its precise function in the 
Hsp90 chaperone machinery is unclear although it is known to participate in the 
functional assembly of the Hsp90 heterocomplexes with the steroid hormone receptors 
and thought to stabilize the mature complexes (62, 108). Recent studies, however 
suggest that it actually serves as a substrate release factor of Hsp90 which efficiently 
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couples the ATP hydrolysis of Hsp90 with the acquisition of its substrate releasing 
conformation (261). Interestingly, it has also been proposed to promote, in conjunction 
with Hsp90, the functional disassembly of transcriptional regulatory complexes 
containing the intracellular receptors in response to cellular signal changes such as 
hormone withdrawal (81). 
Immunophilin: 
The immunophilins are ubiquitous and conserved proteins that possess peptidyl-
prolyl-cis-trans isomerase (PPiase) activity which is inhibitable by immunosuppressive 
drugs such as FK506 and cyclosporin A. Several high molecular weight immunophilins 
such as FKBP52, FKBP51 (FK506-binding proteins) and Cyp40 (cyclosporin A-binding 
protein) have been identified as components of the Hsp90 heterocomplexes containing or 
free of steroid receptors (reviewed in 180). Besides the conserved PPiase domain, they 
all contain a C-terminal TPR domain which mediates their mutually exclusive binding to 
the TPR docking site within the C-terminal domain of Hsp90 (189, 196, 263). Despite 
the obvious potential for their PPlase catalyzed protein folding activity, their precise 
functions within the Hsp90 chaperone machinery are not well understood. In fact, 
inhibition of the PPlase activity either by drugs or mutations does not seem to alter the 
integrity and function of the Hsp90 heterocomplexes containing the immunophilins (66, 
107, 198). Similar to Hsp90, they possess passive chaperone activity in vitro (17, 80), 
and such an activity of FKBP52 was recently mapped to its C-terminal domain which 
also contains its TPR motifs (177). In addition, a role has been proposed for these large 
immunophilins, in the context of Hsp90 complexes, in the cytoplasmic-nuclear 
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trafficking of the steroid hormone receptors by functioning as a physical connector 
between the receptors and the cellular movement machine (179). Such a model is 
supported by several lines of evidence including the co-localization of FKBP52 with the 
microtubules (50) and its direct interaction with both the steroid receptors and the 
molecular motor dynein (84, 222). Consistent with the hypothesis that FKBP52 is 
involved in the intracellular trafficking of steroid receptors, Davies et al recently reported 
a hormone-dependent switching of FKBP51 to FKBP52 in the Hsp90/GR heterocomplex 
and the concomitant recruiting of dynein to the same complex prior to the hormone-
induced GR transport to the nucleus (54). 
Other Hsp90 cochaperones: Literature relevant to p50cdc3l' Hsp90's so-called "kinase-
specific co-chaperone" will be reviewed in Chapter II and IV. Literature relevant to the 
TPR-containing co-chaperone, protein phosphatase 5 (PPS) will be reviewed in Chapter 
III and V. 
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CHAPTER II 
Hsp90 Regulates p50cdc37 Function during the Biogenesis of the Active Conformation 
of the Heme-regulated eIF2a Kinase 
Introduction: 
The .heme-regulated inhibitor (HRI) of protein synthesis is a protein-serine kinase 
which coordinates the synthesis of globin chains with the availability of heme in 
reticulocytes (31, 32). Under heme-deficient conditions, HRI phosphorylates the a-
subunit of eukaryotic translational initiation factor eIF2. Phosphorylation of eIF2a causes 
an inhibition of polypeptide chain initiation and the arrest of protein synthesis, preventing 
the synthesis of apo-globin chains in the absence of heme. HRI is also activated under 
heme-replete conditions in response to a host of other adverse environmental stimuli, 
such as heat shock, agents that generate oxidative stress, and the presence of denatured 
proteins (31, 32). 
The biogenesis and activation of HRI into an active heme-regulatable eIF2a 
kinase requires its functional interaction with the chaperone machinery containing the 90-
kDa heat shock protein (Hsp90) and the 70-kDa heat shock cognate protein (Hsc70) (246, 
248). During HRI biogenesis and its subsequent transformation and activation, several 
discrete HRI intermediates are generated; these intermediates can be distinguished on the 
basis of their competence to become an active kinase in response to heme deficiency or 
upon treatment with sulfhydryl reactive compounds, such as N-ethylmaleimide. 
Immediately after their synthesis, HRI molecules are not active in heme-replete or heme-
deficient rabbit reticulocyte lysate (RRL) and cannot be activated by N-ethylmaleimide 
treatment. This immature population interacts with Hsp90 and Hsc70 (144,146,246,248, 
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259). Subsequent to this immature phase, a "mature-competent" HRI population appears. 
The mature-competent population can be activated by heme-deficiency or treatment with 
N-ethylmaleimide, but remains quiescent in the absence of such "stimuli." The mature-
competent HRI population continues to interact with Hsp90 machinery, and this 
interaction is required to maintain HRI's ability to respond to heme deficiency (246). 
Under heme-deficient conditions, however, a portion of the population of HRI 
molecules "transform" to produce kinase populations with enhanced auto-kinase and 
eIF2a kinase activities. Transformation of HRI requires Hsp90 function and 
autophosphorylation of HRI, and correlates with the production of a population of HRI 
molecules which exhibit retarded electrophoretic mobility on SDS-P AGE (246). This 
transformation frees HRI from its functional requirements for Hsp90 and terminates its 
physical association with Hsp90 machinery (246). 
Hsp90 binds numerous other protein kinases, primarily when they are in relatively 
inactive conformations (reviewed in Refs (15, 206)). However, Hsp90's association with 
inactive kinases reflects its essential positive role in facilitating kinase folding, maturation, 
and activation rather than a recognition of repressed kinase molecules per se. Consistent 
with this model for Hsp90 function, the Hsp90 chaperone machine does not interact with 
previously transformed HRI molecules when their kinase activity is subsequently 
inhibited by hemin addition, nor do such "repressed" HRI molecules require Hsp90 
support to maintain their ability to reactivate in response to heme-deficiency or stress 
(246). Consistent with the specific role of Hsp90 in kinase biogenesis, both repressed HRI 
and transformed HRI exhibit the same slow electrophoretic mobility on SDS-PAGE, 
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indicating that repressed HRI retains the hsp90-independent "transformed" conformation 
(246). 
Hsp90 functions in concert with a number of co-chaperones and cohorts to 
facilitate their clients' acquisition of functional conformations (reviewed in 181). Early 
studies detected a 50-kDa protein present in heterocomplexes formed between Hsp90 and 
viral members of the Src family of protein tyrosine kinases (reviewed in 20). This 50-kDa 
protein has recently been identified as a product of the vertebrate homolog of the yeast 
cell division cycle gene CDC37 (51, 74, 88,175,235). In vitro, the yeast p50cdc37 
homolog exhibits chaperone activity (122). Genetic (48, 59, 71, 122) and biochemical (89, 
235) studies indicate that p50cdc37 plays an essential positive role in supporting a number 
of protein kinases. Therefore, we examined whether p50cdc37 is a component of the Hsp90 
chaperone complex which is required for the maturation and transformation of HRI. In 
this report, we present evidence that p50cdc37 acts in concert with Hsp90 and facilitates the 
transformation and activation of HRI. We further demonstrate that nucleotide-mediated 
conformational switching of Hsp90 regulates the kinase binding activity of p50cdc37_ 
Materials and Methods: 
Construction of Plasmids for Expression of Wild Type and Mutant p5ifdc37 Proteins-Two 
cDNA clones were obtained from Genome Systems, Inc.: one lacking sequences 
encoding the N-terminal 8 amino acids (MVDYSVWD) of human p50cdc37 (dbEST 
number 810394, GenBank™ accession number AA172101 (designated here as 
p50cdc37/N8aa)); and another containing sequence encoding the full-lengthhuman Cdc37 
gene product (dbEST number 321710, GenBank™ accession number R87892 
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( designated here p50cdc37) ). The coding sequence for p50cdc37 /N8aa was ligated into the 
bacterial expression vector pET-30a( + ). Recombinant His-tagged p50cdc37 /N8aa was 
purified on Nf+-NTA resin (Ni2+-nitrilotriacetic acid coupled to agarose, Qiagen), and 
used as antigen to produce polyclonal mouse ascites anti-p50cdc37 antibody. For 
expression of full-length recombinant pSOcdcJ7 in Escherichia coli, the sequence encoding 
full-length p50cdc37 was cloned into the pQE-32 expression vector (Qiagen). (His6)-
pSOcdc37 was expressed in MlS[pREP4] cells and purified on Ni2+-NTA-agarose (Qiagen). 
Coomassie Blue staining of the purified proteins separated by SDS-PAGE indicated that 
the proteins were greater than 90% pure. 
For in vitro translation, sequences encoding p50cdc37 /N8aa or full-length p50cdc37 
were cloned into a modified version of pSP64T (126), and translated by coupled 
transcription/translation in RRL (97). The mutant pSOcdc37 fN8aa protein produced 
includes 11 N-terminal amino acids (MADIGSEFGST) encoded by sequences carried 
over from the pET-30a( +) vector, followed by the coding sequence of the human Cdc37 
gene product from His9 to Val378• The previously described N-terminal deletion mutant of 
human pSOcdcJ7 1acking 163 amino acids from its N terminus (89) ( designated here as 
p50cdc37/m) was similarly cloned into and expressed from pSP64T. Tryptic fingerprints 
were generated from wild type [35S]p50cdc37 and [35S]p50cdc37 /N8aa proteins as described 
previously for de nova synthesized [35S]p561ck kinase (98). 
For in vitro expression, individual domains of HRI were constructed in pSP64T 
and pSP64TL (97) (encoding a (His6)-tag preceding a unique Ncol site) vectors using 
standard PCR cloning techniques. Pairs of oligonucleotide primers corresponding to N-
and C-terminal sequences of each HRI domain were synthesized to include convenient 
26 
built-in restriction sites, Ncol in the 5' primers and EcoRI (for N- and C-terminal kinase 
lobes), Styl (for heme-binding domain) or HindIII (for kinase insertion sequence) in the 
3' primers which were followed by an engineered stop codon. They were coupled in 
PCR reactions using the full-length HRI-pSP64T as the template. The resulting PCR 
products were digested with NcoJ/EcoRI (N- and C-terminal kinase lobes), Ncol/Styl 
(heme-binding domain) or NcoI/HindIII (HindIII end was then filled in to generate a 
bl~nt end) and inserted into the corresponding sites of the pSP64T or pSP64TL vectors. 
Expression and Purification of p50cdc3l Protein Constructs from Eukaryotic Cells-Human 
FLAG-tagged p50cdc3l and FLAG-tagged p50cdc37/l!!C were expressed in and purified 
from Sf9 cells as described previously (89). FLAG-p50cdc37!1:!C lacks 214 amino acids 
from the C terminus of p50cdc37• GST-tagged p50cdc37 was also expressed in and purified 
from COS-1 cells as described previously (89). Proteins were provided by Dr. Nicholas 
Grammatikakis. 
Analysis of the Association of p50cdc37 with HR! in Cultured Mammalian Cells-Human 
K.562 erythroleukemia cells were cultured for 48 h at 37 °C and 5% CO2 in RPMI 
medium supplemented with 10% fetal bovine serum (Life Technologies, Inc.). 
Approximately 1 x 107 geldanamycin-treated (1 µg/ml for 2 h) or untreated (equivalent 
volume of Me2S0 for 2 h) cells were lysed in buffer containing 20 mM HEPES, pH 
7.5, 100 mM NaCl, 0.1 % Nonidet P-40, 1 % TritonX-100, 10% glycerol, 1 mM Na3V04, 
2 mM EGTA, 1 mM dithiothreitol, 50 mM glycerophosphate, 1 mM NaF, 0.4 mM 
phenylmethylsulfonylfluoride, and 10 µg/ml each ofleupeptin and aprotinin, and cell 
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extracts were clarified. Endogenous p50cdc3? was immunoadsorbed from cell extracts via 
a mixture of rabbit, and mouse anti-p50cdc37 (Transduction Laboratories) antibodies bound 
to GammaBind-Plus Sepharose (Amersham Pharmacia Biotech), and the immunopellets 
were washed as described previously (89). Half of the recovered p50cdc3? 
immunocomplexes were analyzed by Western/ECL (Amersham PharmaciaBiotech) for 
the presence of associated HRI, using guinea pig antibody raised against the N-terminal 
154 amino acids of rabbit HRI. Blots were then stripped, and rabbit anti-p50cdc37 antibody 
was used to verify that equivalent amounts of p50cdc3? were adsorbed from each extract. 
The second half of the anti-pSOcdc37 immunocomplexes were analyzed by Western 
blotting with rat anti-Hsp90 monoclonal antibody (SPA-830 from Stressgen). This work 
was done in collaboration with Dr. Nicholas Grammatikakis (Department of 
Microbiology and Immunology, Queen's University, Kingston, Ontario K7L 3N6, 
Canada). 
De Novo Synthesis and Maturation of HR/ in Rabbit Reticulocyte Lysate-Coupled 
transcription/translation (TnT) of plasmids encoding HRI or (His7 )-HRI in rabbit 
reticulocyte lysate (TnT RRL) and the subsequent maturation of the expressed HRI or 
(His7)-HRI in heroin-supplemented or heme-deficient RRL was carried out as described 
previously (246, 248). 
Co-translational Interaction of Hsp90 and p5ifdc3? with HRI-HRI and luciferase were 
synthesized with concomitant [35S]-radiolabeling in separate TnT RRL for 15 min at 
30 °C. TnT RRL was either treated, or not treated with 1 mM puromycin for 5 min at 
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30 °C to release the nascent polypeptide chains from polyribosome. The polyribosomes 
were then isolated by centrifugation and analyzed by Wes tern blotting for Hsp90 and 
p50cdc3l as described previously (246, 248). 
Immunoadsorption of Protein Complexes-Chaperone/cochaperone and chaperone/kinase 
heterocomplexes were analyzed by reciprocal immunoadsorptions utilizing resin-bound 
anti-p50cdc37 and anti-His-tag antibodies as described previously (97). Nonimmunemouse 
IgG (MOPC 21 from Sigma) was used as a control for nonspecific binding. As an 
additional control for nonspecific binding, [35S]HRI lacking the histidine tag was 
assessed in parallel with reactions containing (His7)-[35S]HRI. Relative amounts of 
immunoadsorbed proteins were quantified by scanning densitometry of autoradiograms or 
Western blots. Comparisons of changes in the relative protein levels made in the text 
reflect corrections made for levels of nonspecific binding. 
Assay of the Effect of p50cdc37 and p50cdc37!11C on HR/ Transformation-[35S]HRI or 
(His7 )-[35S]HRI was synthesized in TnT RRL (246, 248). Subsequently, 4 µl of the TnT 
RRL was transferred to heme-deficientRRL (30 µl) which contained 10 µl of 
immunoresin (M2 anti-FLAG-agarose) that had been previously saturated with FLAG-
peptide, FLAG-p50cdc37, or FLAG-p50cdc37/ !1C. The reaction mixtures were incubated at 
30 °C for 1 h. After washing of the immunoresins, the immunoresins were analyzed for 
bound [35S]HRI, HRI kinase activity, and/or associated chaperones, as specified in the 
figure legends. 
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Alternatively, [35S]HRI or (His7 )-[35S]HRI were chased into 7 volumes of heme-
deficient protein synthesizing RRL containing purified (His6)-p50cdc3l (-1.5 µg/µl), GST-
p50cdc3l (-1 µg/µl), or an equivalent volume of the appropriate control buffer. After 1 h of 
maturation at 30 °C, samples were adsorbed to Ni2+-NTA resin (Fig. lOB) or GaG-
agarose containing bound mouse monoclonal anti-(Hiss)-IgG (Fig. 11). Resins were 
subsequently washed and analyzed for kinase activity (246, 248). 
Assay of the Kinase Activity of (His?)-[35SJHRI-To quantify HRI kinase activity, (His7)-
[35S]HRI or [35S]HRI (control for nonspecific binding) was captured from RRL reaction 
mixtures on Ni2+-NTA-agarose (Qiagen) that had been pre-equilibrated with 10 mMTris-
HCl, pH 7.4, 10 mM imidazole, and 50 mM NaF, or by immunoadsorption with anti-
(His5) monoclonal antibody. Assays for eIF2a kinase activity were performed as 
described (246, 248). The kinase activity of HRI was quantified by scanning densitometry 
of the [32P]-labeled eIF2a band visualized by autoradiography and expressed as optical 
density (O.D.) x mm2. 
Results: 
p50cdc37 Interacts with HR! in Concert with Hsp90-To determine whether p50cdc3l was a 
component of the chaperone complex that Hsp90 forms with HRI, we examined the 
ability of anti-His-tag antibodies to co-adsorb Hsp90 and p50cdc3l upon 
immunoadsorption of newly synthesized (His7)-[35S]HRI from RRL (Fig. 3A). As 
previously shown (246), immunoadsorption of (His7 )-[35S]HRI folding intermediates 
immediately after their synthesis (8 min post-translation) specifically co-adsorbed Hsp90. 
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Figure 3. Interaction of endogenous p50ct1c37 and Hsp90 with newly srnthesized 
(His7)-[35S]HRI in RRL. A) (His7)-[35S]HRI (lanes 2, 4, 6, and 8) and [3 S]HRI lacking 
the (His7)-tag (lanes 1, 3, 5, and 7) were synthesized and then matured in normal heme-
deficient (lanes 1, 2, 5, and 6) or hemin-supplemented (lanes 3, 4, 7, and 8) RRL as 
described under "Materials and Methods." Aliquots (30 µl) of the reaction mixtures were 
taken after 8-min (lanes 5-8) or 60-min (lanes 1-4) of maturation and mixed with GaG-
agarose pre-coupled with anti-(Hiss) monoclonal antibody as described under "Materials 
and Methods." After washing the immune pellets, samples were analyzed by SDS-PAGE, 
followed by transfer to polyvinylidene difluoride membrane. (His7)-[35S]HRI was 
visualized by autoradiography (upper panel: TR, transformed HRI with slower 
electrophoretic mobility; MC, mature competent form of HRI with faster electrophoretic 
mobility). Endogenous RRL Hsp90 and p50cdc37 that was specifically co-adsorbed with 
(His7)-[35S]HRI were detected by Western blotting membranes with anti-Hsp90 (middle 
panel) or anti-p50cdc37 (lower panel) antibodies. HC: antibody heavy chain. Band 
densities were quantified by scanning densitometry and expressed as optical 
density x mm2 (numbers above each panel). Densitometry indicated that equivalent 
amounts of total (His7)-[35S]HRI were specifically immunoadsorbed (even lanes). B) Co-
translational interaction ofHRI with Hsp90 and p50cdc37 in RRL: TnT RRLs were 
programmed with HRI (lanes 3 and 4) or luciferase template (lanes 1 and 2) for 15 min at 
30 °C. Translation mixes were then either treated (lanes 2 and 4) or not treated (lanes 
1 and 3) with 1 mM puromycin for 5 min at 30 °C to release the nascent chains, followed 
by separation on 15 to 40% sucrose gradients as described under "Materials and 
Methods." Isolated polyribosomes were analyzed by SDS-PAGE, followed by Western 
blot detection for Hsp90 and p50cdc37_ 
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Immunoadsorption of newly synthesized HRI also co-adsorbed p50cdc37, demonstrating 
the existence of a heterocomplex containing p50cdc3l and these newly synthesized HRI 
molecules. The amount of Hsp90 and p50cdc37 co-adsorbed with HRI was similar whether 
the newly synthesized HRI was immunoadsorbed from heme-replete or heme-deficient 
RRL. Thus, heme did not directly regulate the polypeptide binding activity of Hsp90 (246, 
259) or p50cdc37_ 
Previously, we have demonstrated that Hsp90 interacts with nascent HRI co-
translationally (246). To determine whether p50cdc3l similarly binds to HRI during its 
synthesis on ribosomes, polyribosomes were isolated from RRL that was programmed 
with HRI template. For a negative control, ribosomes were also prepared from RRL that 
was programmed with luciferase template. Western blotting indicated that both Hsp90 
and p50cdc3l were present in the ribosome pellet containing bound nascent HRI 
polypeptide chains (Fig. 3B), but were absent when the nascent polypeptide chains had 
been released by incubation with puromycin prior to isolation of the polyribosomes. Thus, 
p50cdc3l, like Hsp90, becomes specifically associated with HRI prior to the completion of 
kinase synthesis and the release of newly synthesized HRI from the ribosome. 
The interaction of Hsp90 with HRI persists after release of newly synthesized 
HRI from polyribosomes in heme-replete RRL (246). To assess if the interaction between 
p50cdc3l and HRI was similarly maintained, the newly synthesized (His7)-[35S]HRI 
population was subjected to maturational incubations in hemin-supplemented RRL where 
the transformation of HRI into an active kinase is suppressed. After a 60-min incubation 
in the presence of hemin, neither the level of Hsp90 nor p50cdc3l associated with HRI 
declined significantly relative to the level observed immediately after translation (Fig. 3A, 
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lane 4 versus 6 and 8). Thus, in heme-replete RRL, HRI continued to interact with 
p50cdc37 for prolonged periods after its synthesis. 
In heme-deficient RRL, HRI autophosphorylates and transforms into an active 
kinase that no longer interacts with Hsp90 (246). To determine whether transformation of 
HRI similarly terminated its interaction with p50cdc37, the newly synthesized HRI kinase 
population was incubated in hemin-deficient RRL for 60 min. Under these conditions, 
-50% of the pulse-labeled (His7)-[35S]HRI exhibited the slower electrophoretic mobility 
associated with "transformation" (246). The amount of Hsp90 and p50cdc37 that was co-
adsorbed with (His7)-HRI from heme-deficient RRLdecrease by-67 and 75%, 
respectively, relative to that co-adsorbed with the "mature-competent/untransformed" 
HRI population present in RRL held under heme-replete conditions (Fig. 3A, lane 
2 versus 4). Thus, the transformation .of HRI that was induced by hemin deficiency 
correlated with a reduction in the interaction of HRI with Hsp90 and p50cdc37• 
Previously, the interaction between Hsp90 and HRI was demonstrated to be 
specific to the "untransformed" (fast electrophoretic mobility) form of HRI (246). To 
determine whether p50cdc37, like Hsp90, recognized a specific component of the HRI 
population, the kinase populations associated with p50cdc37 were captured by 
immunoadsorption with anti-p50cdc37 antibodies after incubation of newly synthesized 
HRI in heme-replete or heme-deficient RRL for 8 or 60 min (Fig. 4). Only untransformed 
forms of [35S]HRI, consisting of early folding intermediates (8 min chase) or mature-
competent HRI (60 min chase), were specifically coimmunoadsorbed with p50cdc37 from 
either heme-replete or heme-deficient RRL (Fig. 4A, PEL). The 65% decrease in the 
amount of untransformed HRI that was co-adsorbed with p50cdc3l from heme-deficient 
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Figure 4. Interaction of newly synthesized HRI with endogenous p50cdc37 in RRL. 
[35S]HRI was synthesized in TnT RRL and subsequently matured in normal hemin-
supplemented (10 µM hemin) (lanes 1, 2, 5, and 6) or heme-deficient (lanes 3, 4, 7, and 8) 
RRL protein synthesis mixtures as described under "Materials and Methods." Aliquots 
(30 µl) of the reaction mixtures were taken after 8 (lanes 1-4) or 60 min (lanes 5-8) of 
maturation and mixed with GaG-agarose pre-coupled with anti-p50cdc37 polyclonal 
antibodies (lanes 2, 4, 6, and 8) or nonimmune control mouse IgG (lanes 1, 3, 5, and 7) as 
described under "Materials and Methods." A 2-µl aliquot of each reaction was also taken 
at 8 or 60 min for analysis of the forms of [35S]HRI which were present in the RRL 
maturation mixtures prior to immunoadsorption. After washing the immune pellets, 
samples were analyzed by SDS-PAGE, followed by transfer to polyvinflidene difluoride 
membrane and autoradiography. A) [35S]HRI co-adsorbed with p50cdc3 (A , PEL); 
[35S]HRI present in the RRL maturation mixes prior to immunoadsorption (A, UF) 
[35S]HRI*: transformed HRI with slower electrophoretic mobility. Band densities were 
quantified by scanning densitometry and expressed as optical density x mm2 (numbers 
above each panel). B) p50cdc37 that was specifically immunoadsorbed was detected by 
probing the polyvinylidene difluoride membrane of PEL panel with anti-p50cdc37 
polyclonal antibodies. HC: antibody heavy chain. Densitometry indicated that equivalent 
amounts of total [35S]HRI were present during the immunoadsorption ( UF), and that 
equivalent amounts of p50cdc37 were specifically immunoadsorbed. 
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RRL correlated with the approximate 50% transformation of the [35S]HRI population 
after 60 min of incubation in heme-deficient RRL. The observation that transformed 
(slow electrophoretic mobility form) HRI was not coimmunoadsorbed by anti-p50cdc3? 
antibodies is consistent with the data presented in Fig. 3, and supports'the conclusion that 
p50cdc37, like Hsp90, does not interact with transformed HRI. 
Previously, we have demonstrated that the kinase activity of transformed HRI is 
inhibited upon addition of hemin to heme-deficient maturation mixes, and that this 
population of "repressed HRI" molecules does not interact with Hsp90 (246). Similarly, 
we have observed that repressed HRI did not co-adsorb with p50cdc37 from RRL (not 
shown). Thus, p50cdc37 did not bind to transformed HRI regardless of whether the kinase 
was active or repressed. 
The N-terminal Domain of p50cdc3? Binds HRI Independent of Hsp90-Hsp90 and p50cdc37 
both recognize untransformed populations of HRI molecules (Fig. 3 and 4). To 
differentiate between p50cdc3? associating with HRI directly or binding HRI indirectly via 
its interaction with Hsp90, we compared the kinase binding activity of affinity purified 
FLAG-tagged p50cdc3? with that of a C-terminal truncated FLAG-tagged Cdc37 gene 
product (p50cdc37/..1.C). p50cdc37;,1.c had previously been shown to bind the Raf-1 kinase, 
but notHsp90 (89). HRI was readily captured by resins containing the full-length wild-
type Cdc37 gene product and by resins containing the truncated Cdc37 gene product 
p50cdc37!..1.C, but was not captured by anti-FLAG control resins (Fig. 5A, upper panel). In 
contrast, Hsp90 was adsorbed by resins containing the wild-type Cdc37 gene product, but 
only barely detectable amounts of Hsp90 were bound to resins containing p50cdc37;,1.c 
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Figure 5. Effect of geldanamycin on the association of HRI with p50cdc37 and the 
pSOcdc37/~C mutant. A) [35S]HRI was synthesized in TnT RRL in the presence of 
10 µg/ml geldanamycin (lanes 2, 4, and 6) or an equivalent amount of Me2SO (lanes 1, 3, 
and 5), followed by maturation in normal heme-deficient RRL containing M2-agarose 
pre-saturated with control FLAG-peptide (lanes 1 and 2), or Sf9 cell-expressed FLAG-
tagged p50cdc37 (lanes 3 and 4), or FLAG-tagged p50cdc37/~C (lanes 5 and 6) for 60 min at 
30 °C as described under "Materials and Methods," followed by the addition of 20 rnM 
sodium molybdate. After washing the M2-agarose pellets with buffer containing 20 rnM 
sodium molybdate, samples were analyzed by SDS-PAGE, followed by transfer to 
polyvinylidene difluoride membrane. Co-adsorbed [35S]HRI was detected by 
autoradiography (upper panel). Co-adsorbed Hsp90 was visualized by Western blot with 
anti-Hsp90 antibodies (middle panel). Band densities were quantified by scanning 
densitometry and expressed as optical density x mm2 (numbers above each panel). M2 
resin-immobilized FLAG-tagged proteins were visualized by Coomassie Blue staining 
(lower panel, ~C: p50cdc37/~C) . B) (His7)-[35S]HRI (lanes 2 and 4) and [35S]HRI lacking 
(His7)-tag (lanes 1 and 3) were synthesized for 25 min in TnT RRL in the presence of 
10 µg/ml geldanamycin (lanes 3 and 4) or an equivalent amount of Me2SO (lanes 1 and 
2). 20-µl aliquots were immunoadsorbed with GaG-agarose containing bound anti-(His5) 
monoclonal antibody as described under "Materials and Methods." After washing the 
immune pellets, samples were analyzed by SDS-PAGE, followed by transfer to 
polyvinylidene difluoride membrane. (His7)-[35S]HRI was visualized by autoradiography 
(upper panel). Hsp90 (middle panel) and p50cdc37 (lower panel) were detected by Western 
blot with anti-Hsp90 and anti-p50cdc37 antibodies, respectively. HC: antibody heavy chain. 
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truncated Cdc37 gene product (Fig. SA, middle panel). These findings suggested that 
Cdc37 gene products did not bind to kinase folding intermediates indirectly via an 
interaction with kinase-bound Hsp90. 
The above result implied that the C-terminal truncated Cdc37 gene products could 
bind kinase folding intermediates independent of Hsp90 function. To test this, the effects 
of poisoning RRL with the Hsp90-specific antagonist geldanamycin (234, 257) were 
assessed. Consistent with previous reports (89, 235), the ability of full-length FLAG-
p50cdc3? gene product to bind untransformed kinase molecules was markedly reduced 
(67%) in the presence of geldanamycin (Fig. SA, upper panel), but the presence of 
geldanamycin had no inhibitory effect on the interaction of FLAG-p50cdc3? with Hsp90 
(Fig. SA, middle panel). In contrast, inhibition of Hsp90 function by geldanamycin did 
not abrogate the ability of the truncated Cdc37 gene product p50cdc37/!),.C to bind 
untransformed HRI. In fact, geldanamycin treatment appeared to potentiate the kinase 
binding activity of truncated Cdc37 gene products. Thus, the resistance of the interaction 
between p50cdc37/!)..C and HRI to inhibition by geldanamycin indicated that the N-terminal 
half of the Cdc37 gene product was capable of binding kinase folding intermediates 
independent of Hsp90. 
The effects of geldanamycin on chaperone binding to untransformed HRI 
intermediates was confirmed by the reciprocal co-adsorption assays (Fig. SB). (His7)-HRI 
was immunoadsorbed from control or geldanamycin-treated RRL and analyzed for the 
presence of co-adsorbed Hsp90 and p50cdc3?. While the association of Hsp90 and p50cdc3? 
with (His7)-HRI in control RRL was readily detected, treatmentof RRL with 
geldanamycin resulted in the near quantitative disruption of the association of Hsp90 and 
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p50cdc3l with (His7)-HRI (Fig. SB), thus confirming that inhibition ofHsp90 disrupted the 
direct recognition of kinase molecules by p50cdc3l. 
The failure of C-terminal deleted p50cdc3l to bind Hsp90 (89) suggested that the 
elements of p50cdc3l which mediated its interaction with Hsp90 resided in the C-terminal 
domain of p50cdc3l. To further differentiate whether the C-terminal region of p50cdc3l 
contained the Hsp90-binding site or whether it was simply required to maintain the 
structure of an Hsp90-binding site elsewhere in the protein, we constructed the 
corresponding N-terminal deletion mutant of p50cdc3l lacking the first 163 amino acids 
from its N terminus (p50cdc37/m). p50cdc371m was synthesized in TnT RRL and assayed 
for Hsp90 binding. Anti-Hsp90 antibody specifically co-adsorbed [35S]p50cdcJ71m in 
conjunction with Hsp90 (Fig. 6A). Furthermore, anti-His antibodies specifically co-
adsorbed Hsp90 with His-tagged p50cdc371m (Fig. 6B). These findings indicated that the 
C-terminal domain of p50cdc37 contained elements adequate for Hsp90 binding, 
independent of the presence of p50cdc3l,s N-terminal domain. 
p50cdc3l interacts with the N-terminal lobe of the kinase domain of HR! in an Hsp90-
dependent manner-In an attempt to locate the binding site of p50cdc37 in HRI, four major 
domains of HRI, the heme-binding domain (HBO), the N-terminal kinase lobe (NL), the 
kinase insertion sequence (KIS) and the C-terminal kinase lobe (CL) were constructed in 
the RRL expression vector pSP64TL, which was designed to automatically add an N-
terminal (His6)-tag to the inserted coding sequences (32, 192, 247) (Fig. 7A). Four 
different His-tagged domains of HRI were synthesized in separate RRL reactions with 
concomitant radiolabeling with [35S]Met, followed by immunoadsorption with anti-(His5) 
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Figure 6. Interaction of the N-terminal domain deletion mutant of pSOcdc37, 
pSOcdc37/llN, with endogenous Hsp90 in RRL. A) [35S]p50cdc37;m was synthesized in 
TnT RRL at 30 °C for 25 min. Aliquots of (20 µl) TnT RRL containing [35S]p50cdc37;m 
were then immunoadsorbed with goat anti-mouse IgM cross-linked to agarose pre-
coupled with mouse monoclonal anti-Hsp90 IgM, 8D3 (lane 2), or equivalent amount of 
nonimmune mouse IgM (lane 1). Samples were analyzed by SDS-PAGE, followed by 
transfer to polyvinylidene difluoride membrane. Immunoadsorbed Hsp90 was visualized 
by Western blot with anti-Hsp90 antibody (upper panel), and co-adsorbed 
[35S]p50cdc3llllN was detected by autoradiography (lower panel). B) (His6)-
[35S]p50cdc3l/llN was synthesized in TnT RRL at 30 °C for 25 min. Aliquots of (20 µl ) 
TnT RRL containing (His6)-[35S]p50cdc37/m were then immunoadsorbed with GaG-
agarose containing bound anti-(His5)-antibody (lane 2) or an equivalent amount of 
nonimmune mouse IgG (lane 1). Samples were analyzed by SDS-PAGE, followed by 
transfer to polyvinylidene difluoride membrane. Immunoprecipitated (His6)-
[35S]p50cdc37; m was visualized by autoradiography (lower panel) and co-adsorbed 
Hsp90 was detected by Western blot with anti-Hsp90 antibody (upper panel). 
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Figure 7. Interactions of HRI domains with Hsp90 and p50cdc37• A) Domain structure 
of HRI. B) Four different His-tagged domains of HRI, the heme-binding domain (HBD), 
the N-terminal lobe (NL), the kinase insertion sequence (KIS) and the C-terminal lobe 
(CL) along with the wild type HRI (WT) were synthesized with concomitant 
radiolabeling with [35S]Met in separate TnT RRL at 30 °C for 30 min. They were 
subsequently immunoadsorbed to the anti-(His5) antibody (even lanes) or an equal 
amount of nonimmune control mouse IgG antibody (odd lanes), separated on an 8% 
SDS-PAGE and transferred to PVDF membrane. Immunoadsorbed [35S]-labeled HRI 
constructs and the coadsorbed endogenous Hsp90 and p50cdc3? were detected by 
autoradiography (lower panel) and Western blotting analyses (upper and middle panels), 
respectively. C) His-tagged N-terminal lobe of HRI kinase domain was synthesized and 
labeled with [35S]Met in TnT RRL containing 10 µg/ml geldanamycin (Lanes 3 and 4) or 
an equal volume of DMSO (Lanes 1 and 2) at 30 °C for 30 min. RRL reactions were 
subsequently immunoadsorbed to the anti-(His5) antibody (Lanes 2 and 3) or an 
equivalent amount of nonimmune control mouse lgG antibody (Lanes 1 and 4), separated 
on an 8% SDS-PAGE and transferred to PVDF membrane. Immunoadsorbed [35S]-NL 
of HRI (lower panel) and the coadsorbed endogenous Hsp90 (upper panel) and p50cdc3? 
(middle panel) were detected by autoradiography and Western blotting analyses, 
respectively. HC: antibody heavy chain. 
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antibody. The coadsorption of endogenous Hsp90 and p50cdc37 from RRL was 
subsequently assessed by Western blotting analysis (Fig. 7B). While all four domains of 
HRI were synthesized at comparable levels and immunoprecipitated, only the N-terminal 
lobe of the HRI kinase domain pulled down the endogenous p50cdc37 (Fig. 7 B, lane 3). 
The N-terminal kinase lobe also specifically pulled down Hsp90, an observation that is 
consistent with the concerted interactions of Hsp90 and p50cdc37 with the full-length HRI. 
However, the Hsp90-binding was not simply limited to the N-terminal kinase lobe as it 
specifically interacted with the heme-binding domain of HRI as well (Fig. 7B, lane 2). 
Since p50cdc37 interacts with the full-length HRI in a geldanamycin-sensitive 
fashion, we then examined whether its interaction with the N-terminal kinase lobe of HRI 
is also inhibitable by geldanamycin. In doing so, His-tagged N-terminal kinase lobe of 
HRI was synthesized in RRL mixtures containing (Fig. 7 C, lane 3) or lacking (Fig. 7 C, 
lane 2) geldanamycin, and subsequently immunoadsorbed to anti-His resin. 
Coadsorption of the endogenous Hsp90 and p50cdc37 was then analyzed by Western blot. 
As anticipated, like its interaction with the full-length HRI, p50cdc37 bound to the N-
terminal kinase lobe in the same geldanamycin-sensitive fashion, confirming the notion 
that the geldanamycin-inhibitable function of Hsp90 is required for the direct binding of 
p50cdc37 to the client protein HRI. 
Mutation of the N Terminus of p50cdc37 Inhibits Its Binding to HRI-To further characterize 
the domains and motifs of p50cdc37 required for kinase binding, we utilized a p50cdc37 
mutant whose first 8 N-terminal amino acids were replaced by 11 residues encoded by 
irrelevant plasmid sequence (p50cdc37 /N8aa). Two observations indicated that replacement 
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of the first S residues of p50cdc37 did not cause global disruption of p50cdc3l structure. (i) 
This mutation did not compromise the ability of [35S]p50cdc37 /NSaa to associate with 
Hsp90 (Fig. SA). (ii) This mutation did not compromise the structural integrity of 
p50cdc3l lNSaa as determined by mild proteolytic nicking: the sensitivity to protease 
digestion and the pattern of proteolytic fragments generated were essentially the same for 
the p50cdc37 /NSaa and the wild type p50cdc37 proteins (Fig. SB). However, p50cdc37 /NSaa 
was not co-adsorbed with epitope-tagged (His1 )-HRI despite the efficient co-adsorption 
of HRI by wild-type p50cdc3l and the equivalent amounts of each Cdc37 gene product 
present in these assays (Fig. SC). These observations demonstrated that the N-terminal 
S amino acids of p50cdc3l were essential for its interaction with HRI. 
p5ifdc37 Enhances HR! Activity in Heme-deficient RRL in an Hsp90-dependent Fashion-
To further characterize the role of p50cdc37 in the biogenesis of HRI, we examined the 
effect of affinity purified (His6)-p50cdc37 on the transformation and activation of newly 
synthesized [35S]HRI in heme-deficient RRL (Fig. 9). Aliquots of the HRI transformation 
reactions were also taken at the indicated times and analyzed by SOS-PAGE for 
transformation-specific shifts in HRI's electrophoretic mobility (Fig. 9A). Maturation of 
HRI in heme-deficient RRL containing (His6)-p50cdc37 produced transformed HRI 
molecules equivalent to the storage buffer control. However, inclusion of (His6)-pSOcdc37 
in HRI activation reactions increased the proportion of transformed HRI that became 
hyperphosphorylated at all time points examined relative to the control. Results similar to 
those presented in Fig. 9 were also obtained upon supplementing RRL with GST-tagged 
p50cdc3l (not shown: e.g. see Fig. 9). 
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Figure 8. Effect of mutation of the N-terminal amino acids of pSOcdc37 on the 
interaction of pSOcdc37 with HRI and Hsp90. A) Co-adsorption of p50cdc3l /N8aa with 
endogenous Hsp90: [3 5S]p50cdc3l /N8aa was synthesized in TnT RRL at 30 °C for 40 min, 
followed by a 40-min maturation in the presence of ATA (60 µM). An aliquot of the TnT 
RRL mixture (30 µl) was then immunoadsorbed with GaG-agarose containing bound 
mouse polyclonal anti-Hsp90 antibodies (lane 2) or nonimmune mouse lgG (lane 1) as 
described under "Materials and Methods." Samples were separated by SDS-PAGE, 
transferred to polyvinylidene difluoride membrane, and co-adsorbed [3 5S]p50cdc3l /N8aa 
was detected by autoradiography (lower panel) whereas the immunoprecipitated Hsp90 
was visualized by Western blot analysis with anti-Hsp90 antibody Cizper panel). B) 
Comparison of proteolytic peptide mapping between wild type p50c cJl and p50cdc3l /N8aa 
mutant: wild tl,pe p50cdc3l (WI) and p50cdc3l /N8aa (N8aa) were synthesized with 
concomitant 3 S-radiolabeling in separate TnT RRL at 30 °C for 40 min, followed by a 1-
h maturation in the presence of ATA (60 µM). TnT RRL containing [35S]p50cdc37 or 
[35S]p50cdc3l /N8aa were then diluted into 3 volumes of proteolysis assay buffer (98) 
containing four different concentrations of trypsin as specified in the figure, followed by 
a 6-min digestion on ice. Reaction was terminated by adding boiling SDS sample buffer 
to the samples. Proteolytic peptide fragments were separated by 12% SDS-PAGE, 
followed by autoradiography analysis. FL denotes full-length p50cdc3l. C) (His7)-
[35S]HRI was pulse-labeled in TnT RRL. Aliquots (10 µl) of TnT RRL containing (His7)-
[35S]HRI were then chased by incubation in hemin-supplemented RRL containing 
previously synthesized [3 5S]p50cdc3l (PEL: lanes 1 and 2) or [35S]p50cdc3l /N8aa (PEL: 
lanes 3 and 4) for 8 min at 30 °C as described under "Materials and Methods." (His7 )-
[35S ]HRI was immunoadsorbed from the reaction mixtures with anti-(His5) antibody 
(lanes 2 and 3) or equivalent amount of nonimmune mouse IgG (lanes 1 and 4). Samples 
were analyzed by SDS-PAGE, followed by transfer to polyvinylidene difluoride 
membrane. Immunoadsorbed (His7)-[35S]HRI (upper panel of PEL) and co-adsorbed 
[3 5S]p50cdc3l or [35S]p50cdc3l /N8aa (lower panel of PEL) were visualized by 
autoradiography. A 2-µl aliquot of each reaction was also taken prior to 
immunoadsorption to verify that equivalent amounts of [35S]p50cdc3l or 
[35S]p50cdc3l /N8aa were synthesized and present in each reaction mixture ( UF panel). 
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Figure 9. Effect of purified (HisV,-p50cdc37 on HRI transformation (A) and activity 
(B) in heme-deficient RRL. A) [3 S]HRI was pulse-labeled in TnT RRL. TnT RRL 
containing [35S]HRI (3 µl) was then chased into heme-deficient RRL mixture (22 µl) 
which was supplemented with 12 µg of (His6)-p50cdc37 ~even lanes) or an equivalent 
amount of buffer (odd lanes) in which the (His6)-p50cdc 7 was stored as described under 
"Materials and Methods." Aliquots of maturation RRL mixtures were taken after 
0, 10, 20, 30, 45, and 60 min of incubation at 30 °C for direct analysis ofHRI 
transformation. Samples were separated by SDS-PAGE, transferred to polyvinylidene 
difluoride membrane, and visualized by autoradiography. The amount of transformed (TR) 
plus hyperphosphorylated (HP) [35S]HRI was quantified by scanning densitometry and 
expressed as optical density x mm2 (numbers above lanes in panel). B) For anal{csis of 
HRI activity, aliquots (50 µl) of the RRL reaction mixtures containing (His7)-[3 S]HRI 
((His7)-HRI: lanes 3 and 4) or [35S]HRI (NS: lanes 1 and 2) matured in the presence of 
25 µg of (His6)-p50cdc37 (lanes 1 and 3), or an equivalent volume of storage buffer (lanes 
2 and 4) were taken after 60 min of incubation at 30 °C and adsorbed to Ni2+-NTA-
agarose as described under "Materials and Methods." After washing away unbound 
materials, the eIF2a kinase activity of the adsorbed HRI was assayed as described under 
"Materials and Methods." Samples were separated by SDS-PAGE, transferred to 
polyvinylidene difluoride membrane, and [35S]HRI (B, lower panel) and [32P]eIF2a (B, 
upper panel) were detected by autoradiography. The amount of [32P]eIF2a was 
quantified by scanning densitometry and expressed as optical density x mm2 (numbers 
above the eIF2a panel). Densitometry indicated that equivalent amounts of total [35S]HRI 
were specifically immunoadsorbed (lanes 3 and 4). HP: hyperphosphorylated form of 
HRI; TR: transformed form ofHRI; MC: mature competent form ofHRI. 
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The effect of p50cdc3? on the eIF2a kinase activity of HRI was also assessed (Fig. 
9B). After 60 min of incubation, the eIF2a kinase activity of HRI matured in p50cdc3? _ 
supplemented heme-deficient RRL was nearly 3-fold higher relative to HRI matured in 
control RRL supplemented with buffer alone. Thus, the physical association of p50cdc3? 
with untransformed intermediates of HRI appeared to reflect a positive role for this co-
chaperone in HRI maturation/activation pathway, as supplementation of RRL with 
p50cdc37 promoted the acquisition of an active conformation. 
The data presented in Fig. 5 indicated that p50cdc3? required geldanamycin-
inhibitable Hsp90 function for it to form a stable complex with untransformed HRI 
intermediates. To determine whether endogenous Hsp90 function was also required for 
the stimulatory effects ofrecombinant p50cdc3? on HRI transformation and activity, the 
effect of including geldanamycin in the transformation-activation assays was assessed 
(Fig. 10). Similar to the results obtained with (His6)-p50cdc37, supplementation of RRL 
with recombinant GST-p50cdc3? enhanced the eIF2a kinase activity of HRI 3-fold over 
the control, and this enhancement of activity correlated with the generation of a [35S]HRI 
species with a slower electrophoretic mobility (lower panel, denoted HP). Addition of 
geldanamycin inhibited the activation of HRI in both buffer-supplemented control and 
p50cdc37_supplemented heme-deficient RRL (Fig. 10, upper panel). Consistent with this 
finding, the slow electrophoretic form of HRI representing transformed HRI molecules 
was not produced in geldanamycin-poisoned reactions (Fig. 10, lower panel). These 
results indicated that geldanamycin inhibitable Hsp90 function was essential for the 
observed stimulatory effects of p50cdc3? on HRI transformation-activation. 
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Figure 10. The effect of geldanamycin on the ability of GST-p50cdc37 to enhance 
HRI transformation and activation in heme-deficient RRL. (His7)-[35S]HRI (lanes 
2, 4, 6, and 8) and [35S]HRI lacking the (His7)-tag (lanes 1, 3, 5, and 7) were pulse-
labeled in TnT RRL and then chased and matured at 30 °C for 1 h in heme-deficient RRL 
containing GST-p50cdc37 (lanes 1-4) or GST-p50cdc37 purification buffer (lanes 5-8) in the 
presence of 10 µg/ml geldanamycin (lanes 3, 4, 7, and 8) or Me2S0 (lanes 1, 2, 5, and 6) 
as described under "Materials and Methods." RRL maturation mixtures were adjusted to 
20 mM sodium molybdate and immunoadsorbed with GaG-agarose containing bound 
anti-(His5) monoclonal antibody. After washing away unbound material, the eIF2a 
kinase activity of adsorbed HRI was assayed as described under "Materials and 
Methods." Samples were separated by SDS-PAGE, followed by transfer to 
polyvinylidene difluoride membrane. (His7)-[35S]HRI that was specifically 
immunoadsorbed (lower panel) and [32P]eIF2a (upper panel) were detected by 
autoradiography. The amount of [32P]eIF2a was quantified by scanning densitometry and 
expressed as optical density x mm2 (numbers above the eIF2a panel). Densitometry 
indicated that equivalent amounts of total (His7 )-[35S]HRI were specifically 
immunoadsorbed (even lanes). HP: hyperphosphorylated form ofHRI; TR: transformed 
form of HRI; MC: mature competent form of HRI. 
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To further test the hypothesis that the positive effect which p50cdc3? has on HRI 
activity is modulated through its interaction with Hsp90, we examined the effect of the 
p50cdc37/~C mutant on the transformation and activation of HRI in heme-deficientRRL 
(Fig. 11). The data presented in Fig. 5 indicate that complexes formed between HRI and 
the p50cdc37/~C mutant lacked bound Hsp90. Thus, the p50cdc37/~C mutant was predicted 
to retard HRI transformation and activation when added to heme-deficient RRL. (His7)-
HRI (Fig. 11, even lanes) or non-His-tagged HRI (Fig. 11, odd lanes) was synthesized 
and then matured in heme-deficient RRL in the presence of control M2 anti-FLAG tag-
agarose presaturated with FLAG-peptide, FLAG-tagged-p50cdc37, or FLAG-tagged 
p50cdc37J~C. The electrophoretic mobility of the non-His-tagged [35S]HRI that was 
specifically associated with p50cdc3? or p50cdc37/ ~C indicated that the HRI was not 
transformed, and the eIF2a kinase activity of non-His-tagged [35S]HRI bound to p50cdc3? 
and p50cdc37J~C were the same as the activity present in the control pellet for 
nonspecifically bound activity (Fig. 11, lanes 1, 3, and 5). 
The effects of the p50cdc37 and p50cdc37/ ~C mutant on the eIF2a kinase activity 
and electrophoretic properties of the total (His7)-[35S]HRI population matured in these 
RRLs and subsequently adsorbed to anti-His resin were also examined (Fig. 11, lanes 
2, 4, and 6). The elF2a kinase activity of the (His7 )-[35S]HRI that was matured in heme-
deficient RRL in the presence of wild type p50cdc3? was almost twice as high as the eIF2a 
kinase activity present in the control RRL containing M2 anti-FLAG tag-agarose with 
bound FLAG-peptide. In contrast, the eIF2a kinase activity of the (His7 )-HRI that was 
matured in the presence of the p50cdc37/~C mutant was decreased by 60% relative to the 
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Figure 11. Effect of removal of the C-terminal region of p50cdc37 on HRI 
transformation and activation in heme-deficient RRL. (His7)-[35S]HRI (lanes 2, 4, 
and 6) and [35S]HRI lacking the (His1)-tag (lanes 1, 3, and 5) were pulse-labeled in TnT 
RRL and then chased and matured at 30 °C for 1 h in normal heme-deficient RRL 
containing M2-agarose that had been pre-saturated with FLAG peptide (Eastman Kodak 
Co.) (lanes 1 and 2), FLAG-tagged p50cdc37 (lanes 3 and 4), or FLAG-tagged p50cdc37!.::1C 
(lanes 5 and 6) as described under "Materials and Methods." The RRL maturation 
mixtures were then immunoadsorbed with GaG-agarose containing bound anti-(His5) 
monoclonal antibody. After washing away unbound material, the eIF2a kinase activity of 
adsorbed (His7)-HRI was assayed as described under "Materials and Methods." Samples 
were separated by SDS-P AGE, followed by transfer to polyvinylidene difluoride 
membrane. (His7 )-[35S]HRI that was specifically immunoadsorbed (lower panel) and 
[32P]eIF2a (upper panel) were detected by autoradiography. The amount of [32P]eIF2a 
was quantified by scanning densitometry and expressed as O.D. x mm2 (numbers above 
the eIF2a panel). Densitometry indicated that equivalent amounts of total (His7 )-
[35S]HRI were specifically immunoadsorbed (even lanes) . .::1C, p50cdc37/.::1C that was also 
highly phosphorylated and labeled by [y-32P]ATP during the kinase assay."*": an 
unknown protein contaminant present in the purified eIF2 preparation, which became 
phosphorylated and labeled by [y-32P]ATP during kinase assay. 
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matured in the presence of wild type p50cdc37 exhibited a slower electrophoretic mobility 
than the (His7)-[35S]HRI that was matured in control RRL, indicating it had become 
hyperphosphorylated (Fig. 11, lower panel, lane 4 versus 2 (HP)). This shift in 
electrophoretic mobility caused the band to appear more diffuse. However, quantification 
of the total amount of (His7)-[35S]HRI molecules exhibiting slower electrophoretic 
mobilities indicated that nearly the same amount of (His1)-[35S]HRI became transformed 
in RRL supplemented with wild type p50cdc37 (O.D. x mm2 = 4.14) compared with 
control RRL (O.D. x mm2 = 4.11). This observation is consistent with the enhanced 
eIF2akinase activity displayed by the (His7)-[35S]HRI that was matured in the presence 
of wild type p50cdc37• In addition, the fastelectrophoretic mobility of the (His7 )-[35S]HRI 
that was matured in the presence of p50cdc37/ .8C indicated that it remained mostly 
untransformed, consistent with its suppressed kinase activity (Fig. 11, lane 6). These 
results indicate that Cdc37 gene products which do not interact with Hsp90 may act as 
dominant negative inhibitors of p50cdc37 function: a conclusion consistent with the 
observation that Hsp90 is required for p50cdc37 to exert its positive effect on HRI activity 
upon transformation. 
p5(fdc37 Does Not Enhance HRI Activity after Its Transformation-HR! can become 
further activated in RRL after its transformation and release from Hsp90. This further 
activation of transformed HRI is negatively attenuated by the interaction of Hsc70 with 
HRI, and is also accompanied by HRI's hyperphosphorylation (248). To verify that 
p50cdc37 functions are specific to untransformed HRI, HRI was transformed in hemin-
deficient RRL prior to the addition of recombinant p50cdc37 (Fig. 12). As an additional 
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Figure 12. Effect of recombinant FLAG-pSOcdcJ7 on HRI kinase activity upon 
addition subsequent to HRI transformation. (His7)-[35S]HRI was pulse-labeled in TnT 
RRL and chased and matured at 30 °C for I h in normal heme-deficient RRL as 
described under "Materials and Methods." The effect of FLAG-peptide alone (lane 1), 
FLAG-tagged p50cdc3l (lane 2), or FLAG-peptide plus soluble reduced 
carboxymethylated bovine serum albumin (lane 3) was evaluated by incubating the RRL 
maturation mixtures for an additional 20 min at 30 °C. The RRL mixtures were then 
immunoadsorbed with GaG-agarose containing bound anti-(His5) monoclonal antibody. 
A 2-µl aliquot of each maturation mixture was taken prior to immunoprecipitation to 
detect different forms of [35S]HRI generated (UF panel). After washing away the 
unbound material, the eIF2a. kinase activity of adsorbed (His1)-HRI was assayed as 
described under "Materials and Methods." Samples were separated by SDS-PAGE, 
followed by transfer to polyvinylidene difluoride membrane, and autoradiography 
detection of [32P]eIF2a. (PEL panel). The amount of [32P]eIF2a. was quantified by 
scanning densitometry and expressed as O.D. x mm2 (numbers above the PEL panel). 
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control, denatured (reduced carboxymethylated) bovine serum albumin was similarly 
added to heme-deficient RRL after the completion of HRI's transformation to block the 
ability of Hsc70 to negatively attenuate HRI's activation (145,243,248). Addition of 
reduced carboxymethylated bovine serum albumin to heme-deficient RRL stimulated the 
eIF2a. kinase activity ofHRI 4-fold compared with the activity observed in control RRL. 
In contrast, the addition of an equivalent amount of recombinant p50cdc37 to heme-
deficient RRL subsequent to HRI transformation caused little further stimulation of HRI's 
eIF2a. kinase activity (approximately 10%) compared with the control. Therefore, the 
stimulatory effects of p50cdc37 were specific to that HRI population whose transformation 
had been previously documented to be functionally dependent upon geldanamycin-
inhibitable Hsp90 function. 
Interaction of p50cdc37 with HR! in Vivo-Interactions between endogenously expressed 
p50cdc37 and HRI were examined in the chronic myelogenous leukemic K562 cell line to 
determine whether p50cdc37 also interacted with HRI in vivo. K562 cells, cultured in the 
presence or absence of geldanamycin for 2 h, were lysed and endogenous p50cdc37 was 
immunoadsorbed (Fig. 13). Immunoblotting with HRI-specific antibodies indicated that 
HRI was co-adsorbed with p50cdc37 from extracts of control cells (Fig. 13, upper panel). 
However, treatment of K562 cells with geldanamycin abolished the interaction of p50cdc37 
with HRI. In contrast, geldanamycin treatment of K562 cells had no effect on the avid 
interaction between p50cdc37 and Hsp90 in vivo (Fig. 13, middle panel). Stripping and 
reprobing with anti-p50cdc37 antisera verified that equivalent amounts of p50cdc37 were 







Figure 13. Endogenous pSOcdc37 associates with HRI in vivo. Cultured human 
erythroleukemia K562 cells were treated with Me2SO (lane 1) or with 1 µg/ml 
geldanamycin (lane 2) for 2 h. Endogenous p50cdc3l was immunoprecipitated as described 
under "Materials and Methods." Immunocomplexes were separated by SDS-PAGE, 
transferred to polyvinylidene difluoride membrane, and analyzed for the presence of 
p50cdc3l (lower panel) and associated HRI (upper panel). An equivalent aliquot of the 
immunopellet was similarly analyzed for the presence of Hsp90 (middle panel). Proteins 
that were specifically detected when membranes were probed with anti-HRI, anti-p50cdcJ7' 
or anti-Hsp90 antibodies are indicated by solid arrowheads. The detected proteins were 
of the expected molecular weight. Open arrowheads denote the position of the heavy 
chain of the immunoprecipitating anti-p50cdc37 antibodies. Analysis of anti-p50cdcJ7 
immunoadsorptions from two additional sets K562 cell extracts gave similar results. 
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(Fig. 13, lower panel). These results indicated that HRI existed in geldanamycin-sensitive 
native complexes with p50cdc37 in cultured K562 cells. 
Discussion: 
p50cdc37 plays a positive role in facilitating activation of HRI in response to heme-
deficiency. Supplementation of heme-deficient RRL with recombinant p50cdc37 during the 
HRI activation process stimulates the production ofHRI populations with enhanced 
kinase activity and stimulates the production of HRI populations with retarded 
electrophoretic mobilities which are diagnostic of HRI activation/transformation. While 
our present work is the first to directly address the role of p50cdc37 in kinase biogenesis in 
an in vitro model system, these observations are consistent with biochemical and genetic 
data which indicate that p50cdc37 plays an essential positive role in supporting the function 
of numerous protein kinases (59, 71, 89, 122, 143, 166, 235). This positive function is 
consistent with a primary role for p50cdc37 in a striking partnership with Hsp90 as a 
kinase-specific cohort. 
The stimulatory effect of p50cdc37 is specific to the HRI activation process: 
p50cdc37 has no effect on the kinase activity or electrophoretic mobility of HRI when 
added subsequent to HRI's transformation. Consistent with this specificity, p50cdc37 
interacts with newly synthesized HRI and with the inactive HRI population maintained in 
the presence of hemin, but does not interact with HRI that has been transformed in 
response to heme deficiency or with transformed HRI whose activity has been repressed 
by hemin. Therefore, like Hsp90's association with inactive kinases, the interaction of 
p50cdc37 with HRI appears to reflect its role in facilitating kinase folding, maturation, and 
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activation, and not its association with kinase molecules whose activity is repressed per 
se. Similarly, the fast electrophoretic form of Raf-1 has been found to be preferentially 
co-adsorbed with p50cdc37 from cultured cells. The observed specificity of p50cdc37 for 
untransformed HRI intermediates is also consistent with other studies demonstrating that 
p50cdc37 and Hsp90 recognize kinase molecules which represent specific maturation or 
activation intermediates (20, 71, 166, 235). 
Data presented here allowed us to locate the p50cdc37-binding site to the N-
terminal lobe of the conserved kinase domain of HRI, but not to any other domains. This 
region of HRI is also recognized by Hsp90, an observation that is consistent with reports 
on the interactions of Hsp90 and p50cdc37 with the catalytic domains of other client 
kinases, including Raf-1 and KSR (223, 233, 236). The "coincident" bindings of these 
two chaperones to the same HRI domain further implies their functional cooperation in 
terms of regulating client proteins, a notion that has already been suggested by various 
other studies (8, 20, 29, 51, 89, 122, 158,175,211,235,236). Moreover, since Hsp90 
and p50cdc37 interact with the client kinases through direct physical contacts (223, 235) 
and in a non-overlapping fashion, it thus indicates that subtle but significant differences 
must exist in their specific binding sites within the kinase domains of the client proteins. 
Interestingly, besides the N-terminal kinase lobe Hsp90 binds to the unique regulatory 
heme-binding domain (HBD) of HRI as well, a region that is not recognized by p50cdc37• 
In constrast to the interaction between Hsp90 and the N-terminal kinase lobe of HRI, the 
interaction between Hsp90 and the HBD was not affected by the Hsp90 specific inhibitor 
geldanamycin (data not shown). This observation suggests that the interaction of Hsp90 
with the HBD represents its passive (non-ATP-dependent) chaperone function: 
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interacting with partially denatured polypeptides to prevent aggregation. It is in 
agreement with the recent identification of an ATP-independent chaperone site in the C-
terminal region of Hsp90 (209, 264). Taken together, the difference in the recognition 
sites of Hsp90 and p50cdc37 for HRI is consistent with the notion that these two 
chaperones may regulate their common clients differentially in vivo although their 
functions may be cooperative or interdependent in some regards (122). 
p50cdc37 has at least two semi-independent units that mediate its biological activity. 
The N-terminal half of p50cdc37 contains an autonomous kinase-binding unit, since it 
binds HRI (Fig. 5) and Raf-1 (89) when its C-terminal half was deleted. Consistent with 
this localization, the first 8 amino acids at the N terminus of p50cdc37 were found to be 
essential to its kinase binding activity (Fig. 8). Thus, these residues either participate 
directly in kinase binding or provide essential support to the structure of an N-terminal 
kinase-binding domain. Additionally, complexes formed between p50cdc37/tiC and HRI 
(Fig. 5) or Raf-1 (89) lack bound Hsp90. Furthermore, the interaction between 
p50cdc37; tic and HRI was enhanced by geldanamycin (Fig. 5), apparently due to lack of 
competition from endogenous Hsp90/p50cdc37 in the presence of geldanamycin. Thus, the 
N-terminal domain of p50cdc37 binds to HRI directly rather than associating with HRI via 
Hsp90. This finding is consistent with similar conclusions reached previously regarding 
the association of p50cdc37 with Raf-1 or Cdk4 (89, 223, 235). 
In contrast to the N-terminal region, the C-terminal half of p50cdc37 contains one 
or more motifs or domains which mediate its interaction with Hsp90. Deletion of the C-
terminal half of p50cdc37 abolishes its interaction with Hsp90 (Fig. 5), a finding consistent 
with previous in vivo characterizations of the truncated Cdc37 gene product (89). 
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However, it was not previously clear if such truncations directly deleted a discrete Hsp90-
binding domain or motif, or if they indirectly compromised Hsp90 binding by disrupting 
essential support of other protein structures present within the N-terminal half of p50cdc37• 
We demonstrate here that the C-terminal half of p50cdc37 contains semi-autonomous 
Hsp90 binding activity (Fig. 6). Thus, sequences or structures present in the C-terminal 
region of p50cdc37 directly mediate its binding to Hsp90. However, despite the observation 
that the N-terminal domain of p50cdc37 does not stably interact with Hsp90, we cannot 
rule out the possibility that motifs in regions outside of the C terminus of p50cdc37 may 
also contribute directly or indirectly to the interaction of p50cdc37 with Hsp90. 
Our data indicate that p50cdc37 exerts its biochemical effects in cooperation with 
Hsp90. This conclusion is indicated by the observation that the Hsp90-specific inhibitor 
geldanamycin inhibits the ability of recombinant p50cdc37 to stimulate HRI transformation 
(Fig. 10). Geldanamycin similarly inhibits the ability of p50cdc37 overexpression to 
stimulate Raf activation in cultured cells (89), indicating that Hsp90 is required for 
p50cdc37 to exert its positive effect on Raf-1 activation in vivo. Furthermore, these results 
do not reflect a direct disruption of the Hsp90-p50cdc37 interaction (Figs. 5 and 13) (89). 
Instead, geldanamycin disrupts the normal association of p50cdc37 with HRI in RRL and in 
cultured K.562 cells (Figs. 5 and 13). This finding is consistent with previous 
characterization of the effects of geldanamycin on p50cdc37 interactions with CDK4, Raf-1, 
and KSR in vivo (89, 235, 236). 
In contrast, geldanamycin does not inhibit the ability of C-terminal truncated 
Cdc37 gene products to bind kinase folding intermediates; inhibition of Hsp90 actually 
increases the availability of HRI molecules for binding to truncated cdc37 proteins (Fig. 
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5). This observation has 3 important implications. 1) Geldanamycin's disruption of 
p50cdc3? _kinase heterocomplexes does not result from sequestration or masking of kinase-
folding intermediates by geldanamycin-poisoned Hsp90 machinery. 2) The physical 
interaction of full-length p50cdc37 with Hsp90 determines geldanamycin's ability to inhibit 
the binding of p50cdc3? to kinase molecules. 3) Geldanamycin-inhibitable Hsp90 function 
is necessary to assemble heterocomplexes formed directly between kinase molecules and 
full-length p50cdc3? and to chaperone the kinase substrate toward its activation-specific 
conformation. 
Geldanamycin is known to act as a specific inhibitor of Hsp90 through its ability 
to bind avidly within Hsp90's nucleotide-binding pocket, thus blocking the binding of 
ATP (91, 183, 234). This binding prevents nucleotide-mediated switching between 
alternative Hsp90 conformations (91, 99, 116,237) and abolishes Hsp90's ability to 
establish high affinity interactions with its substrates (97, 243), thus inhibiting Hsp90-
supported kinase function. Therefore, geldanamycin's ability to inhibit the binding of wild 
type p50cdc37 to kinase-folding intermediates demonstrates that Hsp90's nucleotide-
mediated conformational switching regulates the direct binding of p50cdc3? to Hsp90's. 
kinase clients. Additionally, our data illuminate potential mechanisms underlying the 
chemotherapeutic potential of benzoquinonoid ansamycins. 
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CHAPTER III 
Evidence That Protein Phosphatase 5 Functions To Negatively Modulate the 
Maturation of the Hsp90-Dependent Heme-Regulated eIF2a Kinase 
Introduction: 
The heme-regulated inhibitor (HRI) of protein synthesis is a protein kinase that 
acts in reticulocytes and reticulocyte lysates to coordinate the synthesis of globin chains 
with the availability of heme (32). Under heme-deficient conditions, HRI becomes 
activated and phosphorylates the a-subunit of the eukaryotic translational initiation factor 
eIF2 at Ser51. Phosphorylation of eIF2a causes the sequestration of eIF2B, the guanine 
nucleotide exchange factor responsible for the recycling of eIF2, in complexes with 
phosphorylated eIF2. The subsequent accumulation of nonfunctional GDP-bound eIF2 
ultimately shuts off initiation of protein synthesis. In addition to heme deficiency, HRI is 
also activated by other environmental or chemical stimuli including heat shock, oxidative 
stress, denatured proteins, and sulfhydryl-reactive reagents (32). 
The activation of HRI under physiological and nonphysiological conditions is 
accompanied by phosphorylation events. While a preponderance of evidence supports the 
notion that the phosphorylation of HRI is autocatalytic (9, 32, 70, 246), 
heterophosphorylation by casein kinase II has also been proposed to regulate HRI 
activation (151). Despite characterizations performed to date, the specific 
phosphorylation/dephosphorylation events regulating HRI function are poorly understood. 
In addition to governing HRI activation, evidence indicates that phosphorylation 
of HRI also regulates its posttranslational maturation and that the pathways for HRI 
maturation and activation overlap (215,246,248). Newly synthesized HRI is inactive and 
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cannot be activated by heme deficiency or treatment with N-ethylmaleimide. This 
"immature" population of HRI is physically associated with chaperone machinery 
containing the 90 kDa heat-inducible phosphoprotein Hsp90 (215,246,248). HRI 
molecules subsequently mature such that they become competent to activate in response 
to heme deficiency or treatment with N-ethylmaleimide. However, this "mature-
competent" form of HRI continues to require physical and functional interactions with 
Hsp90 to maintain the kinase's competence to respond to activating stimuli (246). When 
mature-competent HRI is exposed to activating conditions (e.g., heme deficiency), HRI 
molecules become "transformed". Transformation is characterized by activation of HRI's 
kinase activity and the cessation of physical and functional interactions with Hsp90. 
Transformation of HRI appears to occur through its autophosphorylation, as it requires 
the presence of a conserved lysine in HRI's catalytic pocket (246). Additionally, 
transformed HRI shows retarded electrophoretic mobility on SOS-PAGE (215,246). The 
altered electrophoretic mobility of transformed and hyperphosphorylated HRI on SOS-
P AGE is reversed by pretreatment of samples with alkaline phosphatase (9, 137), 
indicating that the altered electrophoretic mobility of HRI is diagnostic of its altered 
phosphorylation status. While studies to date indicate that autophosphorylation governs 
HRI's Hsp90-dependent activation and transformation (246), HRI is multiply 
phosphorylated in vitro and in vivo (9, 32, 70, 137,215,246,248), and the importance of 
individual phosphorylated residues has yet to be defined. 
The composition of the Hsp90 chaperone machine associated with untransformed 
HRI has been partially characterized in previous studies (97, 144-146, 215,246,248). In 
addition to Hsp90, HRI-chaperone complexes can also contain Hsc70, p50cdc3?' the 
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immunophilin FKBP52, and the nucleotide-responsive cohort p23. Several Hsp90 
cochaperones, such as FKBP52 and p60/Hop, contain tetratricopeptide repeat (TPR) 
motifs (reviewed in 13) that mediate their interaction with Hsp90 (27, 101, 153, 170, 189, 
196). Regarding the p50cdc37_ and TPR-containing components of Hsp90 
heterocomplexes, in vitro competition studies have suggested that these Hsp90 cohorts 
might represent mutually exclusive subunits that compete for binding to the Hsp90 
chaperone "machine" (170,171,223). More recently, however, p50cdc37 and FKBP52 
have been found to bind to Hsp90 simultaneously both in the basal (no kinase client) 
chaperone machine and in client-chaperone heterocomplexes (97). This co-occurrence 
suggests that the poorly characterized role(s) of these proteins is (are) exercised in 
concert during Hsp90-mediated protein folding. 
Protein phosphatase 5 (PPS) is a novel component of the Hsp90 chaperone 
machine (35). PPS has been found in all eukaryotic cells so far examined from yeast to 
humans (41) and has a cytoplasmic/nuclear localization (5, 19, 37, 160, 167,204). PPS 
contains an N-terminal TPR domain that mediates its interaction with Hsp90 (35, 194, 
204) and a C-terminal catalytic phosphatase domain (10, 37, 42). Limited proteolysis of 
PPS has indicated that its phosphatase activity is negatively modulated by its TPR 
domain and a region at its C-terminus (36, 224). Polyunsaturated fatty acids, such as 
arachidonic or linoleic acid, stimulate the phosphatase activity of purified PPS 
substantially and are thought to relieve the autoinhibition of PPS by binding to its TPR 
domain (36, 225). Like the immunophilin FKBP52, competition studies performed in 
vitro suggest that the association of PPS with Hsp90 can be mutually exclusive with 
regard to p50cdc37 and immunophilins (223). 
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The apparent ubiquitous expression of PPS has prompted the conjecture that PPS 
plays an as yet underappreciated role in the regulation of signal transduction within cells 
(41). This hypothesis is supported by the observations that, besides being present in 
heterocomplexes formed between Hsp90 and steroid hormone receptors (35,221), PPS 
has been found to be associated with the atrial natriuretic peptide (ANP) receptor (42), 
the CDC16/CDC27 subunits of the anaphase-promoting complex (APC) (167), the 
apoptosis signal-regulating kinase 1 (ASKl) (160), the A-subunit of phosphatase 2A 
(138), the GANG-MCM3 complex involved in B cell transition (124), and the blue light 
photoreceptor hCRY2 (267). The potential physiological significance of these 
I 
interactions is supported by the observations that PPS overexpression appears to 
negatively regulate glucocorticoid-mediated growth arrest in vivo (272) and PPS appears 
to act as a negative feedback inhibitor of ASKl activation (160). 
In this report, the physical and functional association of PPS with HRI 
maturation/activation intermediates was characterized by biochemical and 
pharmacological approaches in rabbit reticulocyte lysate, lysates of cells in which HRI is 
naturally expressed. Data indicate that PPS is a nonexclusive Hsp90 partner protein that 
associates with HRI during overlapping pathways of HRI maturation and regulation. 
Pharmacological characterizations indicate that this association is functionally relevant. 
The coexistence of PPS and p50cdc37 within Hsp90 heterocomplexes suggests that 
physiological signals that regulate HRI transformation and activation may be modulated 
by the opposing actions of these two Hsp90 cochaperones on HRI. 
Materials and Methods: 
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Reagents-For in vitro translation in rabbit reticulocyte lysate, the EcoRI fragment of 
pCMV6 encoding rat FLAG-tagged PPS (provided by Dr. Michael. Chinkers) (35) was 
ligated into the corresponding site of a modified version of the in vitro transcription 
vector pSP64T (126). For expression in Escherichia coli, the same EcoRI fragment was 
cloned into the corresponding site of the bacterial expression vector pET-30a( + ). The 
resulting construct encoded a recombinant PPS with a relatively large leading sequence of 
approximately 50 amino acids containing a (His6)-tag followed by vector-encoded 
sequence. For expression of the isolated TPR domain, the pET-30a( + )-PPS plasmid was 
digested with HindIII which separates the C-terrninal phosphatase domain from the N-
terrninal TPR domain of PPS, and the resulting large HindIII fragment encoding the TPR 
domain only was self-annealed. Due to the removal of the original stop codon 
immediately following the phosphatase domain of PPS, the resulting TPR domain used 
the one in the pET-30a( +) vector and this had a short C-terminal tail containing a second 
(His6)-tag (AAALEHHHHHH). Recombinant His-tagged FLAG-PPS or His-tagged 
PP5/K97A or PP5/R101A in the pET-15b expression vector (provided by Dr. Michael 
Chinkers) (204) was expressed in BL2l(DE3) cells and purified under native conditions 
as described previously for His-tagged recombinant p50cdc37 (215) for addition into 
reaction mixtures. Rabbit Hsp90 was purified as described previously (242) and used for 
immunization of mice to produce polyclonal ascites anti-Hsp90 antibodies. Other 
antibodies utilized include mouse anti-PPS (P75520, BD Transduction Laboratories), 
antigen affinity-purified mouse antibodies recognizing the Hiss epitope (anti-His-tag) 
(Qiagen), polyclonal ascites antibodies directed against p50cdc37 (97), and M2 anti-FLAG-
tag antibody (Sigma). Rabbit reticulocyte lysate reaction mixtures were assembled, and 
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proteins were synthesized de novo and radiolabeled via coupled transcription and 
translation as previously described (215, 246, 248). 
Assays of the Effects of Pharmacological Agents on HR/ Transformation-His-tagged HRI 
[(His7)-HRI] was synthesized by coupled transcription and translation in rabbit 
reticulocyte lysate for 15 min followed by a 4 min pulse labeling with [35S]Met (215, 246, 
248). Aliquots (6 µL) of the reticulocyte lysate were subsequently transferred to heme-
supplemented or heme-deficient reticulocyte lysate mixtures (44 µL) containing the 
initiation inhibitor aurintricarboxylic acid (ATA, 60 µM final) for HRI 
maturation/activation. These maturation/activation reactions contained or lacked 500 nM 
okadaic acid or nodularin (Calbiochem), 34 µM fostriecin (Calbiochem), or various 
concentrations of arachidonic acid (Cayman) or linoleic acid (Sigma) (50-600 µM) 
individually, as indicated in the figure legends. Control maturation/activation reactions 
contained equal amounts of okadaic acid-7,10,24,28-tetraacetate (Calbiochem) in DMSO 
as the negative control for okadaic acid, DMSO as the vehicle control for geldanamycin, 
water as the vehicle control for nodularin and linoleic acid, 95% ethanol as the vehicle 
control for arachidonic acid, and stearic acid (Sigma) in 100% methanol as the negative 
control for arachidonic acid. After addition of HRI to the drug-treated lysates, the 
reaction mixtures were incubated at 30 ° C for 1 h to allow for HRI maturation/activation. 
To assay for the postmaturational effect of drug additions, (His7)-[35S]HRI was 
synthesized by coupled transcription and translation in reticulocyte lysate and 
matured/activated in heme-deficient reticulocyte lysate for 45 min as described above. 
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The drugs were then added, and the reaction mixtures were incubated for an additional 20 
min at 30 °C. Negative controls were as described above. 
After maturation/activation in reticulocyte lysate, (His7)-[35S]HRI was 
immunoadsorbed from reaction mixtures with mouse anti-(His5) monoclonal antibody 
prebound to agarose containing cross-linked anti-mouse IgG (anti-His-tag antibody resin). 
To assess the interaction of [35S]HRI with Hsp90 and p50cdc37, Hsp90 and p50cdc37 were 
immunoadsorbed with 8D3 anti-Hsp90 or anti-p50cdc37 antibodies as previously described 
(215,246). Reaction mixtures incubated with reticulocyte lysate containing no template 
were used as controls for nonspecific binding. Resins were washed with PIPES buffer (10 
mM, pH 7.2) containing 150 mM NaCl and 50 mM NaF. Immunoadsorbed HRI was 
assayed for its eIF2a kinase activity as previously described (215, 246, 248), and gel 
mobility shifts on SDS-PAGE were used to monitor HRI transformation as previously 
described (215,246,248). Samples were analyzed by SDS-PAGE, electrotransfer to 
PVDF membranes, and autoradiography. 
Protein-Protein Interaction Assays-To assay for the interaction of HRI with the 
endogenous PPS in reticulocyte lysate, (His7 )-[35S]HRI was synthesized by coupled 
transcription and translation in reticulocyte lysate for 30 min at 30 °C, after which lysate 
reactions were immunoadsorbed with anti-His-tag antibody resin. Immunoadsorptions 
were washed with PIPES buffer (10 mM, pH 7.2) containing 150 mM NaCl and 0.5% 
Tween-20. As negative controls, blank reticulocyte lysate reactions lacking DNA 
templates were assessed in parallel adsorptions. Proteins adsorbed or coadsorbed from 
control and experimental reticulocyte lysate were separated on 8% SDS-PAGE gels, 
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transferred to PVDF membranes, and analyzed by autoradiography or by Western 
blotting with antibodies directed against PP5 or other chaperones as indicated. 
In an alternative assay with enhanced sensitivity for the detection of the interaction of 
PP5 with HRI, FLAG-tagged PP5 and HRI were synthesized de novo by coupled 
transcription and translation and radiolabeled in separate reticulocyte lysate reactions for 
30 min at 30 °C. Synthesis and labeling were arrested via addition of ATA (60 µM final) 
for 10 min, and equal volumes of these individual reactions were then mixed. 
Subsequently, the mixed reactions were incubated for 20 min at 30 °C with or without 
addition of pharmacological agents, followed by immunoadsorption of FLAG-tagged PP5 
with M2 anti-FLAG-tag antibody resin. In the reciprocal experiment, (His7)-HRI and 
FLAG-PP5 were synthesized and mixed as described above, followed by 
immunoadsorption of (His7)-HRI with anti-His-tag antibody resin. Immunoadsorptions 
were washed with PIPES buffer (10 mM, pH 7.2) containing 0.5% Tween-20 and NaCl at 
concentrations indicated in the figure legends. Radiolabeled coadsorbing proteins were 
assessed by SDS-PAGE and autoradiography. The presence of other coadsorbed 
chaperones was assessed by Western blotting. Relative amounts of proteins were 
quantified by scanning densitometry. 
To assess the interaction between HRI and PP5 mutants, aliquots of reticulocyte 
lysate containing [35S]HRI generated by coupled transcription and translation were mixed 
with hemin-supplemented lysate that had been supplemented with purified recombinant 
His-tagged PP5, PP5K97A, or PP5/R101A. Reaction mixtures were incubated for 20 min 
at 30 °C, followed by immunoadsorption with anti-His-tag antibody resin. Samples were 
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then analyzed by SOS-PAGE, Coomassie Blue staining, autoradiography, and Western 
blotting. 
Results: 
PPS Is a Nonexclusive Component of HRI-Chaperone Heterocomplexes-Since PPS has 
been reported to interact with Hsp90, we tested the hypothesis that PPS occurred on 
heterocomplexes with the Hsp90-dependent kinase HRI. (His7)-[35S]HRI was synthesized 
de novo by coupled transcription and translation in heme-replete rabbit reticulocyte lysate, 
yielding a mixture of immature and mature-competent Hsp90-dependent molecules due 
to the presence of heme in translation reactions (246). After immunoadsorption of HRI 
with anti-His-tag antibody resin, coadsorbing proteins were detected by SOS-PAGE and 
Western blotting. As we have reported previously, Hsp90 was coadsorbed with newly 
synthesized (His7)-[35S]HRI (Figure 14A). In contrast, no similar (nonspecific) recovery 
of Hsp90 was observed in anti-His-tag immunoadsorptions from reactions lacking (His7 )-
[35S]HRI. Like Hsp90, PPS was coadsorbed with (His7)-[35S]HRI, and this adsorption 
was specific for reactions programmed to synthesize (His7 )-[35S]HRI. These results 
indicated that PPS endogenous to reticulocyte lysate occurred in heterocomplexes with 
HRI molecules. 
To further study the interaction of HRI with PPS in reticulcyte lysate, untagged 
[35S]HRI or (His7)-[35S]HRI and FLAG-tagged [35S]PPS were generated in separate 
reticulocyte lysate reactions. The reactions were then mixed and incubated for 20 min. 
After incubation, PPS (Figure 14B) or HRI (Figure 14C) was immunoadsorbed with anti-
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Figure 14. Interaction ofHRI with PPS in reticulocyte lysate. A) Reticulocyte lysate 
containing (lane 2) or lacking (lane 1) plasmid encoding for (His7)-[35S]HRI was 
incubated for 30 min, HRI was adsorbed with anti-His-tag antibody and samples were 
analyzed as described under "Materials and Methods". (His7)-[35S]HRI and coadsorbed 
endogenous PPS were visualized by autoradiography and Western blotting, respectively. 
[35S]HRI (B) or (His7)-[35S]HRI (C) and FLAG-tagged [35S]PP5 were synthesized in 
separate reticulocyte lysate reaction mixtures for 30 min as described under "Materials 
and Methods". Reticulocyte lysate containing [35S]HRI (B) or FLAG-tagged [35S]PP5 (C) 
was mixed at a 1: 1 ratio with lysate containing (lane 2) or lacking (lane 1) FLAG-tagged 
[35S]PP5 (B) or (His7)-[35S]HRI (C), respectively. After 20 min of incubation, PPS (B) 
and HRI (C) were immunoadsorbed with anti-FLAG-tag and anti-His-tag antibody resin, 
respectively, and analyzed as described under "Materials and Methods". [35S]HRI or 
FLAG-[35S]PP5 and Hsp90 were visualized by autoradiography and Western blotting. D) 
HRI was synthesized in reticulocyte lysate for 15 min as described under "Materials and 
Methods". Aliquots of the reactions were then diluted into 7 volumes ofheme-
supplemented (lanes 1, 2, and 5) or heme-deficient rabbit reticulocyte lysate (lanes 3, 4, 
and 6) containing (lanes 2 and 4) or lacking (lanes 1 and 3) 17 µg/mL purified 
recombinant FLAG-PPS. After 1 h PPS was immunoadsorbed with M2 anti-FLAG-tag 
antibody resin, and samples were analyzed as described under "Materials and Methods". 
FLAG-PPS and coadsorbing [35S]HRI (Pel) were detected by Western blotting and 
autoradiography, respectively. Portions of the maturation mixtures containing the purified 
FLAG-PPS were analyzed in parallel (Input). [35S]HRI*: transformed form ofHRI with 
slower electrophoretic mobility; [35S]HRI: mature-competent form of HRI with faster 
electrophoretic mobility. 
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proteins. Hsp90 was specifically coadsorbed with FLAG-tagged [35S]PP5 (Figure 14B, 
lane 2), a finding consistent with the previously described interaction of these proteins. In 
addition to Hsp90, [35S]HRI was also coadsorbed with FLAG-tagged [35S]PP5, 
confirming the occurrence of PPS in heterocomplexes with HRI molecules. While a low 
level of nonspecific binding of PPS to the anti-His-tag resin was noted in the reciprocal 
experiment (Figure 14C, lane 1), both PPS and Hsp90 were clearly found to be 
coadsorbed specifically with (His7)-[35S]HRI from the reactions (Figure 14C, lane 2). 
To determine whether PPS was associated with a specific population of HRI 
maturation intermediates, newly synthesized [35S]HRI was matured in hemin-
supplemented or heme-deficient reticulocyte lysate that had been supplemented with 
purified recombinant FLAG-PPS. After maturational incubations, FLAG-PPS was 
adsorbed with anti-FLAG antibody resin in the presence of NaF to inhibit phosphatase 
activity. Adsorbing/coadsorbing PPS and HRI were detected by Western blotting and 
autoradiography, respectively. Incubation of HRI in heme-deficient reticulocyte lysate 
resulted in the transformation of approximately 55% of the HRI, as indicated by the 
presence of a band with retarded electrophoretic mobility relative to immature and 
mature-competent forms of HRI (Figure 14D, lanes 5 and 6). The fast electrophoretic 
mobility form (representing immature and/or mature-competent HRI molecules) was the 
primary form of HRI coadsorbed with PPS from heroin-supplemented and heme-deficient 
lysates (Figure 14D, lanes 2 and 4). However, a proportion of HRI with retarded 
electrophoretic mobility (-10% of the total) was also observed to coadsorb with PPS. 
Previous results suggesting that Hsp90 and p50cdc37 interacted exclusively with immature 
and mature-competent (untransformed) forms of HRI (215, 246) were obtained in the 
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absence of NaF. Inclusion of NaF in buffers during anti-Hsp90 and anti-pSOcdcJ7 
imrnunoadsorptions confirmed that a small percentage of HRI with retarded 
electrophoretic mobility was also coadsorbed with these chaperone hetercomplexes ( data 
not shown). These results suggest that HRI becomes phosphorylated while associated 
with Hsp90 heterocomplexes and that chaperone-associated phosphorylated HRI is a 
target for one or more phosphatases present in reticulocyte lysate. 
Although in vitro competition assays have suggested that pSOcdcJ7 is an exclusive 
Hsp90 cohort that does not coexist in heterocomplexes with FKBPS2 and PPS ( 170, 171, 
223), our recent findings are inconsistent with this model: pSOcdcJ7 and FKBPS2 occur 
simultaneously in Hsp90 complexes (97). Since PPS had similarly been postulated to be 
mutually exclusive with regard to pSOcdc37 (223), we examined PPS-Hsp90 complexes to 
determine if pSOcdcJ7 occurred in Hsp90 heterocomplexes with PPS. For these assays, 
FLAG-tagged PPS and/or HRI were (was) synthesized, and the reactions were mixed as 
described above. Proteins coadsorbing with PPS were detected by autoradiography or 
Western blotting. Anti-FLAG imrnunoadsorptions of control reactions that were not 
programmed to synthesize FLAG-tagged PPS retained no detectable Hsp90, pSOcdc37, or 
[35S]HRI, indicating that these adsorptions were not compromised by nonspecific binding 
(Figure lSB, lanes 1, 4, 7, and 10). In contrast, imrnunoadsorptions ofreactions 
programmed to synthesize FLAG-tagged [35S]PPS specifically coadsorbed endogenous 
Hsp90 and pSOcdcJ7 (Figure lSB, lanes 2 and 8). This result confirmed the previously 
described association of Hsp90 with PPS and provided novel evidence for the occurrence 
of pSOcdcJ7 in heterocomplexes containing PPS. Consistent with this finding, the 
occurrence of pSOcdcJ7 in PPS complexes was dramatically enriched in the presence of 
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Figure 15. Effect of geldanamycin (GA) on the interaction ofHRI with PP5 in 
reticulocyte lysate. (His1 )-[35S]HRI was synthesized in reticulocyte lysate mixtures in the 
presence ( +) or absence (-) of 10 µg/mL geldanamycin, and FLAG-[35S]PP5 was 
synthesized in a separate lysate mixture for 30 min as described under "Materials and 
Methods". The reactions were then mixed in a 1: 1 ratio with each other or with lysate 
lacking (His7)-[35S]HRI (A, lane 1) or lysate lacking FLAG-[35S]PP5 (B, lanes 1, 4, 7, 
and 10) and incubated for another 20 min. Reaction mixtures were subsequently 
immunoabsorbed using anti-His-tag antibody resin (A) or M2 anti-FLAG-tag resin (B), 
followed by washing with PIPES buffers (10 mM, pH 7.2) containing no salt (A , lanes 1-
3; B, lanes 1-6) or 500 mM NaCl (A, lanes 4 and 5; B, lanes 7-12), and analyzed as 
described under "Materials and Methods". (His7)-[35S]HRI and FLAG-[35S]PP5, and 
endogenous Hsp90 and p50cdc3l, were visualized by autoradiography and Western 
blotting, respectively. The basal interactions ofFLAG-[35S]PP5 with Hsp90 and p50cdc3l 
in the absence of newly synthesized HRI are shown in panel B, lanes 2, 3, 8, and 9. 
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Hsp90-dependent HRI client (Figure 15B, lanes 5 and 11), indicating that Hsp90, PPS, 
and p50cdc37 can bind to HRI molecules concomitantly. 
The PPS/HR! Interaction Is Only Partially Sensitive to Hsp90 Inhibition by 
Geldanamycin-Geldanamycin is a well-characterized inhibitor of Hsp90 function that 
acts by binding within the ATP-binding pocket of Hsp90 (183, 234). This binding 
enforces an alternative Hsp90 conformation (99) that does not support the formation of 
high-affinity interactions between Hsp90-p50cdcJ7 and Hsp90-dependent kinases, but has 
no effect on the basal interaction of p50cdc37 with Hsp90 (97,215). This binding also 
prevents the Hsp90-dependent recruitment of p50cdc37 to kinase-Hsp90 heterocomplexes, 
indicating that p50cdcJ7 binding to client kinases is regulated by Hsp90's ATP-dependent 
conformational switching (97,215). 
To test the hypothesis that PPS binding to HRI was similarly regulated by Hsp90, 
reactions containing Hsp90-dependent (His7)-[35S]HRI molecules, which were generated 
in the presence or absence of geldanamycin, were mixed with reactions containing 
FLAG-[35S]PP5. These reactions were incubated for 20 min, and HRI was then 
immunoadsorbed with anti-His-tag antibody resin. Immunoresins were washed with 
buffers lacking salt or with buffers containing 0.5 M NaCl, and the proteins that 
coadsorbed with HRI were then assessed by SDS-PAGE, autoradiography, and Western 
blotting. 
As previously described (97, 215),.geldanamycin inhibited the recruitment of 
p50cdc37 to kinase-chaperone heterocomplexes and compromised the typical salt-resistant 
interaction of Hsp90 with its client kinase (Figure 15A). In contrast, geldanamycin only 
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partially inhibited (-50% loss relative to untreated reactions) the association of PP5 with 
client HRI molecules. Furthermore, the binding of PP5 to HRI that did occur in both 
geldanamycin-treated and untreated reticulocyte lysate was not sensitive to high-salt 
washing. Importantly, PP5 remaine~ associated with HRI after high-salt washing of 
immunocomplexes isolated from geldanamycin-treated reticulocyte lysate, conditions 
which quantitatively remove Hsp90 from complexes with client HRI molecules. Thus, 
PP5's association with client kinases was quite different from that observed for the 
p50cdc37: PP5's association with HRI was not quantitatively dependent upon 
geldanamycin-inhibitable Hsp90 function, and PP5 remained tightly bound to HRI 
independent of this function. However, similar to the interaction of p50cdc37 with Hsp90 
(97,215), geldanamycin had no impact on the magnitude of the basal chaperone-
chaperone interaction.of PP5 with Hsp90 (Figure 15B, lanes 2 and 8 versus lanes 3 and 9). 
This novel finding was reexamined using the reciprocal approach: anti-FLAG 
antibody resin was used to immunoadsorb PP5 from reticulocyte lysate reactions 
containing or lacking FLAG-tagged PP5 (Figure 15B, +HRI). Again, PP5's association 
with HRI was decreased by approximately 50% in geldanamycin-treated reticulocyte 
lysate, but HRI remained bound to PP5 when immunocomplexes were washed with high 
salt (Figure 15B, lane 12), a condition which strips Hsp90 from HRI complexes (Figure 
15A, lane 5). Furthermore, the presence of geldanamycin blocked the association of 
p50cdc37 with kinase-chaperone heterocomplexes (Figure 15B, lanes 6 and 12). The 
observation that PP5 remains bound to HRI under conditions that strip Hsp90 from 
immunocomplexes indicates that their interaction is not mediated solely through their 
common association with Hsp90. 
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The HR! binding site is located in the TPR domain of PPS-Studies by different groups 
have already shown that the TPR domain of PPS is sufficient to mediate its interactions 
with multiple proteins (35, 42, 124, 138, 167). To test whether it similarly mediates the 
interaction between PPS and HRI, we constructed the isolated TPR domain in the 
bacterial expression vector and compared the HRI-binding activity of the purified 
recombinant TPR domain with that of the full-length PPS. Recombinant FLAG-tagged 
TPR domain was mixed with RRL containing newly synthesized [35S]HRI in the 
presence (Figure 16, lane 3) or absence (Lane 2) of geldanamycin. In parallel, full-length 
recombinant FLAG-PPS was assayed in the same fashion (Lanes 4 and 5). In addition, 
nonspecific binding of [35S]HRI was monitored by mixing the FLAG-protein-free buffer 
with the [35S]HRI-containing RRL (Lane 1). Reaction mixtures were subsequently 
immunoadsorbed to anti-FLAG resin and the coadsorption of [35S]HRI along with the 
endogenous Hsp90 were examined by autoradiography and Western blotting analyses. 
Consistent with its ability to bind to various proteins, the TPR domain of PPS was also 
sufficient to interact with HRI at a comparative level to that with the full-length PPS, 
indicating that the HRI-binding motif is located in the TPR domain of PPS. Supporting 
this hypothesis, we detected no HRI-binding activity in the catalytic domain of PPS 
which was obtained from the limited trypsinolysis (data not shown). Also, the TPR 
domain interacted with HRI in the same partial GA-sensitive fashion as did the full-
length PPS, further strengthening the hypothesis that the HRI-binding activity, possibly a 
combination of both Hsp90-dependent and independent events, exists solely in the TPR 
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Figure 16. Interaction of the TPR domain of PPS with HRI in reticulocyte lysate. 
[35S]HRI was synthesized in reticulocyte lysate in the presence (lanes 3 and 5) or absence 
(lanes 2 and 4) of 10 µg/mL geldanamycin for 30 min as described under "Materials and 
Methods" . Reaction mixtures containing [35S]HRI were then mixed at a 1: 1 ratio with 
normal heme-supplemented rabbit reticulocyte lysate containing (lanes 3 and 5) or 
lacking (lanes 2 and 4) 10 µg/mL geldanamycin with no additions (lane 1) or with the 
addition of 50 µg/mL purified recombinant wild type (His6)-FLAG-PP5 (lanes 4 and 5) 
or (His6)-FLAG-TPR of PPS (lanes 2 and 3). After a 20-min incubation, reactions were 
absorbed to anti-FLAG-tag antibody resin and anal~zed as described under "Materials 
and Methods". (His6)-FLAG-tagged PPS or TPR, [ 5S]HRI, and Hsp90 were visualized 
by Coomassie blue staining, autoradiography, and Western blotting, respectively. 
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no effect on the basal interaction of the TPR domain with Hsp90. Therefore, the TPR 
domain of PPS appears to mediate its interactions with both the partner Hsp90 and the 
putative client HRI. 
The Geldanamycin-resistant binding site of PP5 resides in the N-terminal heme-binding 
domain of HRI-Besides the two conserved kinase subdomains (N-terminal and C-terminal 
kinase lobes) HRI contains three additional unique regulatory domains/regions, an N-
terminal heme-binding domain (HBD), a kinase-insertion sequence (KIS) located 
between the two kinase lobes, and a short tail sequence at the C-terminus (Chapter II, 
Figure 7A) (32,192,247). We have previously located the Hsp90 binding sites to the 
HBD and N-lobe of HRI and that of p50cdc37 to the N-lobe only (Chapter II, Figure 7B 
and C). Considering the different behavior of PPS from p50cdc3l with regard to the GA-
sensitivity of their interactions with HRI, we hypothesize that they recognize 
topologically different regions of HRI. To test such a hypothesis, four different His-
tagged HRI domains ( except the C-terminal tail) were synthesized separately in RRL 
with concomitant radiolabeling with [35S]Met, which were then mixed with RRL 
containing [35S]-labeled FLAG-PPS. Reaction mixtures were subsequently 
immunoadorbed to anti-His resin, and the coadsorption of FLAG-[35S]PP5 as well as the 
endogenous Hsp90 and p50cdc37 were examined through autoradiography and Western 
blotting analyses, respectively (Figure 17 A). To assess the nonspecific binding of 
FLAG-[35S]PP5, blank RRL lacking TnT expression vector was mixed with the FLAG-
[35S]PP5-containing RRL, followed by the same immunoadsorption procedures. 
Consistent with our hypothesis, PPS interacted specifically with the HBD of HRI, 
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Figure 17. Interaction of the HRI domains with PPS in reticulocyte lysate. A) Individual 
His-tagged HRI domains (HBD, the heme-binding domain; NL, the N-terminal kinase 
lobe; KIS, the kinase insertion sequence; CL, the C-terminal kinase lobe) were 
synthesized and radiolabeled with [35S]-Met in separate TnT reticulocyte lysate reaction 
mixtures for 30 min as described under "Materials and Methods". They were then mixed 
at a 1: 1 ratio with TnT reticulocyte lysate containing newly synthesized FLAG-[35S]PPS 
and incubated for 20 min. A mock reticulocyte lysate reaction lacking the His-tagged 
HRI domain was similarly assembled and mixed with an equal volume of FLAG-
[35S]PPS-containing lysate to assess the nonspecific binding of coadsorbed proteins (lane 
1). Resulting lysate mixtures were subsequently immunoadsorbed to anti-His-tag 
antibody resin and analyzed as described under "Materials and Methods". [35S]-labeled 
His-tagged HRI domains and FLAG-PPS, coadsorbed endogenous Hsp90 and pSOcdc3? 
were visualized by autoradiography and Western blotting analyses, respectively. B) Wild 
type HRI, ~HBD (HRI lacking the N-terminal heme-binding domain) and HBD of HRI 
were synthesized and radiolabeled with [35S]-Met in separate TnT reticulocyte lysate 
reactions in the presence (even-numbered lanes) or absence (odd-numbered lanes) of 10 
µg/mL geldanamycin for 30 min as described under "Materials and Methods". Two 
mock reactions (without cDNA template) containing (lane 2) or lacking (lane 1) 
geldanamycin were also similarly assembled. They were then mixed at a 1: 1 ratio with 
TnT reticulocyte lysate synthesizing FLAG-[35S]PPS which contained (even-number 
lanes) or lacked (odd-numbered lanes) 10 µg/mL geldanamycin and incubated for 20 min. 
Resulting mixtures were subsequently immunoadsorbed to anti-His-tag antibody resin 
and analyzed as described under "Materials and Methods". Coadsorption of FLAG-
[35S]PPS and endogenous Hsp90 and pSOcdc3? was analyzed by autoradiography and 
Western blot, respectively. 
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but not with the N-lobe of HRI which is recognized by pSOcdc37, or KIS or C-lobe of HRI. 
Because Hsp90 binds to HBD (Chapter II, Figure 7), it is possible that the 
interaction between PPS and HBD is mediated indirectly through their common 
associations with Hsp90. To test this possibility, we treated the RRL reaction mixture 
containing (His6)-HBD and FLAG-[35S]PPS with geldanamycin, immunoadsorbed it to 
anti-His resin in the presence of high salt, and examined the coadsorption of FLAG-
[35S]PPS and endogenous Hsp90 through autoradiography and Western blotting analyses, 
respectively (Figure 17B, lanes 3 and 4). As the controls, wild type HRI (Lanes 7 and 8) 
and a deletion mutant lacking the HBD (~HBD) (Lanes Sand 6) were also analyzed for 
their abilities to bind FLAG-[35S]PPS under the same conditions. Nonspecific binding of 
FLAG-[35S]PPS was similarly assessed as described in the previous experiments. 
Consistent with our early observations (97, 99), geldanamycin treatment in conjunction 
with high salt washing of the immunopellet almost completely stripped Hsp90 from the 
wild type HRI and the ~HBD mutant (Lanes 6 and 8 versus Sand 7, respectively). Again, 
the same partial disruption of the interaction of PPS with HRI by geldanamycin was also 
observed. However, surprisingly, we also detected specific interactions between PPS and 
the ~HBD mutant of HRI, which, lacking the HBD, was predicted to be incapable of 
binding PPS. Moreover, its interaction with PPS exhibited the same partial sensitiveness 
to geldanamycin treatment. Therefore, contrary to our hypothesis, additional PPS-
binding site(s) exist(s) in HRI outside the HBD. However, based on our failure to 
identify such binding site(s) in any of the remaining individual domains of HRI, it seems 
likely that it (they) is (are) formed between adjacent domains, none of which alone is 
sufficient to mediate the interaction. As to HBD, high salt wash alone seemed to be able 
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to remove all the Hsp90 molecules from it irrespective of geldanamycin treatment. 
However, although no detectable Hsp90 was observed in association with HBD under 
high salt wash, a specific interaction of PP5 with the HBD was still detected and, most 
importantly geldanamycin treatment had no effect on the magnitude of such an 
interaction. Therefore, our data suggested that HRI is recognized by PP5 at multiple sites 
with the HBD being the one that is resistant to geldanamycin and thus the nucleotide-
regulated conformational switching of Hsp90. This observation helps to explain the 
partial disruption of the interaction between HRI and PP5 by geldanamycin as opposed to 
the complete abolishment of that between p50cdc37 and HRI (Lanes 6 and 8 versus 5 and 7, 
respectively). However, the fact that geldanamycin failed to completely disrupt the 
interaction between PP5 and ~HBD also brought up the possibility that more than one 
type of interactions exist between PP5 and its additional binding sites in HRI, those 
modulated, and not modulated, by the nucleotide-regulated conformational switching of 
Hsp90. 
The Interaction of PPS with HR! Requires the Association of PPS with Hsp90-The 
interaction of PP5 with Hsp90 is modulated through the interaction of conserved 
positively charged amino acid side chains with the conserved EEVD motif at the C-
terminus of Hsp90 (Chapter V, Figure 36) (194, 204). To determine whether the 
interaction of PP5 with HRI is mediated through its association with Hsp90, we examined 
whether PP5 containing mutations of these positively charged amino acid residues, 
PP5/K97A or PP5/Rl01A, that do not bind Hsp90 could interact with newly synthesized 
HRI. Purified recombinant His-tagged wild-type PP5 or PP5 mutants were added to 
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hemin-supplemented reticulocyte lysate and mixed with lysate containing newly 
synthesized HRI in the presence or absence of geldanamycin. While HRI was specifically 
coadsorbed from reticulocyte lysate containing wild-type PP5, little HRI was coadsorbed 
above the nonspecific binding control from lysate containing the PP5/K97 A or 
PP5/R101A mutants (Figure 18). Again geldanamycin reduced the amount of HRI 
coadsorbing with PP5 by approximately 50%. In the presence of geldanamycin, the 
binding of HRI to the PP5 mutants was reduced to the level of the nonspecific 
background. The lack of interaction of the PP5 mutants with HRI further indicates that 
the binding of PP5 to HRI is specific and supports the notion that Hsp90 is responsible 
for targeting PP5 to maturing populations of HRI molecules. 
Impact of PPS Inhibitors: Okadaic Acid and Nodularin Induce Hyperphosphorylation of 
Transformed HR!-To examine the potential significance of the association of PP5 with 
immature/inactive HRI molecules in reticulocyte lysate, the effects of a number of 
phosphatase inhibitors on the Hsp90-dependent maturation, transformation, and 
activation of HRI were examined. (His7)-[35S]HRI was synthesized in reticulocyte lysate 
and subsequently matured in hemin-supplemented or heme-deficient lysate containing 
okadaic acid [PP5, ICso = 7 nM (16)]. Okadaic acid had no effect on the electrophoretic 
mobility or kinase activity of HRI matured in hemin-supplemented lysate [ wherein HRI 
does not undergo Hsp90-dependent transformation (not shown)]. As described previously 
(215, 246, 248), transfer of newly synthesized (His7)-[35S]HRI to heme-deficient 
reiculocyte lysate led to the generation of active HRI kinase molecules (TR), which 
79 





+ + + + GA 
WT K97A R101A 
Figure 18. Effect of mutations that block the binding of PPS to Hsp90 on the interaction 
of PPS with HRI. [35S]HRI was synthesized in reticulocyte lysate in the presence (lanes 2, 
4, 6, and 8) or absence (lanes 1, 3, 5, and 7) of 10 µg/mL geldanamycin for 30 min, as 
described under "Materials and Methods". Reaction mixtures containing [35S]HRI were 
then mixed at a 1: 1 ratio with normal heme-supplemented rabbit reticulocyte lysate 
containing ( even-numbered lanes) or lacking ( odd-numbered lanes) 10 µg/mL 
geldanamycin with no additions (lanes 1 and 2) or with the addition of 50 µg/mL purified 
recombinant wild-type (His6)-PP5 (lanes 3 and 4), (His6)-PP5/K97 A mutant (lanes 5 and 
6), or (His6)-PP5/R101A mutant (lanes 7 and 8). After a 20 min incubation, reactions 
were absorbed to anti-His-tag antibody resin and analyzed as described under "Materials 
and Methods". (His6)-PP5 proteins, [35S]HRI, and Hsp90 were visualized by Coomassie 
blue staining, autoradiography, and Western blotting, respectively. HC: antibody heavy 
chain. 
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exhibited retarded electrophoretic mobility relative to mature-competent HRI molecules 
(MC; Figure 19A, lane 2). 
When compared to the activity of HRI that was matured and activated in control 
reactions, maturation and activation of HRI in reticulocyte lysate containing 500 nM 
okadaic acid led to the generation of HRI populations with increased kinase activity (2-
fold more active than the control) (Figure 19A, lane 3). Incubation in the presence of 
okadaic acid also resulted in the production of HRI molecules with electrophoretic 
mobilities even slower than those typical of the transformation process, suggesting that 
the transformed HRI had become hyperphosphorylated (HP). Consistent with previous 
reports indicating that these mobility shifts are due to phosphorylation events (9, 137), 
treatment of samples with purified alkaline phosphatase generated HRI populations with 
fast electrophoretic mobilities similar to mature-competent HRI (not shown). 
Quantification of the amount of [35S]HRI present in each lane confirmed that equivalent 
amounts of HRI were recovered from each reaction mixture. Thus, the observed increase 
in the phosphorylation of eIF2a represented an increase in the specific kinase activity of 
HRI. 
Since HRI's dependence on Hsp90 chaperone machinery is conditional with 
respect to HRI's activation status, we next examined the impact of okadaic acid when 
applied to HRI populations 45 min after their Hsp90-dependent maturation and activation. 
In contrast to its application concomitant with maturation/activation, addition of okadaic 
acid after HRI maturation/activation did not lead to the enhanced activation of HRI's 
eIF2a kinase activity (Figure 19A, lane 4). In fact, addition of okadaic acid had a slight 
inhibitory effect on the kinase activity of preactivated HRI populations. In addition, 
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Figure 19. Effect of serine-threonine protein phosphatase inhibitors, okadaic acid, 
nodularin, and fostriecin, on HRI transformation and activation in heme-deficient 
reticulocyte lysate. (His7 )-[35S]HRI was synthesized in reticulocyte lysate as described 
under "Materials and Methods". Reactions were then transferred to 7 volumes ofheme-
deficient normal rabbit reticulocyte lysate mixtures supplemented with (A) 500 nM 
okadaic acid-7,10,24,28-tetraacetate (inactive control for okadaic acid)(-, lane 2), 500 
nM okadiac acid (OA, lane 3), or no drug (lane 4) or with (B) 500 nM nodularin (Nod, 
lane 6), 34 µM fostriecin (Fos, lane 8), or equivalent amounts ofH20 as their vehicle 
controls (lanes 5 and 7). The same volume of reticulocyte lysate containing no cDNA 
template was similarly transferred to heme-deficient lysate as the control for any 
nonspecific binding of lysate protein kinase activities (A, lane 1). After 45 min of 
incubation, 500 nM okadaic acid (A, OA, lane 4) or 500 nM nodularin (B, Nod, lane 7) 
was added to the maturation mixture lacking the initial supplementation of drugs, and the 
incubation was continued for an additional 20 min. (His7 )-[35S]HRI was immunoadsorbed 
with anti-His-tag antibody resin, assayed for eIF2a kinase activity, and analyzed as 
described under "Materials and Methods". The amount of [32P]eIF2a was quantified by 
scanning densitometry and expressed as optical density OD*mm2 (numbers below the 
eIF2a panel). HP: hyperphosphorylated form ofHRI; TR: transformed form ofHRI; MC: 
mature-competent form of HRI. 
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almost no HRI with the very slow electrophoretic mobility diagnostic of HRI's 
hyperphosphorylation was observed when okadaic acid was added to reticulocyte lysate 
after most of the HRI had undergone its Hsp90-dependent transformation process. 
Nodularin (104, 105), a water-soluble phosphatase inhibitor with a structure similar to 
microcystin [ICso for PPS of 2.5 nm (16)], had effects comparable to those of okadaic 
acid on HRI's maturation/transformation and activity (Figure 19B, lanes 5-7). 
The effect of a third phosphatase inhibitor, fostriecin, was also examined. 
Maturational reaction mixes were incubated in the presence of 34 µM fostriecin, a 
concentration which is inhibitory to PP2A (ICso = 3.2 nM) but is well below its IC50 for 
PPl (130 µM) and PPS (700 µM) (16,253). Addition of fostriecin caused only a slight 
stimulation of HRI's kinase activity and had little effect on HRI's electrophoretic mobility 
(Figure 19B, lane 8). This result suggested that PP2A did not mediate the effects of 
phosphatase inhibitors on HRI maturation/activation; nonetheless, PPl, as well as PPS, 
remained as a candidate phosphatase. 
Taken together, the experiments described in Figure 19 indicated that the specific 
activity of HRI was enhanced only when phosphatase inhibitors were applied 
concomitant with Hsp90-dependent activation/maturation events. This concomitance 
implied that the compounds were acting at, or upon, this stage of HRI 
maturation/activation. To support this conclusion, we examined the impact of preventing 
HRI maturation/activation by the concurrent addition of the Hsp90 inhibitor 
geldanamycin with okadaic acid. Consistent with the results seen in Figure 19, HRI 
matured/activated in the presence of okadaic acid was 5-fold more active than HRI 
matured in the presence of okadaic acid-7, 10,24,28-tetraacetate, an inactive analogue of 
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Figure 20. Effect of geldanamycin on the stimulation ofHRI activation by okadaic acid. 
(His7)-[35S]HRI was synthesized in rabbit reticulocyte lysate as described under 
"Materials and Methods". (His7)-[35S]HRI was then transferred to 7 volumes ofheme-
deficient normal rabbit reticulocyte lysate mixtures supplemented with DMSO (vehicle 
control, lane 2), 10 µg/mL geldanamycin (GA, lane 3), 500 nM okadaic acid (OA, lane 
4), or 10 µg/mL GA in combination with 500 nM okadaic acid (OA, GA, lane 5). An 
equivalent amount of reticulocyte lysate containing no cDNA template was similarly 
transferred to a heme-deficient lysate mixture containing no drug as the control for 
nonspecific binding of any reticulocyte lysate kinase activities (lane 1). After 60 min of 
incubation, (His7)-[35S]HRI was immunoadsorbed with anti-His-tag antibody resin, 
assayed for eIF2a kinase activity, and analyzed as described under "Materials and 
Methods". The amount of [32P]eIF2a was quantified by scanning densitometry of 
autoradiograms and expressed as optical density OD*mm2 (numbers below the eIF2a 
panel). HP: hyperphosphorylated form ofHRI; TR: transformed form ofHRI; MC: 
mature-competent form ofHRI. 
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okadaic acid (Figure 20). However, HRI synthesized in the presence of geldanamycin 
was inactive irrespective of okadaic acid application. Thus, Hsp90 function was a 
prerequisite for the coincident stimulation of HRI kinase activity induced by okadaic acid. 
Polyunsaturated Fatty Acids Inhibit HR! Transformation and Activation in a Dose-
Dependent Fashion-To further test the hypothesis that PPS function impacted the Hsp90-
dependent maturation/activation of HRI, we examined the effect of arachidonic acid on 
this process. Arachidonic acid is a polyunsaturated fatty acid that stimulates the 
phosphatase activity of PPS in vitro (36, 225). Application of this compound during HRI 
maturation/activation led to the generation of HRI molecules that were deficient in kinase 
activity (Figure 21A, lanes 3-7) relative to those produced in control reactions (Figure 
21A, lane 2). This inhibition was dose-dependent: increasingly higher levels of 
arachidonic acid led to increasingly greater degrees of HRI inhibition. Like the effects 
seen for phosphatase inhibitors (Figure 19), the effects of the phosphatase activator 
arachidonic acid depended on HRI maturation/activation status: application of 
arachidonic acid after 45 min of HRI maturation/activation had only minor effects on the 
activity of HRI (Figure 21A, lanes 9-13). Additionally, the electrophoretic gel shift 
diagnostic of HRI transformation was inhibited by arachidonic acid, an effect consistent 
with its effect on kinase activity. Equivalent results were seen with linoleic acid, another 
polyunsaturated fatty acid activator of PPS (not shown). In contrast, stearic acid, a 
saturated fatty acid that has little capacity to stimulate PP5's activity in vitro (36, 225), 
had little inhibitory effect on HRI's transformation and activation compared to similar 
concentrations of arachidonic or linoleic acid (Figure 21B). Thus, the impact of these 
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Figure 21. Effect of arachidonic acid (A) and stearic acid (B) on HRI transformation and 
activation in heme-deficient reticulocyte lysate. (His7)-[35S]HRI was synthesized in 
reticulocyte lysate as described under "Materials and Methods" and then transferred to 7 
volumes of heme-deficient normal rabbit reticulocyte lysate mixtures supplemented with 
50, 100,200,400, or 600 µM arachidonic acid (A, lanes 3-7), an equivalent amount of 
95% ethanol as the vehicle control (A, lane 2), 100, 200, or 400 µM stearic acid (B, lanes 
2 to 4), or an equivalent amount of methanol as the vehicle control (B, lane 1). (His7 )-
[35S]HRI was also incubated in a duplicate set of heme-deficient reticulocyte lysate 
mixtures lacking the initial supplementation of fatty acids (A, lanes 8-13), to which 50, 
100, 200, 400, or 600 µM arachidonic acid (lanes 9-13) or 95% ethanol (lane 8) was 
added after 45 min of maturation, followed by incubation for another 20 min. An 
equivalent amount of reticulocyte lysate containing no cDNA template was similarly 
transferred to the heme-deficient reticulocyte lysate mixture containing no drug as the 
control for nonspecific binding of any protein kinase activities (A, lane 1). (His7)-
[35S]HRI was immunoadsorbed with anti-His-tag antibody resin, assayed for eIF2a 
kinase activity, and analyzed as described under "Materials and Methods". The amount of 
[32P]eIF2a was quantified by scanning densitometry and expressed as optical density 
OD*mm2 (numbers below the eIF2a panel). [35S]HRI*: transformed form of HRI; 
[35S]HRI: mature-competent form ofHRI. 
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fatty acid compounds was specific to the compound's structures rather than representing a 
nonspecific property of fatty acids per se. 
Polyunsaturated Fatty Acids Disrupt the HRI!Hsp90/p50cdc3l Heterocomplex in a Dose-
Dependent Fashion-Since polyunsaturated fatty acids inhibited the transformation and 
activation of HRI, we examined their effect on the composition of Hsp90-kinase 
heterocomplexes. (His7)-[35S]HRI and FLAG-[35S]PP5 were synthesized in separate 
heme-replete reticulocyte lysate, after which they were mixed and various concentrations 
of fatty acids were added. The reaction mixtures were incubated for an additional 20 min, 
and the composition of chaperone-HR! complexes was subsequently characterized in 
coadsorption assays (Figure 22). 
Addition of arachidonic or linoleic acid to lysate did not result in disruption of the 
basal (no client) interaction of p50cdc3l with Hsp90 (not shown). However, HRI 
heterocomplexes isolated from reticulocyte lysate treated with arachidonic or linoleic 
acid showed compromised association of Hsp90 and p50cdc3l with immature/mature-
competent HRI molecules (Figure 22A, B). This effect was dose-dependent: increasingly 
higher levels of arachidonic or linoleic acid caused increasingly greater deficiencies in 
chaperone association (Figure 22A, B). In contrast, arachidonic and linoleic acid 
treatments had little effect on the interaction of PPS with HRI. We noted, however, that 
high concentrations of both arachidonic and linoleic acid resulted in reproducible 
decreases in levels of (His7)-[35S]HRI recovered from rabbit reticulocyte lysate. To 
quantify chaperone losses in a manner that was compensatory for this loss of HRI, 
protein levels were quantified by densitometry, and the amounts of (His7)-[35S]HRI, 
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Figure 22. Effect of polyunsaturated fatty acids on the integrity of the 
HRI/Hsp90/p50cdc37 ;pp5 heterocomplex. (His7 )-[35S]HRI and FLAG-tagged [35S]PP5 
were synthesized in reticulocyte lysate mixtures as described under "Materials and 
Methods". The reactions were then mixed in a 1:1 ratio and incubated in the presence of 
100, 200, 400, or 800 µM arachidonic acid (A, AA, lanes 3-6), linoleic acid (B, LA, 
lanes 2-5), stearic acid (C, SA, lanes 2-5), or their respective vehicle controls [A, 95% 
ethanol (lane 2); B, H20 (lane 1); C, methanol (lane 1)]. The reticuloc~e lysate mixture 
lacking the (His7)-HRI template was similarly incubated with FLAG-[ 5S]PP5-containing 
lysate as the control for nonspecific binding (A, lane 1). Reaction mixtures were 
immunoadsorbed with anti-His-ta§ antibody resin and analyzed as described under 
"Materials and Methods". (His7)-[ 5S]HRI and coadsorbed FLAG-[35S]PP5, and 
coadsorbed Hsp90 and p50cdc37, were visualized by autoradiography and Western blotting, 
respectively. The amount of each protein was quantified by scanning densitometry and 
expressed as OD*mm2 (numbers above each panel). 
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Hsp90, p50cdc37, and PP5 are presented in Figure 22. The data indicate that the relative 
levels of Hsp90 and p50cdc37, but not PP5, associated with HRI were compromised and 
declined in concert in arachidonic or linoleic acid treated reticulocyte lysate. Finally, 
control experiments using stearic acid confirmed the specificity of the effect: this 
saturated fatty acid did not disrupt the association of Hsp90 and p50cdc37 with HRI 
(Figure 22C). 
Discussion: 
Work done in numerous laboratories over the past 2 decades has firmly 
established that phosphorylation plays an essential role in regulating the function of HRI. 
Nevertheless, the question of whether the function of HRI might be regulated by 
reversible phosphorylation has remained unclear. In this report, we present for the first 
time biochemical and pharmacological evidence that the Hsp90-dependent transformation 
and activation of HRI in response to heme-deficiency are regulated by the activity of a 
phosphatase, and the data indicate that the phosphatase is likely PP5. 
In support of this hypothesis, we find that PP5 is an Hsp90 cohort that occurs in 
complexes with the Hsp90-dependent kinase HRI. The interaction of PP5 with HRI is 
. mediated by its TPR domain and dependent upon Hsp90, as mutations in PP5 that inhibit 
its ability to bind Hsp90 ( 194, 204) also block the interaction of PP5 with HRI (Figure 
18). This effect suggests that Hsp90 plays a direct role in recruiting PP5 to HRI 
heterocomplexes and would be consistent with PP5 's direct association with Hsp90 in the 
absence of the Hsp90 client. 
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The interaction of PPS with HRI occurs in a manner that is distinct from that 
described previously for other Hsp90 cochaperones (97, 215), as the binding of PPS 
molecules to HRI is only partially (50%) inhibited by geldanamycin. The observation that 
PPS coadsorbs with HRI in the presence of geldanamycin, despite the quantitative high-
salt washing of Hsp90 from HRI/PP5 complexes, indicates that PPS can interact directly 
with HRI. Such a direct binding site seems to be located in the unique regulatory heme-
binding domain of HRI as it remains stably bound to PPS even when its associated Hsp90 
is completely removed by high salt wash (Fig. 17B). Geldanamycin has no effect on the 
magnitude of such an interaction, indicating that the binding affinity of PPS for the heme-
binding domain of HRI is not modulated by the nucleotide-regulated conformational 
switching of Hsp90. However, additional binding site(s) of PPS in HRI seem(s) to exist 
as indicated by the observation that the deletion mutant of HRI (LiHBD) which lacks the 
entire heme-binding domain still interacts with PPS. Like its interaction with the full-
length HRI, PPS binds to the LiHBD mutant in the same partial geldanamycin-sensitive 
fashion, indicating that even within regions outside the heme-binding domain both direct 
and indirect binding sites for PPS exist in HRI. Interestingly, these binding sites do not 
seem to be localized in any of the remaining single domains of HRI as no specific 
interactions were observed between them and PPS. Thus, it strongly indicates that they 
are formed instead topologically by adjacent domains of HRI. Nevertheless, the ability 
of mutations that inhibit the interaction of PPS with Hsp90 to block the binding of PPS to 
HRI indicates that the binding of PPS to HRI is still modulated by Hsp90. Taken together, 
these results suggest that the interaction of Hsp90 with PPS is required for the HRI 
binding site of PPS to become accessible and that the binding of PPS to HRI can be 
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initiated through the weak salt-labile interaction that occurs between Hsp90 and HRI in 
the presence of geldanamycin. However, it is clear that the interaction of PPS with HRI 
maturation intermediates differs from that of the Hsp90-regulated cohorts p50cdc37 and 
p23: unlike the binding of p50cdc3l and p23 to Hsp90.,dependent kinases (97, 215), the 
binding of PPS to HRI is not quantitatively dependent upon Hsp90's nucleotide-
dependent conformational switching, and it is likely to result from the multi-site 
recognition and interactions of PPS with HRI. 
Data presented in this paper indicate that PPS and p50cdc37 can occur on the same 
Hsp90 chaperone machinery and that they can coexist in chaperone-client 
heterocomplexes. This conclusion derives from the observation that these Hsp90 cohorts 
co-immunoadsorb under various experimental conditions (Figure 15). Furthermore, 
expression of the Hsp90-client HRI enhances the association of p50cdc37 with PPS 
immunocomplexes (Figure 15). The description here of concomitant binding of PPS and 
p50cdc3l to Hsp90 and Hsp90-client heterocomplexes is consistent with our recent 
demonstration that p50cdc37 and the immunophilin FKBP52 form a novel four-component 
chaperone machine (97). However, the coincident occurrence of p50cdc37 on Hsp90 
complexes with the TPR-containing cohorts FKBP52 and PPS is inconsistent with studies 
that suggest that these components compete for adjacent docking sites on Hsp90 (170, 
171, 223). As we have discussed previously for the four-component Hsp90-p50cdc37_ 
FKBP52-p23 machine (97), the discrepancy between our findings and in vitro 
competition assays may reflect the existence of a dimeric Hsp90 machine (28, 142, 156, 
176, 182) in which each Hsp90 subunit binds a different Hsp90 cohort. 
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Data presented here indicate that one (or more) protein phosphatase(s) has (have) 
the potential to act upon HRI's Hsp90-dependent activation process. This conclusion 
derives from the finding that application of the phosphatase inhibitors okadaic acid and 
nodularin to HRI maturation/activation reactions leads to the generation of hyperactive 
HRI populations (Figure 19). Consistent with this finding, application of compounds that 
activate PP5 in vitro (arachidonic and linoleic acid) leads to the generation of hypoactive 
HRI populations (Figure 21A). The identities of these agents and their effective 
concentrations are consistent with the pharmacological profile of PP5 (16, 36,225). 
While the concentration of free arachidonate has been reported to reach 180 µM during 
brain ischemia (168), we feel that it would be premature to propose that the 
supraphysiological concentrations of unsaturated fatty acids used in this study act 
similarly in vivo. In fact, it has been postulated that the high micromolar concentration of 
polyunsaturated fatty acids required to activate PP5 in vitro is due to their poor solubility 
in aqueous solution, and the inability of saturated long chain fatty acids to do so is a 
result of their even lower solubility under the same condition. This speculation has 
recently been confirmed by Ramsey et al as the more water-soluble derivatives of the 
long chain fatty acids, their CoA-esters, were able to activate PP5 at physiological 
concentrations. More importantly, both saturated and unsaturated fatty acyl-CoA esters 
were able to activate PP5 at similar concentrations (193). Therefore, the inability of the 
control stearic acid to have the same effect on HRI phosphorylation level and kinase 
activity as arachidonic and linoleic acid may simply result from the extremely low 
concentration of soluble stearic acid in rabbit reticulocyte lysate. Future experiments 
employing the putative physiological activators of PP5, the fatty acyl-CoA esters, as well 
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as the appropriate controls should confirm our data presented here. Nonetheless, 
utilization of these agents enables us to manipulate PPS activity in reticulocyte lysate-
based assays, and overcomes many of the limitations inherent to the study of PPS, 
notably, PPS's autoinhibition (36, 121, 225) and the potential requisite roles of trans-
acting PPS modulators, partners, or competitors. In addition, supporting our hypothesis 
on the functional regulation of HRI by PPS, we do note that addition of the recombinant 
PPS catalytic domain to HRI transformation reactions has effects qualitatively similar to 
those of fatty acid stimulators: resultant HRI populations have decreased kinase activity. 
The phosphatase(s) responsible for these effects can only impact HRI function 
concomitant with HRI maturation/transformation processes: the pharmacological 
response of HRI to phosphatase inhibition/activation is wholly dependent upon the timing 
drug application (Figures 19 and 21). Thus, we propose two models for the action of PPS 
on HRI maturation. 
In the first model, PPS may dephosphorylate HRI during its maturation/activation. 
This interpretation is supported by the finding that HRI with retarded electrophoretic 
mobility can be detected in Hsp90 heterocomplexes when the phophatase inhibitor NaF 
was present during the immunoadsorption protocol. Furthermore, this interpretation is 
consistent with our recent demonstration that phosphorylation of Hsp90-dependent 
kinases is one possible mechanism for generating Hsp90-independent kinase populations. 
For the Src-family kinases, Lek and Hck, point mutations of their C-terminal regulatory 
tyrosines generate kinase populations which show continuous requirements for Hsp90 
function (12, 98, 213); however, their wild-type counterparts do not show such a 
continuous requirement and, instead, flow vectorially from Hsp90-dependent to Hsp90-
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independent forms. Similarly, HRI is released from its continuous requirement for Hsp90 
function by conditions that activate its kinase activity, and release correlates with kinase 
autophosphorylation (215,246). Furthermore, Hsp90 function is required for activation 
and phosphorylation of Mos, but once activated, Mos no longer requires Hsp90 to 
support its function (75). However, while circumstantial evidence suggests that kinase 
phosphorylation may represent an important determinant of kinase maturity and Hsp90 
independence, direct correlations between Hsp90 dependence and specific kinase 
phosphorylation sites have not yet been documented. Nonetheless, these evolving models 
describing Hsp90's support of protein structure suggest that phosphorylation is an 
important determinant of Hsp90 dependence, and the physical and functional 
involvement of PPS in these processes is consistent with these models. In this model of 
HRI dephosphorylation coincident with the maturation/activation process, PPS might 
modulate HRI's response to activating stimuli. Such modulation could be postulated to be 
an important tuning of translational repression given HRI's action on eIF2a and the 
potency of translational inhibition by this mechanism. 
As an alternative model, PPS may act directly upon Hsp90-chaperone machinery 
to regulate its function(s). While Hsp90 is often described as the "signal-transduction 
chaperone", due to its apparent specificity for signal transduction proteins, and the Hsp90 
chaperone machinery is often described as "regulating" the function of its clients, few 
characterizations have attempted to discriminate between housekeeping roles for Hsp90 
versus regulated roles for Hsp90 in signal transduction. Regarding this last possibility, 
our data could result from the direct action of PPS on Hsp90 and/or its partner 
cochaperones. Consistent with this model, Hsp90 (65, 109, 132, 133,252,255), p50cdc37 
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(21), p60/Hop (131, 135), and FKBP52 (157) are phosphoproteins, and recent studies 
suggest that the phosphorylation status of Hsp90 machinery may be linked to its 
chaperoning function (20, 106, 131, 135, 154, 157,239,268). Thus, PPS might regulate 
Hsp90 function by modulating the phosphorylation status of one or more components of 
the Hsp90 machine. Models postulating regulated Hsp90 function are further supported 
by the apparent specificity of cohorts for individual Hsp90 clients (56, 199). This 
evidence for modulation of Hsp90 function is consistent with the finding that PPS 
overexpression negatively regulates glucocorticoid-mediated growth arrest in vivo (272) 
and our observation that PPS plays a negative role in HRI's Hsp90-dependent 
maturation/activation. 
This negative role for PPS in HRI's maturation/activation contrasts sharply with 
the previously described positive role that another Hsp90 partner protein p50cdc37 plays 
during this process (215). Thus, PPS and p50cdc37 have opposing influences upon the 
Hsp90-dependent process of HRI maturation and activation, yet both can coexist in 
Hsp90-client kinase complexes. Within the context of regulated Hsp90 function, it is 
reasonable to speculate that these opposing effects must somehow be coordinated during 
proper execution of Hsp90 function in vivo. Furthermore, it is likely that coordination of 
the opposing effects of these two proteins plays a role in the regulation of the activity of 
other Hsp90-dependent signal transduction proteins in addition to HRI. 
Irrespective of the finer details by which PPS may act, our data indicate that this 
Hsp90 partner protein plays a negative role in regulating the activity of an Hsp90 client 
during its Hsp90-dependent maturational process. The finding that PPS down-regulates 
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an Hsp90-dependent process supports models for regulated Hsp90 function and describes 
a novel potential substrate for PP5 function in vivo. 
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CHAPTER IV 
Domain mapping and functional dissection of p50cdc37 
Introduction: 
Originally identified in budding yeast as one of the ST ART mutants arrested at 
the G 1 phase (7 4, 197), the protein product of CDC3 7 gene in different species has been 
under extensive genetic and biochemical investigations over the past two decades. Its 
ability to control the cell cycle in yeast lies, at least partially on the fact that it · 
functionally regulates both the stability and cyclin-binding affinity of cdc28, one of the 
key cyclin-dependent protein kinases (CDK) involved in cell cycle progression in 
eukaryotic cells through some unknown mechanism (71, 86). Along the same line of 
being important in cell cycle regulation in yeast, the CDC37 gene product has also been 
found to genetically interact with several other kinases including Mps 1, a kinase required 
for spindle pole body duplication (214), Kin28, a putative CDK member of the p34cdc2 
family (251) and casein kinase II, an ubiquitous kinase also required for cell cycle 
progression in yeast (87) which were compromised in either their levels or activities or 
both in yeast strains with cdc37 mutations. In Drosophila, genetic studies put a 
functional link between CDC37 and the sevenless receptor tyrosine kinase, suggesting 
that it is involved in mitogen-activated protein kinase (MAPK) pathway as well (48). 
Unlike yeast and Drosophila, the vertebrate homolog of Cdc37 has long been 
known as the 50-kDa phospho-protein associated with the viral oncogenic protein kinase 
pp6ov-src in the same complex with the 90-kDa heat shock protein Hsp90 (20, 22, 169, 
256) before its identity was revealed in recent years (51, 175,235). Subsequent studies 
have functionally linked it to a wide range of proteins most of which belong to the 
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eukaryotic protein kinase family. Examples include cyclin-dependent protein kinases, 
such as: CDK4 (51, 129,235), CDK6 (129, 139) and CDK9 (69, 166); members of Src 
tyrosine kinase family such as pp60v-src, Lek and Hck (59, 97,175,211); casein kinase II 
(87, 122); Raf-1 (89, 245); mitogen-activated protein kinase MOK (158); heme-regulated 
eIF2a kinase HRI (215); IKB kinase IKK (29); and most recently Akt (8). Significantly, 
all these kinases are known clients of Hsp90 which coexists in all the Cdc37 /kinase 
heterocomplexes. As a result, it is dubbed the "kinase-specific cohort of Hsp90". 
However, with its new client proteins emerging rapidly, it appears that the substrate 
specificity of Cdc37 may be broader than was envisioned previously. Cdc37 has recently 
been found in association with the androgen receptor (77, 195) and reverse transcriptase 
(254) in mammalian systems both of which depend on the functional Cdc37 for their 
activities. Nonetheless, protein kinases still represent the vast majority of Cdc37 clients. 
Working closely together, mammalian Cdc37 interacts directly with its partner 
Hsp90. This binding site has been assigned to the C-terminal half of the human Cdc37 
(165-378) resulting from an arbitrary bisection (215). The same bisection also generated 
an N-terminal half of Cdc37 (1-164) which binds to several client proteins independently 
of Hsp90 (89,215,254). Therefore, mammalian Cdc37 seems to possess direct binding 
sites for the clients and partner Hsp90 at the N-terminal and C-terminal regions, 
respectively. Although it seems to agree with the model in which Cdc37 functions as the 
"kinase-targeting subunit of Hsp90" (89, 235), studies in our and other labs argue against 
such a simple role of Cdc37 as being the passive "tethering" adaptor between Hsp90 and 
the clients. First, under low ionic condition, geldanamycin (GA), an Hsp90-specific 
inhibitor, abolished the binding of Cdc37 to its client HRI completely while leaving that 
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of Hsp90 to HRI intact (97), indicating that 1) Hsp90 has the ability to bind client kinases 
independently of Cdc37 and 2) rather than rigidly bridging between Hsp90 and the 
clients, Cdc37 undergoes conformational change induced by nucleotide-modulated 
conformational switching of Hsp90 that affects its binding affinity for the clients. 
Second, overexpression of the N-terminal half of Cdc37, which is unable to bind Hsp90, 
similarly enhanced the binding of Hsp90 to Hck, although to a lesser extent than does the 
full length Cdc37, thus indicating that Cdc37, rather than simply recruiting Hsp90 to the 
clients, actually alters the clients allosterically in preparation for their high affinity 
binding to Hsp90 (211). Recently, a novel domain structure of mammalian Cdc37 has 
been proposed by Scholz et al based primarily on sequence alignment analyses. In 
contrast to the arbitrary bisection, they predicted a three-domain structure for the 
mammalian Cdc37 and showed that its middle domain (145-264 of human Cdc37) bears 
the Hsp90-binding site. However, no specific functions of the N-terminal and C-terminal 
domains of Cdc37 were suggested or identified (212). 
Contrary to its mammalian homologues, yeast Cdc37 has proven contradictory 
regarding its ability to bind Hsp90 and the clients. Although Abbas-Terki et al. recently 
reported the detection of specific associations of yeast Cdc37 with Hsp90 and its putative 
client Stell (1), most attempts by other groups failed to observe such interactions (71, 
86). It thus indicates a somewhat different mechanism by which the yeast Cdc37 
functions in vivo relative to its mammalian homologues. In addition, the difference may 
also be expected based on the distant relationship of the yeast Cdc37 to its mammalian 
homologues at the amino acid sequence level. Yeast Cdc37 shares only 19% overall 
identity with its mammalian homologues, from which it differs considerably throughout 
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almost the entire sequence including the region that mediates Hsp90-binding by its 
corresponding mammalian homologues. Interestingly, the most conserved residues of 
Cdc37 are located at the N-terminal 30 or so residues, which are over 50% identical and 
70% conserved among its homologues from yeast to human, suggesting that they are 
functionally important for some evolutionarily conserved activity of Cdc37 (51,235). 
Consistent with such a hypothesis, previous studies in our lab have shown that the N-
terrninal eight amino acids of human Cdc37 are essential for its HRI-binding activity 
(215). 
In order to better understand Cdc37 regarding its structure-function relationship, 
we attempted to unveil its true domain architecture, upon which further biochemical 
characterizations can be carried out. Utilizing the conventional limited protease-nicking 
technique in conjunction with the MALDI-TOF mass spectrometry analysis, we revealed 
a novel three-domain structure of Cdc37 that is slightly different from that proposed by 
Schulz et al (212). Biochemical characterizations assigned the kinase- and Hsp90-
binding activities to its N-terminal and central domains, respectively. Additionally, we 
carried out alanine scanning site-directed mutagenesis at the N-terminus of human 
Cdc37, and identified four residues that are critical for its HRI-binding activity. 
Materials and Methods: 
Protein purification from E. coli-(His6)-Cdc37 (in pQE32 expression vector) (215) was 
overexpressed in M15[pREP4] E.coli strain for 3 hr at 30 °C. Cells were harvested and 
lysed in 50 mM NaH2P04 buffer (pH 8.0) containing 300 mM NaCl and 5 mM imidazole 
with sonication. Cell lysate was treated with DNase (5 µg/ml) and RNase A (10 µg/ml) 
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for 15 min on ice and centrifuged at 10,000xg for 30 min at 4 °C. Supernatant was mixed 
with 500 µl Ni2+-NTA resin (Qiagen) for 2 hr at 4 °C, followed by washing with 50 mM 
NaH2P04 buffer (pH 8.0) containing 300 mM NaCl and 20 mM imidazole. (His6)-Cdc37 
was eluted by 2 ml of 50 mM NaH2P04 buffer (pH 8.0) containing 300 mM NaCl and 
250 mM imidazole, and then dialyzed against 10 mM PIPES buffer (pH 7.2) containing 
150mMNaC1. 
In-gel trypsin digestion-Gel pieces containing the major proteolytic fragments of (His6)-
Cdc37 were washed with water and 50% acetonitrile (ACN) sequentially for 15 min each. 
Gel pieces were subsequently dehydrated by a brief soaking in 100% ACN, which was 
then replaced by 50 mM NH4HC03 to allow rehydration. Afterwards, the same volume 
of ACN was added and gel pieces were washed with 50% ACN/25mM NH4HC03 for 15 
min. Washes were repeated until little residual Coomassie blue is visible. Gel pieces 
were dried down completely in a speed vacuum centrifuge, rehydrated in 10 mM 
DTT/100 mM N~HC03 for 45 min at 56 °C (reduction), followed by 30 min incubation 
in 55 mM iodoacetamide/100 mM NH4HC03 at room temperature (alkylation). They 
were then dried down again and rehydrated in 30 µl of 12.5 ng/µl trypsin (Promega, 
sequencing grade) prepared in 50 mM NH4HC03 and 5 mM CaC}i. After incubation at 
37 °C for 12 hr or longer, the digestion fluid was removed and stored in separate tubes. 
Peptides trapped inside the gel pieces were further extracted with 50 µl of 50% 
acetonitrile/0.1 % TF A twice, both of which was then combined with the digestion fluid 
removed earlier. Pooled peptide mixtures were subsequently concentrated in a speed 
vacuum centrifuge to a final volume of 10-20 µ1. 
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MALDI-TOF mass spectrometry analysis-Saturated a-cyano-4-hydroxycinnamic acid 
(matrix) was prepared in 50% acetonitrile/0.1 % TFA. 1.0 µl aliquot of the concentrated 
peptide mixtures was spotted onto the MALDI plate, which was immediately covered by 
the same volume of saturated matrix solution. After drying completely, peptide samples 
were analyzed using the Voyager "DE-PRO" matrix-assisted laser desorption-ionization 
time-of-flight mass spectrometer (MALDI-TOF) (Applied Biosystems). Mass spectra 
were acquired in both linear and reflector modes, and compared to the predicted peptide 
mass fingerprints of (His6)-Cdc37 generated by trypsinolysis. 
Immunoprecipitations from RRL-V arious Cdc37 constructs were synthesized and 
radiolabeled with [35S]Met in TnT RRL for 30 min at 30 °C, followed by 10 min chase 
with the addition of 60 µM protein synthesis initiation inhibitor aurintricarboxylic acid. 
To study their Hsp90-binding properties, they were either directly absorbed to the anti-
(Hiss) antibody-coupled agarose resin or coadsorbed to that bound with the monoclonal 
anti-Hsp90 antibody 8D3. Their interactions with Hsp90 were then assessed by Western 
blot or autoradiography, respectively. To examine their kinase-binding activities, non-
His-tagged versions of the domains were mixed with the TnT RRL containing newly 
synthesized (His1)-[35S]HRI, coadsorbed by the anti-(His5) antibody and then analyzed by 
autoradiography. Immunoresins were washed 4 times with 10 mM PIPES buffer (pH 
7.2) containing 150 mM NaCl and 0.5% Tween-20. 
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Limited protease nicking in vitro-Purified recombinant (His6)-Cdc37 was mixed with 
various concentrations of TPCK-treated trypsin (Sigma) in 10 mM Tris-HCl buffer (pH 
7.4) containing 150 mM NaCl, 4 mM CaClz and 0.1 mM EDTA. Digestion was carried 
out either on ice for 6 min or at 37 °C for 30 min, and immediately stopped by boiling in 
SDS sample buffer. Protein/enzyme ratio for trypsin digest (gig) ranged from 2000: 1 to 
250: 1 at 37 °C and from 200: 1 to 10: 1 on ice. Chymotrypsin digest was carried out at 37 
°C for 20 min in the same buffer as described above and at similar protein/enzyme ratios 
to that for trypsin. 
To affinity purify the N-terminal tryptic fragments of (His6)-Cdc37, reactions 
were stopped by adding trypsin inhibitor (Sigma) at an inhibitor/trypsin ratio of 1 :4 (g/g), 
1 % SDS and 100 mM P-mercaptoethanol (as the final concentrations). The reaction 
mixture was further diluted 5 times with NaH2P04 buffer (50 mM final concentration, pH 
8.0) to reduce the concentrations of SDS and P-mercaptoethanol, which would otherwise 
interfere with the binding of His-tagged fragments to Ni2+ resin. Diluted reactions were 
absorbed to Ni2+-NTA resin (Qiagen) for 1 hr at room temperature, which were then 
washed 4 times with 50 mM NaH2P04 buffer (pH 8.0) containing 1 M NaCl, 1 % Triton 
X-100 and 8 M urea. Ni2+-NTA resin was subsequently washed twice with TBS before 
boiling in SDS sample buffer. 
Limited protease nicking in RRL-Wild-type and mutant Cdc37 were synthesized and 
radiolabeled with [35S]-Met in TnT RRL at 30 °C for 30 min and matured for 1 hr in the 
presence of 60 µM aurintricarboxylic acid. RRL reactions were chilled on ice and the 
desired concentrations of TPCK-treated trypsin (Sigma) were applied in 10 mM Tris-HCl 
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buffer (pH 7.4) containing 150 mM NaCl, 4 mM CaCh and 0.1 mM EDTA. Digestion 
was carried out on ice for 6 min and immediately terminated by boiling in SDS sample 
buffer. Samples were then separated on SDS-PAGE and analyzed by autoradiography. 
Construction of plasmids for Cdc37 domains-PCR fragments were generated using 
oligonucleotide primers corresponding to the border regions of each different domain of 
human Cdc37 coding sequence. PCR products were digested with appropriate restriction 
enzymes whose consensus sites were built in the oligonucleotide primers (Ncol site in the 
5' primers and Sacl or BarnHI in the 3' primers), and subsequently ligated into the 
corresponding sites of the expression vectors pSP64T and pSP64TL. This work was 
done by Wenjun Huang, who was a research technician in our lab during the course of 
this study. 
Site-directed mutagenesis-Point mutations at the N-terminus of Cdc37 were introduced 
using standard PCR-based method. Seven sets of oligonucleotides (upper primers) 
corresponding to the N-terminus of human Cdc37 and containing the desired-X-A 
mutations at the specific codons were synthesized to include a short 5' anchoring 
sequence with a Bglll and Ncol sites immediately preceding the Cdc37 coding sequence. 
Another anti-sense oligonucleotide (lower primer) which corresponds to the region 
approximately 250 bp downstream of the unique DraIII site in the coding sequence of 
Cdc37 was used as the lower primer. PCR reactions were carried out using the wild-type 
pSP64T-Cdc37 (215) plasmid as the template. The PCR products (850 bp) were digested 
with Bglll/DraIII and the resulting DNA fragments (550 bp) were used to replace the 
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corresponding region of the wild-type pSP64T-Cdc37 plasmid. Desired mutations were 
subsequently confirmed by sequencing. To introduce the N-terminal (His6)-tag to Cdc37 
mutants, their entire coding sequences were digested from the pSP64T vector as 
Ncol/EcoRI fragments and cloned into the corresponding sites of the pSP64TL vector 
(97). 
Results: 
1) Domain mapping of Cdc37: 
Early studies in our and other laboratories have shown that the kinase-binding site 
of Cdc37 resides in its N-terminal half (Cdc37/AC) whereas the Hsp90-binding site is 
located in its C-terminal half (Cdc37/AN) (89,215). However, this bisection of Cdc37 
was rather arbitrary based on little knowledge of its true domain architecture. Here in 
this report, we attempted to determine the authentic domain structure of Cdc37 by limited 
protease nicking technique in conjunction with MALDI-TOF mass spectrometry analysis. 
a) Generating the domain map: limited proteolytic fingerprint of purified recombinant 
Cdc37-Recombinant (His6)-Cdc37 purified from E. coli was subjected to limited 
proteolysis in vitro with a wide range of concentrations of trypsin. The idea is to find the 
optimal condition under which only the most flexible and solvent accessible inter-domain 
regions of Cdc37 are cleaved, thus to generate a domain map of Cdc37. As shown in Fig. 
23A, a nice proteolytic fingerprint of Cdc37 was generated at a protein/enzyme ratio (g/g) 
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Figure 23. Limited trypsinolysis of purified recombinant (His6)-Cdc37. A) 5 µg purified 
recombinant (His6)-Cdc37 was digested with trypsin at substrate/enzyme ratios of 200: 1 
(lane 2), 50: 1 (lane 3) and 12: 1 (lane 4), respectively as described under "Materials and 
Methods". A mock digestion containing equal amount of trypsin-free buffer was set up 
in parallel as the uncut control (lane 1). Digestion was carried out for 6 min on ice and 
stopped immediately by mixing with boiling SDS sample buffer. Proteolytic fragments 
were subsequently separated on a 12% SDS-polyacrylarnide gel, transferred to PVDF 
membrane and stained with Coomassie brilliant blue R250 (CBB, left panel). After 
imaging, the same membrane was bleached (with methanol to remove the dye) and 
immunoblotted with the anti-(His5) antibody (WB, right panel). B) 10 µg purified 
recombinant (His6)-Cdc37 was digested with trypsin at a substrate/enzyme ratio of 200: 1 
for 6 min on ice. Digestion was terminated by mixing with the trypsin inhibitor along 
with SDS and ~-mercaptoethanol at concentrations as described under "Materials and 
Methods". Reaction was further diluted and absorbed to Ni2+-NTA resin. After 
collecting the unbound material, resin was washed and the absorbed Cdc37 fragments 
were subsequently eluted by SDS sample buffer. Finally, both the bound and unbound 
Cdc37 fragments were analyzed side by side on a 12% SDS-polyacrylamide gel, 
transferred to PVDF membrane and detected by staining with Coomassie Brilliant Blue 
R250 (CBB). FL: full-length (His6)-Cdc37. 
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protein, 46 kDa, 36 kDa, 34 kDa and 18 kDa. There were also some minor fragments 
which were likely to result from aggressive internal cleavage of Cdc37 domains. As the 
trypsin concentration increased, however, a novel 21 kDa fragment appeared and 
remained intact whereas most other fragments started to attenuate and disappear. The 
high protease-resistance of this particular fragment indicates that its tertiary structure is 
highly compact and solvent inaccessible, which are the main structural criteria for protein 
domains. 
To assist interpreting the map, proteolytic fragments were transferred to PVDF 
membrane and immunoblotted with anti-His-tag antibody. In doing so, we determined 
that 46 kDa, 36 kDa and 18 kDa are N-terminal fragments, whereas 34 kDa and the most 
protease-resistant 21 kDa are either internal or C-terminal fragments (Fig. 23A). To 
further simplify the mapping process, we carried out the digestion at the optimal 1 :200 
ratio, and divided the entire mixture of tryptic fragments into two fractions by affinity 
purifying those N-terminal fragments with anti-His-tag antibody and leaving the internal 
and/or C-terminal fragments behind (Fig. 23B). For some reason, the 36 kDa fragment 
appeared to be a minor proteolytic product in this experiment (Fig. 23B: Lane 1). It 
co~ld be due to slight inconsistency in experimental conditions such as substrate/enzyme 
ratio and/or the quality of purified Cdc37 between experiments. Despite the subtle 
variation, consistent with the Western blotting result, the 46 kDa, 36 kDa and 18 kDa 
fragments were specifically immunoadsorbed by anti-His-tag antibody whereas the 34 
kDa fragment was not. These major proteolytic fragments were subsequently excised 
from the SDS-PAGE and subjected to further in-gel digest and MALDI-TOF mass 
spectrometry analysis. 
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b) Solving the domain map: in-gel trypsin digest and MALDI-TOF MS analysis of major 
proteolytic fragments of Cdc37-In-gel digestion by sequence-specific proteases coupled 
with matrix-assisted laser/desorption ionization-time of flight mass spectrometry 
(MALDI-TOF MS) analysis has emerged as a powerful and widely used tool for 
proteomic studies. It can be used for various purposes including protein identification 
which relies on the fact that each different protein gives its unique peptide mass 
fingerprint upon digestion with a sequence-specific protease. Here adopting the same 
principle, we used this integrated technique in an attempt to solve the domain structure of 
Cdc37. The idea is to digest each of the major Cdc37 fragments (resulting from trypsin 
nicking) representing its putative domains with trypsin, generate a unique peptide mass 
fingerprint for each of them using MALDI-TOF mass spectrometry, deduce their amino 
acid sequences and thus solve the domain structure of Cdc37. 
As described above, the major proteolytic nicking fragments of Cdc37 were in-gel 
digested by trypsin and analyzed by MALDI-TOF MS. Their experimental peptide mass 
fingerprints were then compared to that predicted based on the amino acid sequence of 
full-length Cdc37 as a result of complete or partial trypsinolysis. Confident matches 
between the experimental and theoretical peptides are summarized in Table 3. Consistent 
with the Western blotting and immunoadsorption results, no N-terminal peptides of 
Cdc37 were identified for the 34 k:Da and 21 k:Da fragments. MS data indicated that they 
both start at Ser-127, which was later confirmed by Edman degradation sequencing. The 
21 kDa fragment appears to end at Arg-283 as suggested by 
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Major Cdc37 Measured mass Calculated mass Covered sequences 
fragments (Da) (Da) 
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a peptides resulting from partial trypsin digestion 
Table 3. Mass spectrometry analysis of major proteolytic fragments of Cdc37 
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the MS data. However, since Arg-283 is immediately followed by two Lys and one Arg 
residues, which would be cleaved off by trypsin upon complete digestion, the precise C-
terminus of the 21 kDa fragment could not be determined. Nonetheless, it suggests that 
residues at or around R283KKR286 represent one of the major flexible and solvent 
accessible regions of Cdc37 which could be an inter-domain junction. Supporting this 
hypothesis, the 36 kDa fragment was mapped to a large N-terminal Cdc37 fragment 
which also ends around R 283KKR 286• As to the 34 kDa fragment, MS data suggested that 
it terminates at Lys-369. However, complete trypsinolysis of the last nine amino acids of 
Cdc37, T370GDEKDVSV378, should give rise to two rather short peptides, DVSV (418 
Da) and TGDEK (549 Da), which are below the detection limit and buried under too 
many low mass noises of MALDI-TOF MS, respectively. Therefore, it remains unclear 
whether the 34 kDa fragment contains the last nine amino acids of Cdc37 or not. 
Analysis of the 18 kDa fragment indicated that it contains amino acids 1-126 of 
Cdc37, which is consistent with the fact that it reacted with the anti-His-tag antibody. 
Most importantly, it suggested that the second inter-domain junction of Cdc37 resides 
between K126 and S127, or at their proximity. Examination of the 46 kDa fragment 
assigned it to residues 1-347 or 1-352, indicating that another protease-sensitive region 
exists around K347 and/or K352• However, since this region is very close to the C-
terminus of Cdc37, it is probably not a true inter-domain junction. Instead, it may a 
flexible intra-domain region which structurally separates the last 25-30 amino acids of 
Cdc37 from the major part of its C-terminal domain. Take together, MS data 
successfully mapped all the major Cdc37 proteolytic nicking fragments to the full-length 
protein, and strongly suggested a three-domain structure of Cdc37 (Fig. 24). 
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Figure 24. Domain structure of Cdc37. A) Mapping of the major proteolytic fragments 
of Cdc37 resulting from limited trypsinolysis by MALDI-TOF. Two major trypsin 
cutting sites representing putative inter-domain junctions are shown by large arrows 
pointing to the exact or approximate locations. One minor cutting site possibly 
representing an intra-domain junction is shown by a small arrow. Major proteolytic 
fragments of Cdc37 are also shown according to their individual locations. B) 
Dissection of Cdc37 based on its domain structure (shown in A). Dl, D2 and D3 are the 
putative individual domains whereas D12 and D23 are fusions of adjacent domains. The 
arbitrary domains Cdc37 I !iC and Cdc37 I t1N which have been characterized previously 
are also shown here. 
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2) Characterizations of different Cdc37 domains regarding their abilities to bind HRI 
andHsp90: 
Early studies have assigned the kinase- and Hsp90-binding sites of Cdc37 to its 
arbitrary N-terminal (AC, 1-163) and C-terminal (LlN, 164-378) regions, respectively (89, 
215). Based on our novel domain structure of Cdc37, we predict that the authentic N-
terminal domain (Dl, 1-126) bears the kinase-binding site whereas the central domain 
(D2, 127-283) interacts with Hsp90. To characterize them in RRL, all three domains of 
Cdc37 were cloned into the pSP64T vector which drives efficient protein synthesis in 
RRL. Two additional constructs were also made to combine neighboring domains, 
named D12 and D23. This is to ensure that we do not miss any potential kinase and/or 
Hsp90 binding motifs of Cdc37 that are presented cooperatively by adjacent domains 
rather than solely by individual domains. Various Cdc37 constructs were synthesized in 
RRL, and their HRI- or Hsp90-binding abilities were subsequently assessed through 
immunoprecipitation coupled with Western blotting and autoradiography analyses. 
a) Hsp90-binding site resides in the central domain (D2) of Cdc37-To examine the 
Hsp90-binding abilities of the individual Cdc37 domains, His-tagged versions of all five 
constructs were individually synthesized in RRL with concomitant radiolabeling with 
[35S]Met and subsequently immunoadsorbed by anti-His-tag antibody. Full-length Cdc37 
as well as the two arbitrary domains, AC and LlN were also synthesized to serve as the 
controls. Coadsorption of endogenous Hsp90 with all these cdc37 constructs was then 
assessed through Western blot (Fig. 25). Consistent with the early data, full-length 
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Figure 25. Hsp90-binding activities of Cdc37 dissection products. Eight different (His6)-
tagged Cdc37 constructs (full-length, Dl, D2, D3, D12, D23, Cdc37/~C and Cdc37/L1N) 
were synthesized with concomitant radiolabeling with [35S]Met in TnT RRL containing 
(even-number lanes) or lacking (odd-number lanes) 10 µg/ml geldanamycin (GA) at 30 
~C for 30 min followed by 10 min chase upon the addition of 60 µM aurintricarboxylic 
acid. Two mock RRL reactions lacking the exogenous DNA templates were assessed in 
parallel as the nonspecific controls (lanes 1 and 2). All the reactions were subsequently 
immunoprecipitated by the anti-(His5) antibody and separated on a 10% SDS-
polyacrylamide gel. Proteins were then transferred to PVDF membrane, and analyzed by 
autoradiography (lower panel, immunoadsorbed [35S]-labeled Cdc37 domain constructs) 
or Western blotting (upper panel, coadsorbed endogenous Hsp90) analyses, respectively. 
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central domain D2 bound to Hsp90, whereas the other two domains Dl and D3 did not. 
As predicted, D12 and D23 both of which contain the central domain D2 also specifically 
pulled down endogenous Hsp90. Therefore, the ,Hsp90-binding site is located to the 
central domain D2 of Cdc37. 
As a molecular chaperone, Hsp90 could interact with the Cdc37 domains simply 
because they are misfolded due to the lack of stabilizing interactions with other parts of 
the protein or because certain parts become exposed upon dissection which would be 
normally buried inside the full-length protein. To rule out such a possibility, GA was 
included in the same set of RRL reactions synthesizing different Cdc37 constructs as 
described above. If D2 is recognized by Hsp90 as an unfolded client, GA should disrupt 
such an interaction like it does to other clients of Hsp90 (29, 89, 97, 215). However, 
geldanamycin should not have any effect if D2 binds to Hsp90 as a cohort like full-length 
Cdc37. As expected, GA had no effect on the interaction between Hsp90 and D2, 
indicating that it is behaving as a cohort rather than a client of Hsp90. Consistently, GA 
also had no effect on the interactions of Hsp90 with full-length Cdc37, D12 and D23. 
However, quite surprisingly the interaction between Hsp90 and the arbitrary L\N was 
actually enhanced several fold by GA treatment, a novel observation that we do not fully 
understand at this moment. 
b) Kinase-binding site is located in the authentic N-terminal domain (DJ) of Cdc37-To 
test the hypothesis that D 1 possesses the kinase-binding site of Cdc37, it was synthesized 
and labeled with [35S]Met in RRL, which was then mixed with RRL containing newly 
synthesized (His1)-HRI. (His7)-HRI was immunoadsorbed to anti-His-tag antibody and 
114 
the coadsorption of [35S]Dl was assessed by autoradiography. D12 was also analyzed 
similarly regarding its HRI-binding activity (Fig. 26). Consistent with our hypothesis, 
both Dl and D12 were specifically coadsorbed by (His7)-HRI, indicating that the 
authentic N-terminal domain of Cdc37 contains the kinase-binding site. To assess the 
possibility that Cdc37 possesses additional kinase-binding sites elsewhere in the protein, 
D2 and D23 were also examined for their abilities to bind HRI. However, neither of 
these constructs interacted with (His7)-HRI specifically, further supporting the hypothesis 
that Dl is the only kinase-binding domain of Cdc37 (data not shown). 
Early works have shown that Cdc37 binds to HRI in an Hsp90-dependent manner 
which can be fully disrupted by GA treatment. However, the interaction between the 
arbitrary AC and HRI was found to be GA-insensitive, which is presumably due to the 
fact that in the absence of the C-terminal Hsp90-binding domain, the kinase-binding site 
is no longer under control of the nucleotide-regulated conformational switching of Hsp90 
(215). With no detectable ability to bind Hsp90, we predicted that Dl would interact 
with HRI in the same GA-insensitive fashion as AC, whereas Dl2 would behave the 
same as the full-length Cdc37 because of its Hsp90 binding by D2. Surprisingly, 
however GA not only disrupted the interaction between D12 and HRI, but also disrupted 
the interaction between D 1 and HRI. Therefore, it seems that unlike AC, the kinase-
binding activity of D 1 is somehow regulated by Hsp90 through an unknown mechanism. 
3) N-terminal residues of Cdc37 are essential for its interaction with HR/: 
Sequence alignment classified the first 30 or so amino acids as the most 
conserved region of Cdc37 homologues from different species, indicating that they are 
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Figure 26. HRI-binding activities of Dl and D12 constructs of Cdc37. Dl and D12 were 
synthesized with concomitant radiolabeling with [35S]Met in separate TnT RRL 
containing (lanes 3, 4, 7 and 8) or lacking (lanes 1, 2, 5 and 6) 10 µg/rnl geldanamycin 
(GA) at 30 °C for 30 min. After 10 min chase with 60 µM aurintricarboxylic acid, they 
were mixed with either mock (lanes 1, 3, 5 and 7) or newly synthesized (His7)-HRI-
containing (lanes 2, 4, 6 and 8) TnT RRL and further incubated at 30 °C for 25 min. 
Resulting RRL mixtures were then subjected to immunoadsorption using the anti-(His5) 
antibody and analyzed on a 10% SDS-polyacrylamide gel. Proteins were subsequently 
transferred to PVDF membrane, and the coasorbed [35S]-labeled Dl (PEL, left panel) and 
D12 (PEL, right panel) were visualized by autoradiography analysis. Aliquots of RRL 
mixtures were taken prior to immunoadsorption and analyzed to show that geldanamycin 
had no effect on the synthesis level of Dl and D12 (INPUT). 
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functionally essential (51,235). Our early studies on the Cdc37 mutant, N8aa whose first 
eight amino acids were replaced by a short irrelevant sequence, have indicated that these 
eight amino acids are critical for the kinase-binding, but not the Hsp90-binding activity of 
Cdc37 (215). This finding is also consistent with the fact that the N-terminal domain of 
Cdc37 (Dl) interacts with the kinase. Here we sought to examine the first eight amino 
acids of Cdc37 individually by site-directed mutagenesis, attempting to pinpoint the ones 
that are directly involved in kinase-binding. Amino acids 2 through 8 of Cdc37 were 
mutated to alanine individually, and the resulting mutants were cloned into the pSP64T or 
pSP64TL vector for in vitro translation in RRL. 
a) Val-2, Asp-3, Tyr-4 and Trp-7 are important for the HRI-binding activity of Cdc37-To 
examine the kinase-binding properties of the seven different mutants of Cdc37, their non-
His-tagged versions were synthesized and labeled with [35S]Met in TnT RRL reactions, 
which were then mixed with RRL containing newly synthesized (His7)-HRI. Reaction 
mixtures were subjected to immunoadsorption by anti-His-tag antibody, and the 
coadsorption of [35S]-labeled Cdc37 mutants with HRI were subsequently analyzed by 
autoradiography (Fig. 27). In doing so, we identified Tyr-4 and Trp-7 as two essential 
residues for the kinase-binding activity of Cdc37 as demonstrated by the observation that 
Y4A and W7A mutants completely failed to be coadsorbed with (His7)-HRI. Asp-3 also 
seemed to be important for the kinase-binding of Cdc37 as well since its mutation to 
alanine reduced the interaction of Cdc37 with HRI by approximately 10 fold. 
Additionally, the binding affinity of V2A mutant for HRI was also decreased about 3 
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Figure 27. HRI-binding activities of the N-terminal point mutants of Cdc37. Wild type 
and the N-terminal point mutants of Cdc37 were synthesized and labeled with [35S]Met in 
separate TnT RRL reactions at 30 °C for 30 min. Following a 10-min chase with 60 µM 
aurintricarboxylic acid, each RRL reaction was mixed with an equal volume of TnT RRL 
containing newly synthesized (His7)-HRI and further incubated for 25 min (PEL, lanes 2 
to 9). A duplicate TnT RRL reaction synthesizing the wild type Cdc37 was mixed with a 
mock TnT RRL mixture lacking (His7)-HRI to serve as the nonspecific binding control 
(lane 1). Resulting mixtures were subjected to immunoadsorption with the anti-(His5) 
antibody, separated on an 8% SDS-polyacrylarnide gel and transferred to PVDF 
membrane. Immunoadsorbed (His7)-HRI was detected by Western blot (PEL, lower 
panel), whereas the coadsorbed [35S]-labeled Cdc37 mutants were analyzed by 
autoradiography (PEL, upper panel). Equivalent aliquots were taken from each different 
Cdc37 reaction prior to immunoadsorption to ensure the constructs were generated at 
comparable levels (INPUT). 
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Conversely, mutation of Ser-5, Val-6 and Asp-8 had no effect on the ability of Cdc37 to 
bind HRI, which thus ruled out their involvement in the kinase-binding by Cdc37. Thus, 
these mutagenesis studies identified four important residues out of the first eight amino 
acids of Cdc37 that are important for its interaction with HRI. These findings not only 
agree with the fact that D 1 domain contains the kinase-binding site, but also suggests that 
such a function is mediated primarily by the highly conserved 30 or so N-terminal 
residues of Cdc37. 
Working with mutants, there is always a chance for the altered function of the 
proteins to be caused by unwanted global conformational changes rather than by the 
expected change of properties of specific residues. To test whether the inability of the 
Cdc37 mutants to bind HRI was due to any mutation-induced global conformational 
changes, we carried out mild trypsin nicking experiments on all of the mutant constructs. 
Different fragmentation patterns and/or sensitivities to proteases are expected for mutants 
with compromised structures in comparison to the wild-type protein. As shown in Fig. 
28, wild type and mutant Cdc37 proteins were synthesized and radiolabeled with 
[35S]Met in separate TnT RRL reactions to which increasing amounts of trypsin were 
added subsequently. The resulting nicking reactions were then analyzed by SDS-PAGE 
and autoradiography. In doing so, we detected little differences in both the fragmentation 
patterns and sensitivities to trypsinolysis between the wild type Cdc37 and its mutants, 
indicating that no global conformational changes have been induced by the mutations. 
These findings further underscore the importance of these :N-terminal amino acids in 
mediating the interaction of Cdc37 with its client proteins. 
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Figure 28. Comparison of proteolytic peptide mapping between wild type Cdc37 and its 
N-terminal mutants. Wild type (WT) and mutant forms of Cdc37 were synthesized with 
concomitant radiolabeling with [35S]Met in separate TnT RRL reactions at 30 °c for 30 
min, followed by a 1 hr maturation in the presence of 60 µM aurintricarboxylic acid. 
Reactions were chilled briefly on ice and diluted into 3 volumes of proteolysis buffer (as 
described under "Materials and Methods") containing four different concentrations of 
trypsin as specified in the figure. Digestion was carried out for 6 min on ice and 
terminated immediately by mixing the samples with boiling SDS sample buffer. 
Proteolytic peptide fragments were separated by 12% SDS-polyacrylamide gel, followed 
by autoradiography analysis. FL denotes full-length Cdc37. 
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b) The interaction of Cdc37 with Hsp90 is not affected by the N-terminal mutations-Early 
works done in our lab have indicated that the full-length Cdc37 requires functional Hsp90 
to acquire its kinase-binding ability as the Hsp90-specific inhibitor, GA, completely 
abolishes its interaction with HRI (215). Therefore, another possible cause for the 
diminished or lost kinase-binding by the Cdc37 mutants is that, unlike the wild type 
Cdc37, they are unable to form complexes with Hsp90. To examine such a possibility, 
two reciprocal approaches were taken in which the interactions of different Cdc37 
mutants with Hsp90 were compared to the wild type Cdc37. In the first approach, · 
different Cdc37 mutants were synthesized and radiolabeled with [35S]Met in RRL, 
followed by immunoprecipitation of the endogenous Hsp90 and coadsorption of [35S]-
labeled Cdc37 mutants (Fig. 29A). Autoradiogram showed that except for W7 A, all of 
the other mutants bound Hsp90 at a similar level to the wild type Cdc37, indicating that 
their binding affinities for Hsp90 were not affected by the mutations. As to W7 A, there 
was roughly 50% decrease in its binding to Hsp90 compared to the wild type Cdc37. 
Similar results were obtained in the reciprocal experiment in which the His-tagged Cdc37 
mutants were synthesized in TnT RRL and immunoadsorbed by the anti-His-tag 
antibody. Coadsorption of the endogenous Hsp90 was subsequently detected by Western 
blotting (Fig. 29B). Again, W7 A showed a loss of Hsp90-binding, whereas the other 
mutants interacted with Hsp90 at essentially the same level compared to the wild type 
Cdc37. Therefore, the data presented here further strengthen the hypothesis that theN-
terminal amino acids including Val-2, Asp-3 and Tyr-4 are directly involved in the 
interaction of Cdc37 and its client kinase. 
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Figure 29. Hsp90-binding activities of the N-terminal point mutants of Cdc37. A) Wild 
tyr,e and mutant forms of Cdc37 were synthesized with concomitant radiolabeling with 
[3 S]Met in separate TnT RRL reactions at 30 °C for 30 min, followed by a 10 min chase 
with 60 µM aurintricarboxylic acid. They were then immunoadsorbed with the 
monoclonal anti-Hsp90 antibody 8D3 (even-number lanes) or nonimmune control IgM 
antibody (odd-number lanes) and separated on an 8% SDS-polyacrylarnide gel. Proteins 
were transferred to PVDF membrane, and the immunoadsorbed endogenous Hsp90 and 
coadsorbed [35S]-labeled Cdc37 proteins were subsequently detected by Western blotting 
and autoradiography analyses, respectively (PEL). Equivalent aliquots were taken from 
the Cdc37 translation mixtures prior to immunoadsorption to show that the constructs 
were synthesized at comparable levels (INPUT). B) (His6)-tagged wild type and mutant 
forms of Cdc37 were synthesized and radiolabeled with [35S]Met in separate TnT RRL 
reactions at 30 °C for 30 min. After a 10 min chase with 60 µM aurintricarboxylic acid, 
they were immunoadsorbed by the anti-(His5) antibody and separated on an 8% SDS-
polyacrylamide gel. Proteins were transferred to PVDF membrane, and analyzed by 
Western blotting (coadsorbed endogenous Hsp90) or autoradiography (different [35S]-
labeled Cdc37 proteins). 
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Discussion: 
Data presented in this report indicate a three-domain structure of human Cdc37, 
which has also been suggested by Scholz et al recently (212). In their report, based on 
the amino acid sequence alignment of Cdc37 and Hare, an Hsp90-associating relative of 
Cdc37 from multiple species, they predict a three-domain structure of Cdc37 that is 
strikingly similar to ours. However, their middle domain D2 (120 amino acids ranging 
from 145-264) is 18 and 19 amino acids shorter than ours (157 amino acids ranging from 
127-283) from the N- and C-terminal ends, respectively. Despite these minor 
differences, both D2 constructs are able to bind Hsp90, indicating that all or most of the 
Hsp90-interacting motifs occur within the central 120 amino acids of Cdc37. Indeed, the 
region of Cdc37 involved in the direct interaction with Hsp90 could even be minimized 
by 19 more residues based on the fact that the arbitrary C-terminal domain L\N (starting at 
Met164) is also sufficient to bind Hsp90 (215). Therefore, it is quite likely that the extra 
37 amino acids that lie outside of the central 120 residues, are either part of the middle 
domain of Cdc37 to which they may be structurally or functionally important, or 
representing an interdomain region that functionally couples the adjacent N-terminal 
domain (Dl) and the middle domain (D2) of Cdc37. The hypothesis that these 37 amino 
acids are part of the middle domain of Cdc37 is strongly supported by the observation 
that our D2 fragment is highly resistant to proteolysis, a property usually possessed by 
intact domains with compact three-dimensional structures. Our confidence is further 
strengthened by the finding that limited proteolysis of Cdc37 by chymotrypsin generates 
a strikingly similar pattern of fragments to that by trypsin (data not shown). 
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Data presented here also allow us to identify a novel kinase-binding domain of 
Cdc37 (Dl) which has not been reported previously. It contains the first 126 amino acids 
of Cdc37, 37 resides shorter than the previously characterized arbitrary N-terminal 
Cdc37/~C domain. Dl binds to HRI specifically, however unlike Cdc37/~C the 
interaction can be disrupted by the Hsp90-specific inhibitor geldanamycin. This result is 
rather puzzling considering the fact that Dl lacks any Hsp90-binding activity, which 
predicts that it is not controlled by the nucleotide-regulated conformational switching of 
Hsp90. Despite the lack of a convincing explanation, it seems reasonable to speculate 
that it is the 37 amino acids present in Cdc37/~C but missing from Dl that makes the 
difference in the geldanamycin-responsiveness of their HRI-binding activities. 
Interestingly, sequence alignment of the Dl domain of human Cdc37 with the Hsc70-
interacting Bag domain suggests that they share a significant number of conserved 
residues that are critical for the direct binding of the Bag domain to the ATPase domain 
of Hsc70 (229). In one alignment, the conserved residues of Cdc37 (within amino acids 
41-67) and the Bag domain correspond precisely with regards to their positions, 
suggesting that a similar binding surface for Hsc70 can be formed if this region of Cdc37 
adopts a similar helical bundle structure with the identical length to that in the Bag 
domain (Fig. 30A). Alternatively, residues in the third helix of the Bag domain that are 
involved in its direct interaction with Hsc70 can also be aligned to a further downstream 
region of Cdc37 (within amino acids 92-100) with equal confidence (Fig. 30B). This 
implies that two or more potential helices, with different lengths relative to the two 
helices of the Bag domain, can be formed within the Dl domain of Cdc37 and arranged 
topologically to create a similar Hsc70 binding surface. Indeed, secondary structure 
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Figure 30. Sequence alignment of the Dl domain of Cdc37 (human) with the minimal 
Bag domain of Bag-lM (human, Genbank accession number Q99933). Only the region 
of Dl (41-73) that shares conserved residues with the Bag domain is shown here. The 
minimal Bag domain (151-264 for human Bag-lM) contains three a-helices in which the 
helix 2 and 3 interact directly with the ATPase domain of Hsc70 (Helix 1 is not shown) 
(229). Residues of the Bag domain that are both critical for the interaction with the 
ATPase domain of Hsc70 and absolutely conserved across species ranging from yeast to 
human are indicated by numbers. A) and B) represent two alternative alignments 
between the Dl domain of Cdc37 and the Bag domain of Bag-lM. Residues of Cdc37 
located between the two conserved regions (to the Bag domain) are not shown in the 
second alignment (B). 
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prediction indicates that a-helices are highly possible for this region of mammalian 
Cdc37 (data not shown). Supporting such a hypothesis, we are able to observe specific 
interactions of full-length Cdc37, and to a lesser extent Cdc37/~C, with Hsc70 in RRL 
(data not shown). However, such an interaction can not be detected for Dl, indicating 
that the extra 37 amino acids present in Cdc37/~C are required for the stable interaction 
between Cdc37 and Hsc70. Based on the fact that Hsc70 possesses its own Hsp90-
independent kinase-binding activity (243, 248), it is tempting to speculate that in the 
presence of geldanamycin, Cdc37 I ~C interacts with HRI in an Hsc70-dependent, but 
Hsp90-independent fashion. However, in the context of the full-length Cdc37, 
geldanamycin can still exert its inhibitory effect on the HRI-binding of Cdc37 through its 
association with mediated by the central domain. As to D 1, without the stable interaction 
with Hsc70, it relies solely on the geldanamycin-inhibitable Hsp90 function for its HRI-
binding activity. Nonetheless, in this model another assumption needs to be made: that is 
the geldanamycin-inhibitable function of Hsp90 is required for HRI to achieve its Cdc37-
binding competent conformation. This hypothesis then helps to explain the puzzle that 
even being physically free from Hsp90, the HRl-binding activity of Dl is still controlled 
by the nucleotide-regulated conformational switching of Hsp90. 
The functional importance of these 37 amino acids for Cdc37 is also implicated 
by another interesting, yet puzzling finding. It appears that the presence or absence of 
these 37 amino acids from the middle domain of Cdc37 somehow determines whether its 
association with Hsp90 is sensitive to geldanamycin. Full-length Cdc37, D2 and D23 
containing these residues interact with Hsp90 in a geldanamycin-insensitive fashion. 
However, the arbitrary Cdc37/m construct which lacks these amino acids exhibits an 
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enhanced affinity for Hsp90 in the presence of geldanamycin (Fig. 25). Additionally, 
novobiocin, another Hsp90 inhibitor that targets the putative C-terminal nucleotide-
binding pocket of Hsp90 (140,141,232), also seems to have a strange effect on the 
conformation of the Cdc37 I L1N construct. It surprisingly leads to a physical masking of 
the N-terminal His-tag of Cdc37/L1N, which causes its inaccessibility to the anti-His 
antibody in the immunoprecipitation experiment (data not shown). Therefore, besides 
their potential roles in mediating the interaction of Cdc37 with Hsc70, these 37 amino 
acids may also be directly involved in modulating the interaction between Cdc37 and 
Hsp90 in response to the nucleotide-regulated conformational switching of Hsp90. 
Site-directed mutagenesis of the N-terminal eight amino acids of Cdc37 ( except 
the starting methionine) allowed us to pinpoint four residues that are critical for its 
interaction with HRI: V2; D3; Y4; and W7. It substantiates our early finding that 
replacing the first eight amino acids of Cdc37 with an unrelated sequence completely 
abolishes its ability to bind HRI, and also indicates that the actual kinase-recognition 
site(s) of Cdc37 may be located at the N-terminal region of the Dl domain. Sequence 
alignment of Cdc37 homologues from different species ranging from yeast to human 
reveals that the first 30 or so amino acids are the most conserved region of the whole 
protein, and three out of the four residues, D3, Y 4 and W7, that we have identified to be 
critical for the HRI-binding of Cdc37 are absolutely invariant. Therefore, it implies that 
large aromatic amino acids at positions 4 and 7 (Y 4 and W7) are required for the kinase-
binding activity of Cdc37. Whereas alanine mutations at Y4 and W7 may have caused 
subtle conformational change at the N-terminal region of Cdc37 that contributes to its 
loss of kinase-binding (which was likely undetectable by protease nicking due to the 
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close proximity of Y 4 and W7 to the N-terminus of Cdc37), future studies by mutating 
them to phenylalanine or aliphatic hydrophobic residues such as leucine should provide 
better evidence for whether large aromatic amino acids are absolutely required at these 
two positions for Cdc37 to bind kinases. As to V2, although it is replaced by an 
isoleucine residue in yeast Cdc37, the conserved hydrophobicity predicts a similar 
function for it in mediating protein-protein interactions. In contrast, V6 and D8, which 
do not seem to be important for the interaction of Cdc37 with HRI, are poorly conserved 
in lower species such as yeast and drosophila. It is noteworthy that the additional 
downstream residues within the first 30 or so amino acids of Cdc37 are also well 
conserved, suggesting that they are functionally or structurally important as well (51, 
235). Considering that even the distantly related yeast Cdc37 has been reported to bind 
the protein kinase Stell (1), our data presented here strongly suggest an evolutionarily 
conserved function of these N-terminal amino acids in recognizing and binding the client 
proteins of Cdc37. Nonetheless, more mutagenesis studies of the additional conserved 
Cdc37 residues need to be carried out in order to fully understand their importance. 
Despite their abolished or compromised abilities to bind HRI, these N-terminal 
Cdc37 mutants seem to be normal in their abilities to bind Hsp90 except for the W7 A 
mutant whose interaction with Hsp90 is reduced by approximately 50% compared to that 
of the wild type Cdc37. Several significant implications can be derived from these 
observations. 1) It substantiates the notion that Cdc37 binds to the client proteins through 
direct interactions rather than the passive bridging by Hsp90. Such a notion has been 
well supported by several lines of evidence including the ability of the purified Cdc37 to 
interact with the purified CDK4 (235) and Raf-1 (223) in vitro and the ability of the 
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Hsp90-binding deficient Cdc37//iC mutant to interact with a number of kinases both in 
vivo and in vitro (89, 215). Here it is confirmed again by our data, since in a passive 
bridging model these defective N-terminal Cdc37 mutants should be present in the same 
heterocomplex with Hsp90 and HRI simply because they are able to bind Hsp90. 2) 
Hsp90 depends upon functional Cdc37 to bind its client kinases. This notion derives 
from the finding that the subpopulation of Hsp90 that is associated with the Cdc37 
mutants becomes incapable of binding HRI as well. Although it may seem to agree with 
the prevalent model in which Cdc37 is the kinase-targeting subunit of Hsp90 (89, 235), 
several lines of evidence suggest that it is not simply acting as an adaptor between Hsp90 
and the client kinases. First, as previously demonstrated, Cdc37 quantitatively 
dissociates from HRI upon GA treatment, whereas Hsp90 is still bound to HRI albeit the 
interaction becomes salt-labile (97). This observation thus argues against the passive 
tethering model in which Hsp90 is predicted to be incapable of binding HRI in the 
absence of the adaptor Cdc37. Although passively targeting of client kinases to Hsp90 
may represent one possible aspect of its function, it appears that Cdc37 also actively 
facilitates the acquisition of the Hsp90-binding conformations of client kinases. This 
hypothesis has already been suggested by the limited ability of the Cdc37//iC mutant to 
promote the association between the temperature-sensitive mutant of Hck and Hsp90 
despite its inability to bind Hsp90 (211). However, such a potential function of Cdc37 
may be client-specific because Cdc37 //iC actually decreases the interaction of Hsp90 
with another kinase, Raf-1 (89). 3) Alternatively, the above mentioned data can also be 
interpreted by the possibility that these Cdc37 mutants abolish the kinase-binding ability 
of Hsp90. Since the kinase-binding activity of Cdc37 is controlled by Hsp90 through its 
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nucleotide-regulated conformational switching (29, 89, 97,215), it is equally likely that 
the kinase-binding activity of Hsp90 is regulated by Cdc37 as well. However, in such a 
scenario the N-terminal residues of Cdc37 are expected to make contacts, which are 
possibly transient and labile, with Hsp90 that is bound to its central domain, or instead 
they may interact with residues from the middle domain of Cdc37 to affect the associated 
Hsp90 indirectly. 4) Indeed, such inter-domain communications of Cdc37 are also 
implied by other lines of evidence. For instance, we notice that compared to the full-
length Cdc37 and D12, D2 and Cdc37/~N exhibit weaker binding affinity for Hsp90, 
suggesting that the N-terminal kinase-binding domain of Cdc37 may somehow facilitate 
the Hsp90-binding by the middle domain. Similarly, D 1 seems to bind HRI weaker than 
the full length Cdc37 and D12, indicating that similar cooperation occurs between these 
two domains of Cdc37 with regards to its kinase-binding. 5) An additional line of 
evidence which supports a direct communication between the N-terminal kinase-binding 
domain and the central Hsp90-binding domain of Cdc37, is our observation that the W7 A 
mutant of Cdc37 is not only compromised in its ability to bind HRI, but also its ability to 
interact with Hsp90. 
Taken together, data presented in this report unveil to us a novel domain structure 
of Cdc37 that has not been reported previously. Biochemical characterizations allow us 
to assign the HRI- and Hsp90-binding activities of Cdc37 to its N-terminal and central 
domains, respectively. A 37-amino acid stretch immediately following the N-terminal 
domain of Cdc37 seems to be important in determining the geldanamycin-responsiveness 
of Cdc37's interaction with both HRI and Hsp90. In addition, site-directed mutagenesis 
studies pinpointed four amino acids at the N-terminus of Cdc37 that are critical for its 
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HRI-binding activity. Unfortunately, we failed to identify any biological functions for 
the C-terminal domain of Cdc37. It remains to be seen whether it is important for some 
yet unknown aspects of Cdc37 function. 
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CHAPTERV 
Identification of post-translational phosphorylation sites on Met3 mutant of HRI 
and the TPR domain of PPS 
Introduction: 
The reversible phosphorylation of proteins is one of the most important post-
translational modifications that regulate virtually all aspects of eukaryotic cell life. Since 
its discovery in mid-1950s, reversible phosphorylation has been found to alter protein 
functions in almost every conceivable way, such as changing their biological activities, 
stabilizing or signaling for degradation, facilitating or inhibiting subcellular translocation, 
and promoting or disrupting protein-protein interactions. It is now believed that 30% of 
cellular proteins encoded by the human genome contain covalently bound phosphate, and 
abnormal level of protein phosphorylation gives rise to various human diseases including 
cancer, diabetes, arthritis and neurodegenerative disease (43, 44). 
Counteracting each other at the opposite sides of reversible phosphorylation, 
protein kinases and phosphatases are under tight functional controls in vivo. In fact, some 
of them proved to be modified and regulated by reversible phosphorylation events 
themselves. For protein kinases, with the knowledge on their structures and functions 
growing rapidly in recent years, a good number of them have been found to undergo 
reversible phosphorylation that plays important roles in regulating their biological 
activities. Phosphorylation of specific serine, threonine, or tyrosine residues may occur 
at various sites catalyzed either by the kinases themselves (autophosphorylation) or other 
kinases, and the impacts on their kinase activities may either be positive or negative 
(118). As described in the early chapters, the heme-regulated inhibitor of protein 
132 
synthesis (HRI) belongs to the small family of eukaryotic eIF2a kinases which also 
includes the double-stranded RNA-activated protein kinase (PKR), yeast GCN2 (general 
£Ontrol non-gerepressible-2) and the recently identified endoplasmic reticulum (ER)-
localized PEK (Qancreatic ~IF2a kinase) or PERK (EKR-like ER _kinase) (94, 217). 
These kinases share extensive homology within their catalytic domains (34), but differ 
substantially within their regulatory domains (32,207). One common feature shared by 
these eIF2a kinases is that their activation is accompanied by autophosphorylation, which 
is believed to play an essential role in regulating their activities (32, 186, 207, 266). 
Recent studies on PKR have identified several autophosphorylation sites in both its 
regulatory and catalytic domains and their significance with regards to PKR kinase 
activity has also been characterized. Localized within the central region between the 
RNA-binding and catalytic domains, three adjacent residues, Ser-242, Thr-255 and Thr-
258 all appear to undergo autophosphorylation upon PKR activation in vitro. 
Interestingly, mutation of Thr-258 to alanine reduces PKR function both in vitro and in 
vivo, whereas mutation of Ser-242 or Thr-255 to alanine exhibits no effect. And yet 
simultaneous mutations of all three sites to alanine further exacerbate the inhibitory effect 
caused by Thr-258 mutation (241). An additional autophosphorylation site has also been 
identified at Thr-446, which is located in the conserved activation loop of PKR catalytic 
domain. An adjacent residue, Thr-451 which is also located in the activation loop of 
PKR, was suggested to be a potential autophosphorylation site of PKR. Importantly, site-
directed mutagenesis experiments demonstrated their importance in maintaining high-
level kinase activity of PKR both in vitro and in vivo. Interestingly, Thr-882 and Thr-887 
located in the activation loop of yeast GCN2 corresponding exactly to Thr-446 and Thr-
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451 in PKR, were found to be important for GCN2 kinase activity and likely to undergo 
autophosphorylation upon GCN2 activation (201). Thus, it seems that phosphorylation at 
both conserved and unique sites of the eIF2a kinases plays important yet distinct roles in 
regulating their activities. Although it is known as a fact that both HRI and PERK/PEK 
undergo multiple phosphorylations which are essential for their kinase functions (9, 217, 
246), no specific phosphorylation sites have been identified for either of these kinases so 
far. 
As with protein kinases, there has been emerging evidence supporting the notion 
that protein phosphatases are under similar functional controls by reversible 
phosphorylation. Protein phosphatase 1 (PPl) and 2A (PP2A), two major 
serine/threonine-specific members of the eukaryotic PPP family (45), have been reported 
to become phosphorylated at the C-terminus of their catalytic subunits, which inhibits the 
activities of both phosphatases concomitantly. PP le (PPl catalytic subunit) is 
phosphorylated at Thr-320 by CDK2 and its phosphatase activity is inhibited in a cell-
cycle-dependent manner (64,260). As to PP2Ac, two neighboring residues, Thr-304 and 
Tyr-307 are the targets for the "autophosphorylation-activated protein kinase" and 
tyrosine kinases such as p6ov-src, p561ck, and epidermal growth factor and insulin 
receptors. Like PP le, phosphorylation of Thr-304 and Tyr-307 of PP2A correlates with 
its loss of activity as well (18, 30, 93). In addition, regulatory subunits of both PPl and 
PP2A have been reported to harbor phosphorylation sites, whose modification 
functionally regulates the corresponding catalytic subunits in different ways. For 
instance, phosphorylation of the targeting GM subunit of PPl at Ser-67 by cAMP-
dependent protein kinase (PKA) disrupts its interaction with PPlc and hence releases 
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PP le from glycogen and selectively inhibits its regulation of glycogen metabolism (57, 
58). Interestingly, PKA has also been reported to phosphorylate the 74-kDa B" subunit 
of PP2A at three serine residues without dissociating it from PP2Ac, and it stimulates the 
phosphatase activity of PP2A towards a certain subset of its substrates (249). 
Identified by three different groups in 1994, protein phosphatase 5 (PPS) is a 
unique member of the PPP family in that its conserved catalytic domain is fused to an N-
terminal tetratricopeptide repeat domain (TPR) (10, 37, 42). The basal activity of PPS 
appears to be maintained at an extraordinarily low level in vivo due, at least in part, to the 
autoinhibition from its TPR domain. Polyunsaturated fatty acids stimulate PP5's activity 
in vitro presumably by relieving such autoinhibition through binding to the TPR domain 
(36, 224, 225). Although much effort has been made on elucidating the mechanisms by 
which PPS is regulated by its TPR domain and potential physiological activators, little is 
known about whether reversible phosphorylation occurs on PPS and plays any roles in 
modulating its function. 
In this report, we attempted to identify the phosphorylation sites on HRI that 
become modified upon its activation induced by heme-deficiency utilizing MALDI-TOF 
mass spectrometry in conjunction with biochemical and molecular biological techniques. 
As a result, we found that heme-deficiency induc~s phosphorylation of HRI within its 
unique regulatory kinase insertion domain and it occurs at either Ser-255 or Ser-260. As 
to PPS, we found that its isolated TPR domain also undergoes phosphorylation upon 
incubation in okadaic acid (OA)-treated RRL, and phosphorylation is accompanied by a 
characteristic electrophoretic mobility shift on SDS-PAGE. Using MALDI-TOF mass 
spectrometry and site-directed mutagenesis analyses such a phosphorylation site was 
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located to Ser-160 which resides near the end of the extended a7 helix of the TPR 
domain (53). Mutating it to alanine completely abolished the QA-induced electrophoretic 
mobility shift of the TPR domain. Additionally, such a site seems to be phosphorylated 
by protein kinase A (PKA) in vivo as suggested by the finding that both cyclic AMP and 
purified PKA were able to quantitatively shift the TPR domain molecules to the slower 
migrating form as induced by OA in vitro. The potential significances of these 
phosphorylation sites on both proteins were further discussed. 
Materials and Methods: 
Construction of the plasmids-pET30a-PP5 (216) was digested with HindIII (One site 
exists in PPS coding sequence between its TPR and phosphatase domains, and the other 
is in pET30a vector downstream of PPS coding sequence) to cleave off the coding 
sequence for the C-terminal phosphatase domain, and the remaining large HindIII 
fragment with the TPR domain alone in the pET30a vector was self-annealed. The 
resulting construct gave rise to a His-tagged recombinant TPR domain with a relatively 
large leader sequence (around 50 aa) encoded by the pET30a vector followed by a 
FLAG-tag (originated from the parent plasmid pCMV6-FLAG-PP5) and the PPS coding 
sequence. Due to the fact that the original stop codon in the PPS coding sequence was 
cleaved off along with the phosphatase domain, the new TPR construct used the one 
present in pET30a (3' to the multiple cloning region), and subsequently added a short tail 
sequence (AAALEHHHHHH) along with another His-tag ( engineered in pET30a as an 
alternative to the N-terminal tag) C-terminal to the TPR coding sequence. Therefore, the 
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resulting recombinant TPR domain contains two (His6)-tags at both ends and a FLAG-tag 
proceeding the coding sequence. 
Preparation of protein samples for MALDI-TOF mass spectrometry analysis-(His6)-Met3 
(192) was synthesized in TnT RRL at 30 °C for 40 min prior to chasing and maturing in 7 
volumes of heme-supplemented or heme-deficient RRL mixtures containing or lacking 
10 µg/ml geldanamycin for 3 hr. The maturation mixtures were subjected to 
immunoprecipitation using anti-(His5) antibody, followed by washing with 20 mM PIPES 
buffer (pH 7.4) containing 500 mM NaCl and 0.5% Tween-20. Protein samples were 
separated on 7.5% SDS-PAGE, visualized subsequently via staining in 0.1 % Coomassie 
brilliant blue R250 (dissolved in 50% methanol and 10% acetic acid) for 30 min and 
destaining in 50% methanol and 10% acetic acid for 3 hr. Gels were soaked in distilled 
water for 30 min, from which the pieces containing (His6)-Met3 were subsequently 
excised. 
The recombinant TPR domain of PPS (pET30a-TPR) was overexpressed in E. 
coli BL21(DE3) strain and purified under non-denaturing condition as described 
previously (215). To cleave off the His-tag along with the large leader sequence 
(encoded by the pET30a vector), the purified recombinant TPR was treated with 
enterokinase (Novagen) at a protein/enzyme ratio of 50: 1 µg/unit for 8 hr at 22 °C, 
followed by removal of the enterokinase using the Ekapture agarose (Novagen). 
Following reconstitution into heme-supplemented RRL containing or lacking 500 nM 
okadaic acid (Calbiochem) for 40 min, TPR was immunoprecipitated by M2 anti-FLAG 
antibody (Sigma), washed four times with 10 mM PIPES buffer (pH 7.2) containing 150 
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mM NaCl and 0.5% Tween-20, and analyzed on a 10% SDS-PAGE. After staining and 
destaining, gel pieces containing the TPR domain were excised. 
In-gel protease digest-Gel pieces containing the proteins of interest were washed with 
water and 50% acetonitrile (ACN) sequentially for 15 min each. Gel slices were 
subsequently dehydrated by briefly soaking in 100% ACN, which was then replaced by 
50 mM NH4HC03 to allow rehydration. Afterwards, the same volume of ACN was 
added and gel pieces were washed with 50% ACN/25mM NH4HC03 for 15 min. Washes 
were repeated until no residual Coomassie blue was visible. Gel pieces were dried down 
completely in a speed vacuum centrifuge, rehydrated in 10 mM DTT/100 mM NH4HC03 
for 45 min at 56 °C (reduction), followed by 30 min incubation in 55 mM 
iodoacetamide/100 mM NH4HC03 at room temperature (alkylation). Gel slices were 
then dried down and rehydrated in 30 µl of 12.5 ng/µl trypsin (Promega, sequencing 
grade) prepared in 50 mM NH4HC03 and 5 mM CaCh or V8 Glu-C (Calbiochem, 
sequencing grade) in 50 mM NH4HC03. After incubation at 37 °C for 12 hr or longer, 
the digestion fluid was removed and stored in separate tubes. Peptides trapped inside the 
gel pieces were further extracted with 50 µl of 50% acetonitrile/0.1 % TF A twice, both of 
which was then combined with the digestion fluid removed earlier. Pooled peptide 
mixtures were subsequently concentrated in a speed vacuum centrifuge to a final volume 
of 10-20 µ1. 
MALDI-TOF mass spectrometry analysis-Saturated a-cyano-4-hydroxycinnamic acid 
(matrix) (Sigma) was prepared in 50% acetonitrile/0.1 % TF A. 1.0 µl aliquot of the 
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concentrated peptide mixtures was spotted onto the MALDI plate, which was 
immediately covered by the same volume of saturated matrix solution. After drying 
completely, peptide samples were analyzed using the Voyager DE-PRO matrix-assisted 
laser desorption-ionization time-of-flight mass spectrometer (MALDI-TOF) (Applied 
Biosystems). Mass spectra were acquired in both linear and reflector modes, and 
compared to the predicted peptide mass fingerprints of HRI-Met3 or PP5-TPR generated 
by trypsin or VS Glu-C. Additionally, peptide samples of Met3 were also analyzed by 
the Bruker Reflex III MALDI-TOF mass spectrometer. To gain sequence information on 
the 2757.26-Da peptide of Met3 which seemed to correspond to residues 249-272 (of 
wild-type HRI), it was selected by the ion gate and subjected to the post-source decay 
(PSD) analysis in the reflector mode using the Bruker Reflex III MALDI-TOF mass 
spectrometer. Amino acid sequence was deduced based on the fragmentation pattern of 
the peptide, and it was matched to residues 249-272 of HRI as expected. 
In vitro phosphorylation assay-PKA-catalyzed phosphorylation reaction was carried out 
following the procedures as described elsewhere (249). Enterokinase-cleaved purified 
recombinant TPR domain (5 µg) was incubated with the catalytic subunit of PKA (15 
units) (Sigma) in a 70 µl reaction for 1 hr at 30 °C in 20 mM HEPES-NaOH buffer (pH 
7.4) containing 5 mM Mg(CH3C00)2, 0.5 mM dithiothreitol and 50 µM ATP. A control 
reaction including everything but PKA was carried out in parallel. Reactions were 
terminated by mixing with boiling SDS sample buffer, and subsequently analyzed on 
SDS-PAGE. 
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As to [32P]-labeling in RRL, enterokinase-cleaved purified recombinant TPR 
domain (2 µg) was reconstituted into 40 µl RRL mixture containing 500 nM okadaic acid 
or its inactive analog okadaic acid-7,10,24,28-tetraacetate (Calbiochem) and incubated at 
30 °C for 5 min. 15 µCi of [y-32P]ATP was then added to the RRL mixtures followed by 
15 min incubation. Reactions were subsequently immunoadsorbed to the M2 anti-FLAG-
tag antibody (Sigma), followed by washing four times with 10 mM PIPES buffer (pH 
7.2) containing 150 mM NaCl and 0.5% Tween-20. Samples were separated on SDS-
PAGE and analyzed by autoradiography. 
Treatment ofTPR domain with okadaic acid and cyclic AMP in RRL-Enterokinase-
cleaved purified recombinant TPR domain of PP5 (1 µg) (wild type, S160A or S164A 
mutant) was reconstituted into the heme-supplemented normal RRL (30 µl) containing 
okadaic acid (Calbiochem) (concentrations specified in figure legends) and/or cyclic 
AMP (Sigma) (concentrations specified in figure legends). After incubation at 30 °C for 
30-40 min (as specified in figure legends), RRL reactions were subjected to 
immunoadsorption with the M2 anti-FLAG-tag antibody (Sigma) followed by washing 
four times with 10 mM PIPES (pH 7.2) buffer containing 150 mM NaCl and 0.5% 
Tween-20. Samples were subsequently separated on SDS-PAGE, transferred to PVDF 
membrane and analyzed by staining with Coomassie brilliant blue R250 or Western blot 
using the anti-FLAG-tag antibody. 
Alkaline phosphatase (AP) treatment of the TPR domain-Enterokinase-cleaved purified 
recombinant TPR domain (1 µg) was reconstituted into RRL mixtures (40 µl) containing 
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500 nM okadaic acid or its inactive analog okadaic acid-7,10,24,28-tetraacetate 
(Calbiochem) and incubated at 30 °C for 40 min. Reactions were then subjected to 
immunoadsorption using the anti-FLAG-tag antibody (Sigma) and washed four times 
with 10 mM PIPES buffer (pH 7.2) containing 150 mM NaCl and 0.5% Tween-20. 
Resin-bound TPR proteins were subsequently treated with alkaline phosphatase (5 units, 
Promega) in the 50 mM Tris-HCl (pH 9.3) buffer containing 1 mM MgCh, 0.1 mM 
ZnClz and 1 mM spermidine (Promega) at 37 °C for 1 hr. Reaction was terminated by 
mixing with the boiling SDS sample buffer and analyzed on SDS-PAGE. Proteins were 
transferred to PVDF membrane and immunoblotted using the anti-FLAG-tag antibody. 
Site-directed mutagenesis-Point mutations of Ser-255 and Ser-260 of HRI were carried 
out using a PCR-based method. We took advantage of two unique internal restriction 
sites within the cDNA sequence of HRI, Dram and AflII that are about 400 bps apart. 
Dram is located approximately 70 and 80 bps upstream of the Ser-255 and Ser-260 
codons, respectively. To introduce the S-A mutations at Ser-255 and Ser-260, two 
oligonucleotides (5' primers for PCR) corresponding to the region of HRI spanning from 
the Dram site to the downstream codons encoding either Ser-255 or Ser-260 were 
synthesized, and the desired mutations were engineered at either Ser codon. For the 3' 
primer, another oligonucleotide was synthesized which corresponds to the region of HRI 
that harbors the unique AflII site. PCR reactions were carried out using the pSP64T-HRI 
plasmid (246) as the template and the resulting DNA fragments were digested with Dram 
and AflII and used to replace the corresponding region in the wild-type pSP64T-HRI 
plasmid. The desired mutations were subsequently confirmed by sequencing. To make 
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the double mutations at both Ser-255 and Ser-260, the PCR reaction was carried out 
using the 5' primer containing the S260A mutation and the pSP64T-HRI-S255A plasmid 
as the template. Additionally, to add the (His6)-tag to the N-terminus of the HRI mutants, 
they were cleaved from the pSP64T vector as a NcoI/MluI fragment and cloned into the 
corresponding sites of pSP64TL which is a modified version of pSP64T that encodes an 
(His6)-tag preceding the Ncol site (97). 
Similar strategy was used to introduce the S-A mutations to Ser-160 and Ser-
164 of the TPR domain of PP5. A unique HindIII site that sits between the N-terminal 
TPR and C-terminal phosphatase domains of PP5 was used to clone the TPR domain out 
of the full-length PP5 by PCR. Two oligonucleotides (3' primers) encoding the inter-
domain region of PP5 were synthesized to include the S-A mutations at either Ser-160 or 
Ser-164 along with the HindIII site that is approximately 50 and 60 bps downstream of 
the two Ser codons, respectively. Another oligonucleotide (5' primer) encoding the N-
terminus of PP5 was also engineered to include an EcoRI and a BamHI site preceding the 
start codon. They were coupled in PCR reactions using the wild type pSP64T-PP5 
plasmid (216) as the template. The 600-bp PCR product was digested with 
BamHI/HindIII and cloned into the corresponding sites of pET30a vector, and the desired 
mutations were confirmed by sequencing. To introduce these mutations into the full-
length PP5, the phosphatase domain of PP5 was excised from the pCMV6 vector (35) as 
a HindIII fragment and inserted into the same site of the pET30a-TPR mutants (S 160A or 
S164A). To transfer the full-length PP5 mutants into the RRL-specialized pSP64T and 
pSP64TL (encoding an (His6)-tag) vectors, they were excised from pET30a as an EcoRI 
fragment and subcloned into the same site of pSP64T and pSP64TL vectors. 
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Results: 
1) TPR domain of PPS: 
a) Okadaic acid induces phosphorylation of the TPR domain of PPS-To investigate 
whether post-translational phosphorylation occurs on PPS, we first examined whether it is 
able to undergo any electrophoretic mobility shift on SOS-PAGE which often serves as 
an indicator of protein phosphorylation events. Rabbit reticulocyte lysate (RRL) was 
used as a quasi-physiological system in which purified recombinant PPS was 
reconstituted and analyzed. Qkadaic acid (QA), a serine-threonine phosphatase inhibitor, 
was included in the reaction mix to prevent any possible dephosphorylation of PPS from 
occurring either catalyzed by itself or by other endogenous protein phosphatase(s) in 
RRL. In addition to the full-length protein, we also analyzed the isolated recombinant 
TPR domain of PPS in the same experiment based on a potential protein kinase A (PKA) 
phosphorylation site near its C-terminus (DEHRR.S.160VVDS for rat and 
DEHKR.S.160VVDS for human PPS)~ As shown in Fig. 31, there was no detectable level 
of electrophoretic mobility shift for the full-length PPS in response to QA treatment. 
This was confirmed in a separate experiment in which the de novo synthesized PPS was 
analyzed in RRL (data not shown). Interestingly, an electrophoretic mobility shift was 
observed for a portion of the TPR molecules (less than SO%) in QA-treated RRL (Fig. 
31), indicating that phosphorylation occurs on the TPR domain of PPS when it is 
separated from the phosphatase domain. 
To confirm that it is phosphorylation that correlates with the electrophoretic 
mobility shift of the TPR domain, we took on two different approaches. In the first 
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Figure 31. Okadaic acid (QA) induces electrophoretic mobility shift of the TPR domain 
of PPS. Purified recombinant full-length PPS or its isolated TPR domain was 
reconstituted into RRL mixtures lacking (lane 1) or containing 10 nM (lane 2), 100 nM 
(lane 3) or 500 nM (lane 4) okadaic acid. Following incubation at 30 °C for 40 min, they 
were immunoprecipitated by the anti-FLAG-tag antibody and analyzed on a 10% SDS-
polyacrylamide gel. Proteins were transferred to PVDF membrane and subsequently 
stained with Coomassie brilliant blue R250. Slower: slower migrating form of the TPR 
domain; Faster: faster migrating form of the TPR domain. 
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approach, we treated the recombinant TPR domain with OA in RRL, immunoprecipitated 
it using anti-FLAG-tag antibody and treated it with alkaline phosphatase (AP) in vitro. 
Consistent with being caused by phosphorylation, the electrophoretic mobility shift of 
TPR induced by OA was abolished by AP treatment (Fig. 32A). In the second and more 
straightforward approach, we radiolabeled the recombinant TPR domain with [y-32P]ATP 
in RRL in the presence or absence of OA. Whereas trace level of [32P]-labeling of TPR 
was observed in the absence of OA, the labeling intensity was enhanced substantially in 
its presence. More importantly, after superimposing the [32P]-autoradiogram with the 
immunoblotted membrane, we found that the [32P]-labeled protein band corresponded 
precisely to the slower migrating form of TPR, further supporting our hypothesis that 
phosphorylation occurs on the TPR domain of PP5 and correlates directly with its 
electrophoretic mobility shift on SDS-PAGE (Fig. 32B). The fact that only in the 
presence of OA did we observe the significant level of phosphorylation on TPR also 
suggests that it is a reversible process controlled by specific protein kinase(s) and 
phosphatase( s). 
b) Protein kinase A phosphorylates the TPR domain of PPS-To investigate whether the 
QA-induced phosphorylation of the TPR domain occurs on the potential PKA site 
mentioned above, we examined the effect of cyclic AMP ( cAMP), the physiological 
activator of PKA, on the electrophoretic mobility of the recombinant TPR in RRL. As 
shown in Fig. 33A, cAMP caused a small fraction of the TPR molecules to undergo the 
same electrophoretic mobility shift as that caused by OA. More significantly, 
simultaneous treatment of cAMP and OA quantitatively shifted all TPR molecules to 
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Figure 32. The okadaic acid (OA)-induced electrophoretic mobility shift of TPR results 
from phosphorylation. A) Alkaline phosphatase (AP) treatment of the TPR domain. 
Purified recombinant TPR domain was reconstituted into RRL mixtures containing 500 
nM okadaic acid (lanes 3 and 4) or its inactive analog okadaic acid-7,10,24,28-
tetraacetate (lanes 1 and 2) and incubated at 30 cc for 40 min. Reactions were then 
subjected to immunoadsorption using the anti-FLAG-tag antibody, and the resin-bound 
TPR domain was treated with alkaline phosphatase (AP) (lanes 2 and 4) or equal 
volumes of enzyme-free buffer (lanes 1 and 3) at 37 cc for 1 hr as described under 
"Materials and Methods". Reactions were terminated by boiling SDS sample buffer and 
samples were subsequently analyzed on a 10% SDS-polyacrylamide gel. Proteins were 
transferred to PVDF membrane and immunoblotted with the anti-FLAG-tag antibody. B) 
[32P]-labeling of the reconstituted TPR domain in RRL. Purified recombinant TPR 
domain was reconstituted into RRL containing 500 nM okadaic acid (lane 2) or okadaic 
acid-7,10,24,28-tetraacetate (lane 1), incubated at 30 cc for 5 min followed by addition 
of [y-32P]ATP and another 15 min incubation. RRL mixtures were subsequently 
immunoadsorbed by the anti-FLAG-tag antibody, separated on a 10% SDS-
polyacrylamide gel, transferred to PVDF membrane and analyzed by autoradiography 
(AD). The same membrane was also Western blotted with the anti-FLAG-tag antibody 
and used to superimpose against the [32P]-autoradiogram (WB). Slower: slower 
migrating form of the TPR domain; Faster: faster migrating form of the TPR domain. 
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their slower migrating form. These findings strongly suggest that PKA phosphorylates 
the TPR domain of PPS at the above mentioned consensus site (Ser-160), and that such a 
site is readily dephosphorylated in RRL, and possibly in vivo, by certain protein 
phosphatase( s). 
To confirm these observations, we carried out an in vitro PKA kinase assay 
using the recombinant TPR domain as the substrate (Fig. 33B). The constitutively active 
catalytic subunit of PKA was used and cAMP (which activates PKA through binding to 
the regulatory subunit) was omitted from the reaction. As we expected, incubation with 
the PKA catalytic subunit shifted almost the entire population of the TPR molecules to 
the slower migrating form, showing that the TPR domain was nearly quantitatively 
phosphorylated by PKA in vitro. Taken together, our data strongly suggested that PKA 
phosphorylates PPS in its TPR domain, which may represent an important mechanism by 
which PPS function is regulated in vivo. 
c) MALDI-TOF mass spectrometry analysis of phosphorylation site(s) in PPS TPR-To 
gain more direct evidence for the PKA-catalyzed phosphorylation at Ser-160 of the TPR 
domain of PPS, we analyzed its two distinct migrating forms using MALDI-TOF mass 
spectrometry. Purified recombinant TPR was treated with OA in RRL, 
immunoprecipitated and separated on SDS-PAGE. Gel pieces containing faster or slower 
migrating forms of TPR were excised and subjected to in-gel digestion with trypsin or V8 
Glu-C. Resulting peptide mixtures were subsequently analyzed by MALDI-TOF MS. 
Useful information was obtained by comparing the experimental peptide mass fingerprint 
with that predicted based on the amino acid sequence of the recombinant TPR 
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Figure 33. Protein kinase A (PKA) phosphorylates the TPR domain of PPS in vitro. A) 
Purified recombinant TPR domain of PPS was reconstituted into RRL containing 500 nM 
okadaic acid (OA, even-number lanes) or its inactive analog okadaic acid-7, 10,24,28-
tetraacetate (-, odd-number lanes) in the absence (lanes 1 and 2) or presence of 5 µM 
(lanes 3 and 4) , 50 µM (lanes 5 and 6) and 500 µM (lanes 7 and 8) cyclic AMP (cAMP). 
Reactions were incubated at 30 °C for 40 min and immunoabsorbed by the anti-FLAG-
tag antibody. Proteins were analyzed on a 10 % SDS-polyacrylamide gel, transferred to 
PVDF membrane, and immunoblotted with the anti-FLAG-tag antibody. B) Purified 
recombinant TPR domain was treated with the catalytic subunit of PKA at 30 °C for 1 hr 
(lane 2) as described under "Materials and Methods". A control reaction containing the 
same amount of TPR but lacking PKA was carried out in parallel (lane 1). Reactions 
were terminated by mixing with the SDS sample buffer, separated on a 10% SDS-
polyacrylamide gel, transferred to PVDF membrane and analyzed by staining with 
Coomassie brilliant blue R250. Slower: slower migrating form of the TPR domain; 
Faster: faster migrating form of the TPR domain. 
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domain as a result of partial or complete digestion by trypsin or VS Glu-C. In doing so 
with the trypsin digestion of the faster TPR migrating form, we identified a peptide with a 
measured mass of 2313.67 Da which corresponds to the calculated mass (2314.06 Da) of 
a predicted TPR fragment spanning residues 160-180 and containing the consensus PK.A 
site Ser-160 along with three other serines and one threonine (Ser-164, Ser-169, Ser-177 
and Thr-171). Interestingly, this peptide was not found in the spectrum of the slower 
migrating form of TPR. Instead, we detected a 2394.46 Da peptide, which is 
approximately 80 Da higher than that found for the faster migrating form of TPR. 
Similarly, a predicted TPR peptide resulting from partial trysinolysis that spans residues 
159-180 (2470.17 Da) and contains all five above mentioned serine/threonine residues 
was identified for the faster, but not the slower migrating form of TPR, whereas a peptide 
of 80 Da higher (2549.16 Da) was found for the slower migrating form of TPR only 
(Table 4). These findings suggest that one of the five serine/threonine residues within the 
TPR peptide containing residues 160-180 is phosphorylated in response to OA and cAMP 
treatment, which correlates with the electrophoretic mobility shift. It is also important to 
note that the consensus phosphorylation site for PK.A, Ser-160, resides in this peptide. 
To more closely define the phosphorylation site, in-gel digest of the TPR 
domain was carried out using a different protease, VS Glu-C which is capable of 
generating an entirely different peptide mass fingerprint of a protein from that generated 
by trypsin. In doing so, we detected a peptide of 1425.99 Da that corresponds to the 
calculated mass (1425.74 Da) of a predicted TPR fragment spanning residues 157-168 
and containing Ser-160 and Ser-164 for the faster but not the slower migrating form of 
TPR, whereas a peptide with a molecular mass roughly 80 Da higher (1505.57 Da) was 
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Recombinant 
TPR Measured mass Calculated mass Covered sequence 
Slower Faster (Da) (Da) 
form form 
-y 2313.67 2314.06 S10°VVDSLD1ESMTIEDEYSGPK180 
-y 2394.46 2314.06+80(P03) ~iouVVD~LD1E~MIIEDEY~GPK1~u 
-y 2470.23a 2470.17a RmSVVDSLD1ESMTIEDEYSGPK1~u 
-y 2549.16a 2470.l 7+80(P03) a Rm~VVD~LDIE~MIIEDEY~GPKrnu 
a peptides resulting from partial trypsin digest 
Bold and underlined serine residues represent the potential phosphorylation sites 
Table 4. MALDI-TOF MS analysis of tryptic peptides of recombinant TPR domain 
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only observed for the slower migrating form. Additionally, a peptide (2138.09 Da) 
spanning residues 150-168 which resulted from partial V8 Glu-C digestion was identified 
for the faster migrating form of TPR, whereas a peptide with a molecular mass 
approximately 80 Da higher (2218.09 Da) was found for its slower migrating form 
instead (Table 5). Therefore, the putative phosphorylation site of TPR was successfully 
narrowed down to two candidates, Ser-160 and Ser-164 one of which is the consensus 
phosphorylation site for PKA. 
d) Site-directed mutagenesis studies of Ser-160 and Ser-164 in PPS TPR--To verify the 
MALDI-TOF MS data and identify the exact phosphorylation site in the TPR domain of 
PPS, we mutated the two candidate residues, Ser-160 and Ser-164 to alanines individually 
and examined their electrophoretic behaviors in response to OA and cAMP treatments. 
Significantly, the recombinant S160A mutant of TPR lost its ability to undergo the 
electrophoretic mobility shift in response to OA and cAMP treatments, whereas the 
S164A mutant behaved the same as the wild type TPR (Fig 34A & B). Therefore, our 
data clearly demonstrated that Ser-160 is the phosphorylation site in the TPR domain of 
PPS whose modification by PKA is stimulated by OA and cAMP treatments. 
2) Met-3 mutant of HRJ: 
a) Quantitative transformation of Met-3 mutant of HR/ in response to heme-deficiency in 
RRL-Transformation and activation of HRI is accompanied by autophosphorylation as 
well as its characteristic electrophoretic mobility shift on SDS-PAGE. To identify the 
phosphorylation sites on HRI which become modified upon activation, we faced the 
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Recombinant TPR 
Measured mass Calculated mass Covered sequence 
Slower Faster (Da) (Da) 
form form 
...; 1425.99 1425.74 H lJ 'RRSVVDSLDIE 10~ 
...; 1505.57 1425.74+80(P03) HlJ'RR§VVD§LDIE'M 
...; 2138.64a 2138.09a RDU AIAGDEHRRSVVDSLD1E1M 
...; 2219.05 a 2138.09+80(P03) a RmAIAGDEHRR§VVD§LDIE10~ 
a peptides resulting from partial V8 Glu-C digest 
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Figure 34. S 160A mutant of the TPR domain is unable to undergo the electrophoretic 
mobility shift induced by okadaic acid (OA) and cyclic AMP (cAMP). A) Purified 
recombinant wild type (lanes 1 and 2), S160A (lanes 3 and 4) and S164A (lanes 5 and 6) 
mutants of the TPR domain were reconstituted into separate RRL reactions containing 
500 nM okadaic acid (OA, lanes 2, 4 and 6) or its inactive analog okadaic acid-
7, 10,24,28-tetraacetate (-, lanes 1, 3 and 5) and incubated at 30 °C for 40 min. Proteins 
were separated on a 10% SDS-polyacrylamide gel, transferred to PVDF membrane and 
immunoblotted with the anti-FLAG-tag antibody. B) Purified recombinant S160A (lanes 
1-4) and S164A (lanes 5-8) mutants of the TPR domain were reconstituted into RRL 
reactions lacking (lanes 1 and 5) or containing 500 nM okadaic acid (OA, lanes 3 and 7), 
50 µM cAMP (lanes 2 and 6) or a combination of both (lanes 4 and 8), and incubated at 
30 °C for 40 min. Proteins were separated on a 10% SDS-polyacrylamide gel, 
transferred to PVDF membrane and immunoblotted with the anti-FLAG-tag antibody. 
Slower: slower migrating form of the TPR domain; Faster: faster migrating form of the 
TPR domain. 
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challenge of obtaining a homogenous population of transformed/activated HRI 
molecules. Unfortunately in RRL, for some unknown reasons only half of the de nova 
synthesized HRI molecules are able to transform into the slower migrating form in 
response to heme-deficiency. Due to the difficulty in separating the two closely-
migrating forms of wild-type HRI on SDS-PAGE, we turned to the Met-3 mutant of HRI 
which lacks the majority of the N-terminal heme-binding domain. Previous studies have 
indicated that it is much less heme-responsive than the wild-type HRI, therefore it may be 
regulated differently in terms of the ability to autophosphorylate and activate in response 
to heme-deficiency (192). Surprisingly, upon incubation in heme-deficient RRL for 3 
hours, newly synthesized Met-3 almost quantitatively transformed into the slower 
migrating form, an observation that has never been made for the wild-type HRI under the 
same condition (Fig. 35). Based on the assumption that the electrophoretic mobility is 
caused, at least partially, by phosphorylation events, Met-3 mutant appeared to be a better 
choice for identifying phosphorylation sites of HRI than the wild-type protein because of 
the ease of obtaining its transformed and phosphorylated form in homogeneity. 
b) MALDI-TOF mass spectrometry analysis of phosphorylation sites in Met-3 mutant of 
HRI--Following quantitative transformation in heme-deficient RRL, (His7)-Met-3 was 
immunoprecipitated and applied on SDS-PAGE from which gel pieces containing the 
transformed (His7)-Met-3 were excised and subjected to in-gel trypsin digestion. As the 
presumed hypophosphorylated control, (His7)-Met-3 was also synthesized and matured in 
heme-supplemented RRL containing GA (a specific inhibitor of Hsp90 which is essential 









Figure 35. Met-3 mutant of HRI undergoes quantitative transformation into the slower 
migrating form on SDS-PAGE upon 3 hr incubation in heme-deficient RRL. Met-3 
mutant of HRI was synthesized in TnT RRL at 30 °C for 15 min, followed by a 4-min 
pulse-label with [35S]Met. [35S]-Met3-containing TnT RRL was subsequently transferred 
into 7 volumes of heme-supplemented RRL containing geldanamycin (lane 1) or normal 
heme-deficient RRL mix (lane 2) and incubated at 30 °C for 1 hr. Aliquots of both 
reactions were analyzed on an 8% SDS-polyacrylamide gel and visualized by 
autoradiography. Transformed: transformed HRI with slower electrophoretic mobility; 
Untransformed: untransformed HRI with faster electrophoretic mobility. 
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subjected to the same in-gel digest procedures. The resulting peptide mixtures of both 
forms of (His7)-Met-3 were then analyzed by MALDI-TOF mass spectrometry. After 
comparing the experimental spectra with the calculated peptide mass fingerprint 
produced by partial or complete trypsin digestion of (His7)-Met-3, we identified a peptide 
with a measured mass of 2067.01 Da which corresponds to the calculated mass (2067.06 
Da) of a predicted (His7)-Met-3 peptide spanning residues 249-266 (numbering based on 
the wild-type rabbit HRI) and containing two serines, Ser-255 and Ser-260. However, 
this peptide was only observed for the untransformed (His1)-Met-3. As to the 
transformed (His7)-Met-3, a different peptide with a molecular mass roughly 80 Da 
higher (2147.04 Da) was detected in the spectrum, indicating that the peptide spanning 
residues 249-266 was phosphorylated either on Ser-255 or 260. Supporting this 
hypothesis, partial trypsin digestion of the untransformed (His7)-Met-3 generated a 
peptide (2757.34 Da) that corresponds to a predicted fragment (2757.39 Da) spanning 
residues 249-272 and harboring the same two serines. However, in the spectrum of the 
transformed (His7)-Met-3, a peptide with a measured mass approximately 80 Da higher 
(2837 .25 Da) was found instead (Table 6). Further evidence for the single-site 
phosphorylation between residues 249 and 272 included the finding that following post-
source decay (PSD) of the 2837 .25 Da peptide, a novel fragment (2739.25 Da) of 98 Da 
smaller was detected, characteristic of the metastable decomposition of the phosphate 
group (H3P04) from the parent peptide. Furthermore, PSD-assisted amino acid 
sequencing of the 2757.34 Da peptide confirmed its identity as the region spanning 
residues 249-272 of HRI. Therefore, our data suggested that either Ser-255 or Ser-260 
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(His7)-Met-3 
transformed untranformed Measured Calculated mass 
mass (Da) (Da) 
..J 2067.01 2067.06 
..J 2147.04 2067 .06+80(P03) 
..J 2757.34a,IJ 2757.39° 
..J 2837.25° 2757.39+80(P03)° 
a peptide sequenced by post-source decay (PSD) 








Bold and underlined serine residues represent the candidate phosphorylation sites. 
Table 6. MALDI-TOF MS analysis of tryptic peptides of (His7)-Met-3 
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becomes phosphorylated upon HRI transformation and activation in response to heme-
deficiency. 
Discussion: 
Driven by the hypothesis that reversible phosphorylation occurs on and 
functionally regulates both HRI and PPS, we have searched and found strong evidence 
for specific phosphorylation sites on both proteins using a combination of biochemical, 
molecular biological and MALDI-TOF mass spectrometry analyses. Out of multiple 
elusive phosphorylation sites on HRI (9), we have successfully detected one in its unique 
kinase insertion sequence (between the two conserved kinase subdomains) and narrowed 
the possibility down to two candidates, Ser-255 or Ser-260. As to PPS, a novel 
phosphorylation site was identified at Ser-160, which is located near the end of the 
extended seventh helix of its N-terminal TPR domain (53). The possible significances of 
these two sites are discussed below. 
Early studies indicated that phosphorylation level of HRI correlate with its kinase 
activity (70). Recently, Bauer et al found that HRI is multiply phosphorylated at serine, 
thereonine and to a lesser extent, tyrosine residues upon activation, which is essential for 
HRI to adopt the stable and active conformation as a homodimer (9). However, their 
identities remain elusive. Based on the recent identification of two conserved 
phosphorylation sites in the activation loop of PKR (Thr-446, Thr-451) and GCN2 (Thr-
882, rhr-887) (201) and the striking similarities within the kinase domains of eIF2a 
kinases (34), it is tempting to speculate that the corresponding sites (Thr-483, Thr-488) in 
the activation loop of HRI are also phosphorylated upon activation. As with most other 
kinases, possible phosphorylation of the activation loop of HRI is expected to activate it 
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by inducing local conformational changes within its active site and consequently altering 
its binding affinities for substrate (55, 265) or ATP, or changing the phosphoryl transfer 
reaction itself (2, 119). 
One common feature shared by many protein kinases is the ability of 
phosphorylation within their regulatory domains/sequences to alter their functions in 
distinct ways. Besides the conserved kinase domain, HRI contains two additional 
regulatory domains: an N-terminal heme-binding domain (HBD) and an insertion 
sequence (KIS) located between its two kinase lobes (32). The HBD bears the major 
heme-binding site of HRI whose stable occupation by heme is thought to play a role in 
facilitating the proper folding and maintaining the stability of HRI in reticulocytes (247). 
Interestingly, KIS has recently been identified as the possible second heme-binding 
domain of HRI. In contrast to HBD, KIS binds heme rather weakly but reversibly, and is 
thought to be responsible for the rapid down-regulation of HRI activity by heme (192). 
In addition, KIS seems to undergo multiple phosphorylations as indicated by the 
reproducible laddering appearance of its different electrophoretic migrating forms on 
SDS-PAGE (data not shown). Significantly, such a hypothesis was strongly supported by 
our evidence here for specific phosphorylation of Ser-255 or Ser-260 within KIS upon 
activation of HRI by heme-deficiency. However, its functional importance remains 
unclear at this point. Our initial studies in which either Ser-255 or Ser-260 was mutated 
to alanine failed to result in any significant changes in the eIF2a kinase activity of HRI in 
response to heme-deficiency ( data not shown). It then seems that this particular 
phosphorylation event in KIS is not essential for the activation of HRI by heme-
deficiency. This is not totally unexpected given the huge number of potential 
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phosphorylation sites on HRI and the complexity and possible redundancy of their 
individual and/or coordinated effects on HRI function. Therefore, simply mutating one 
of its autophosphorylation sites may not be able to generate detectable, if any, phenotypic 
changes of the HRI protein. 
Alternatively, phosphorylation of Ser-255 or Ser-260 may alter functional 
aspect(s) ofHRI other than the activation process induced by heme-deficiency per se. 
One good candidate is the heme-binding ability of KIS. We speculate that 
phosphorylation within KIS inhibits its ability to bind heme and conversely heme-binding 
to KIS inhibits its multiple phosphorylation. This speculation is based on several lines of 
evidence. 1) Heme-binding and multiple phosphorylation have opposing effects on HRI 
function. While the former down regulates HRI kinase activity (70, 246), the latter is 
essential for its activation (9). 2) Heme-binding has been reported to inhibit ATP 
binding by HRI (33), which may potentially prevent HRI from autophosphorylating 
within and/or outside the KIS and transforming into the active state. 3) The 
phosphorylation level of HRI reciprocally correlates with its readiness of being repressed 
and bound by heme. While transformed HRI with moderate level of phosphorylation is 
readily repressed by heme, hyperactivated and hyperphosphorylated HRI becomes much 
less sensitive to inhibition by heme (32, 70). Considering the possible role of KIS in 
reversible heme-binding and rapid down-regulation of HRI activity, it is tempting to 
speculate that multiple phosphorylations within KIS primarily regulate the transition of 
HRI from the low-activity/heme-sensitive state to the high-activity/heme-resistant state. 
Future experiments designed to compare the heme-responsiveness of transformed wild 
type and S255A or S260A mutants of HRI at finer scales may shed light on such a 
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hypothesis. Nonetheless, the exact mechanism by which heme-binding and multiple 
phosphorylation of HRI counteract each other is probably very complicated and difficult 
to determine until more phosphorylation sites are identified in future studies. 
Over the past few years, various studies on PP5 clearly demonstrated the 
importance of its TPR domain for its biological function. First, TPR domain targets the 
catalytic domain of PP5 to specific client and partner proteins. Second, TPR domain 
inhibits the phosphatase activity of PP5, presumably by binding directly to and 
interfering with the catalytic domain. Finally, TPR domain is believed to possess the 
binding site for the polyunsaturated fatty acid activators of PP5, such as arachidonic acid, 
which relieves the autoinhibition by freeing the catalytic domain from the physical 
masking by the TPR domain (41). Here in this report this domain becomes more 
interesting with our novel finding that it undergoes reversible phosphorylation. The 
phosphorylation site, Ser-160, is located near the end of the last a helix of the TPR 
domain, which is positioned at the junction between the TPR and phosphatase domains 
(Fig. 36) (53). One could easily imagine that introducing a phosphate group at an inter-
domain junction would cause dramatic conformational changes of the protein as a result 
of tightening or loosening of the domain-domain interactions. Such examples have been 
well established in many protein kinases where single-site phosphorylation of the 
activation loop, sandwiched by two kinase lobes, triggers conformational changes far 
beyond the phosphorylation site, and ultimately leads to kinase activation (119). As for 
PP5, such a global conformational change induced by single-site phosphorylation at Ser-
160 is also possible, and the controlled opening and closing of the two-domain structure 
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Figure 36. Crystal structure of the isolated TPR domain of PPS (PDB code, lAl 7) shown 
in ribbons. Ser-160 which was identified as the in vitro phosphorylation site is labeled 
and shown in sticks. It is located towards the end of the extended seventh a-helix of the 
TPR domain. Lys-32, Lys-97 and Arg-101 which are involved in interacting with the C-
terminus of Hsp90 are also labeled and shown in sticks. They are located in the first and 
fifth a-helices but all within and pointing to the center of the Hsp90-binding groove of 
the TPR domain (top view). 
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of PPS may consequently relieve or maintain the autoinhibition of its phosphatase activity 
by the TPR domain. 
Unfortunately, our preliminary data do not seem to support such a hypothesis. 
Mutagenesis studies in which Ser-160 is mutated to either alanine or glutamate showed 
little impact on the phosphatase activity of PPS when assayed in vitro using p-nitrophenyl 
phosphate (pNPP) as the substrate. Although we can not rule out the possibility that 
phosphorylation of Ser-160 is functionally unimportant to PPS, the failure of the 
mutations to alter the phosphatase activity of PPS could be due to other reasons. 1) PPS 
purified from E. coli is likely to be quantitatively unphosphorylated due to its efficient 
auto-dephosphorylation and the lack of appropriate protein kinases. This hypothesis is 
supported by the finding that even in the eukaryotic RRL system which contains its 
putative kinase PKA, little phosphorylation of TPR could be detected without addition of 
the phosphatase inhibitor (Fig. 31), suggesting that the equilibrium of the reversible 
phosphorylation on Ser-160 is normally in favor of the dephosphorylation reaction. 
Therefore, it is highly possible that both the wild type PPS and the S 160A mutant that we 
tested were equally unphosphorylated, which then explains their same levels of 
phosphatase activities. As to the Sl60E mutant, although in many cases the monoanionic 
glutamate closely mimics the dianionic phospho-serine, subtle differences still exist in 
their three-dimensional structures, hydrogen bonding properties and charges, which are 
the key determinants of specific phosphorylation-induced structural and functional 
changes of proteins. Therefore it is possible that the S160E mutant can not imitate the 
phosphorylated state of PPS well enough, which then explains their similar levels of 
phosphatase activity. 2) Although pNPP is routinely used as the in vitro substrate for 
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most protein phosphatases, its simple structure must be very different from those of the 
true physiological substrates of the phosphatases. Therefore, subtle conformational 
changes of PPS caused by phosphorylation ( or the phosphorylation-mimicking S/E 
mutation) that are sufficient to alter its activity towards the true clients might be blind to 
the small pNPP molecule. It thus seems difficult to address the true functional 
significance of this phosphorylation event for PPS until its physiological substrates are 
identified. 
Alternatively, instead of affecting the catalytic activity of PPS, phosphorylation of 
Ser-160 may be regulating other aspects of PPS function. One possible mechanism is 
that it alters the binding affinity of the TPR domain for specific set(s) of PPS substrates 
and/or partners. TPR domains consisting of multiple TPR motifs have the potential to 
possess distinct binding sites for different proteins (128, 244). Containing three TPR 
motifs, the single TPR domain of PPS may be able to interact with different proteins via 
different binding sites. In fact, such a possibility has already been suggested by the 
recent finding that an edge of the TPR domain of PPS that is outside the main Hsp90-
binding groove may be interacting with its phosphatase domain and responsible for 
autoinhibition (121). It is also similarly implicated by our observation that the TPR 
domain of PPS interacts with Hsp90 and HRI simultaneously and its interaction with HRI 
is not entirely mediated by Hsp90, which indicates a separate binding site of the TPR 
domain for HRI that is different from that for Hsp90 (Chapter ill, Figure 16). Reversible 
phosphorylation of Ser-160 may serve as a conformational switch for the TPR domain of 
PPS which shifts its binding affinity in favor or disfavor of specific client or partner 
proteins in response to different cellular conditions. Indeed, mounting evidence suggests 
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a general role of reversible phosphorylation in regulating protein-protein 
association/dissociation (118). Such examples include phosphorylation-induced 
association between the CREB (fyclic AMP response ~lement ]2inding protein) and CBP 
(CREB ]2inding nrotein) (190, 191), phosphorylation-promoted dimerization of STAT 
(signal transducers and activators of transcription) ( 40), and phosphorylation-induced 
dissociation of the inactivation domain from the K+ channel ( 4) and that of Rb 
(Retinoblastoma tumor suppressor protein) from its various targets (123). Three-
dimensional structures of these protein revealed that in some cases phosphorylation alters 
protein-protein interaction through electrostatic repulsion or attraction, which causes 
conformational changes near or distant from the phosphorylation sites. Nonetheless, 
novel physiological interacting proteins of PP5 need to be identified in order to examine 
such a hypothesis. Finally, phosphorylation of Ser-160 may be involved in some yet 
unknown aspects of PP5 function, or it may regulate PP5 in redundancy with other 





The 90-kDa heat shock protein (Hsp90) is an abundant and essential molecular 
chaperone in eukaryotic cells. Contrary to other members of the chaperone family, only a 
small number of in vivo substrates have been identified for Hsp90 to date, and the most 
common feature shared by these known Hsp90 clients is that the majority of them play 
critical roles in cellular signal transduction. In all these cases, association of the client 
proteins with Hsp90 is essential for their stability and/or activity. While the underlying 
mechanism of Hsp90 function still remains largely unknown, studies over the past decade 
revealed that its in vivo chaperone activity is differentially, yet coordinately regulated by 
a highly conserved group of proteins, the so-called cohorts or co-chaperones. In this 
study, we focused on two of these co-chaperones, namely pSOcdc3l and protein 
phosphatase S (PPS) and examined their roles in the Hsp90-dependent biogenesis of the 
heme-regulated eIF2a kinase (HRI), which has been previously established to be an in 
vivo substrate of Hsp90. In addition, we also studied the structure-function relationship 
of pSOcdc37 and obtained an authentic domain structure in which its kinase- and Hsp90-
binding activities are segregated into two different regions. Finally, since regulatory 
proteins are often subjected to functional controls themselves, we sought to examine the 
possibility that PPS undergoes post-translational phosphorylation and if so, where the 
phosphorylation site(s) is (are). Summarized below are the key points of this study which 
shed new light on our current understanding of the Hsp90 chaperone system and require 
further investigations. 
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p50cdc3l and PPS- "nonexclusive rivals on the same team": Functional analyses of the 
client protein HRI clearly demonstrated the difference between the two Hsp90 cohorts, 
pSOcdc37 and PPS, with regards to their regulatory effects on HRI and possibly other 
substrates. pSOcdc37, in concert with Hsp90, facilitates the maturation and activation of 
HRI in response to its natural stimulus, heme-deficiency. In contrast, pharmacological 
evidence suggests that PPS inhibits such a process. While the actions of these two Hsp90 
co-chaperones on HRI are poorly understood mechanistically at this moment, one 
surprising finding was that both pSOcdc3l and PPS can be recovered in the same Hsp90 
heterocomplex, and their coexistence can be further enhanced by the presence of the 
client protein HRI. Although this result is contradictory to the prevailing hypothesis that 
pSOcdc3l and the TPR-containing cohorts of Hsp90 are mutually exclusive with regards to 
their binding to Hsp90 (223), it strongly supports the authenticity of our earlier finding 
that pSOcdc3l and another TPR-containing cohort of Hsp90, FKBPS2, coexist in both the 
basal and client-bound Hsp90 heterocomplexes (97). As discussed in the early sections, 
the apparent discrepancy between our finding and others is likely related to the fact that 
Hsp90 exists and functions as a dimer in which each monomer binds a different cohort 
(Fig. 37). It is possible that within the simple reductionist system of an in vitro 
competition assay, which has been primarily used to build the "mutually exclusive" 
model (as opposed to the quasi-physiological RRL system that we used here), certain 
elements could be missing that are critical for the formation of a "proper" Hsp90 dimer, 
which has the ability to accommodate both pSOcdc37 and a TPR-containing cohort. 
Considering the dynamic and complex nature of Hsp90 structure and function, which are 
controlled by both nucleotides and various binding partners, a better and more complete 
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Figure 37. Proposed chaperone pathway for the maturation/activation of protein kinases 
by Hsp90 machinery. This model was built upon our current knowledge of the 
maturation and activation of some of the Hsp90-dependent protein kinases as well as the 
postulation that protein kinases share a similar Hsp90-mediated folding pathway as the 
steroid hormone receptors (SHRs) (Fig. 1). However, this is very likely to be a simplified 
model, and inaccuracy may exsit due to our incomplete understanding of this pathway. 
Hsp90-dependent protein kinases enter the cyclic pathway by binding to the Hsp70 
system containing its co-chaperone Hsp40/DnaJ. Currently, it is not known whether 
p48/Hip and p60/Hop (see Chapter 1) are involved in the folding pathway of protein 
kinases, thus they are not included here. We call this kinase/Hsp70/Hsp40 
heterocomplex "the early complex" based on the presumed similarity between the folding 
pathways ofHsp90-dependent protein kinases and SHRs. The early complex proceeds to 
the "intermediate complex" as a result of dissociation ofHsp40/DnaJ (which is proposed 
on the basis of the SHR folding pathway) and association of an Hsp90 dimer. Hsp90 and 
Hsp70 in the intermediate complex are subsequently replaced by an Hsp90 dimer, which 
is bound by p50cdc3? at one monomer and an immunophilin or protein phosphatase 5 (PPS) 
at the other. The coexistence of p50cdc37 and a TPR-containing cohort on an Hsp90 dimer 
is suggested by our recent finding that p50cdc37 can be co-adsorbed from the rabbit 
reticulocyte lysate in anti-FKBP52 and anti-PPS immunoprecipitations (97, 215). The 
same Hsp90 dimer also contains p23, whose binding requires the ATP-bound 
conformation of Hsp90 and is inhibited by geldanamycin. The resulting "late complex" 
subsequently dissociates, which is supposedly promoted by ATP hydrolysis ofHsp90. 
The protein kinases either become folded, active and Hsp90-independent, or reenter the 
pathway for further rounds of folding until they reach their folded and active states. 
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understanding of its in vivo function seems to require experimental approaches of more 
than one type. 
The above mentioned data also suggested a model in which the chaperone activity 
of Hsp90 complexes towards HRI and possibly other client proteins, are functionally 
coordinated by opposing actions of the two coexisting cohorts, pSOcdc37 and PPS. This 
model is consistent with the arising notion that multiprotein complexes or so-called 
regulatory modules exist in vivo, which harbor enzymes or proteins with opposing 
regulatory activities towards their cornrnon targets, thereby enhancing their regulatory 
efficiency and/or specificity. Within the Hsp90 heterocomplex, although pSOcdc37 is 
likely to exert its positive effect on HRI directly (as a chaperone), it is not clear what the 
true target(s) of PPS is (are) at this moment. Assuming it is the serine-threonine 
phosphatase activity of PPS that is responsible for down-regulating HRI activity, PPS 
could dephosphorylate the client protein HRI directly, or alternatively dephosphorylate 
Hsp90 and/or its other cohorts and alter their chaperone activities. Future studies should 
be directed towards identifying the true target(s) of PPS in the Hsp90/client 
heterocomplexes. 
Potential functional regulation of PPS by post-translational phosphorylation: Studies 
here successfully identified a post-translational phosphorylation site at Ser-160 in the 
TPR domain of PPS. Ser-160 is within a consensus phosphorylation site for protein 
kinase A (PKA) which is able to phosphorylate this site in vitro. The phosphorylation 
site Ser-160 is located at the inter-domain region between the TPR and phosphatase 
domains of PPS. Despite of the obvious potential of Ser-160 as a phosphorylation-
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controlled conformational switch of PP5, mutating it to either alanine or glutamate failed 
to cause any significant changes in the phosphatase activity of PP5 towards the artificial 
substrate p-nitrophenyl phosphate. Nonetheless, phosphorylation at Ser-160 could still be 
important to PP5, with regards to either its phosphatase activity or other functional 
aspects such as TPR-domain mediated protein-protein interactions with potential 
substrates and/or partners. To unveil the significance of this phosphorylation site of PP5, 
future studies should be directed towards identifying more in vivo clients or partner 
proteins of PP5, towards whom its phosphatase activity or binding affinity may be altered 
by the reversible phosphorylation at Ser-160. Despite of this uncertainty, our result raises 
the possibility that in vivo PP5 function is controlled by post-translational 
phosphorylation, and tentatively adds it to the growing list of phosphorylation-regulated 
cohorts of Hsp90, substantiating the notion that regulatory proteins such as molecular 
chaperones are subjected to functional regulations in vivo as well. 
Hsc70-a possible binding partner of p50cdc37: Data presented here indicate for the first 
time, that an interaction between p50cdc37 and Hsc70 exists. Supporting this observation 
is our finding that p50cdc37, within its N-terminalkinase-binding domain (Dl), shares a 
number of conserved residues with the Bag domain, that are directly involved in the 
binding of Bag-1 to the ATPase domain of Hsc70. The possibility of a direct interaction 
between p50cdc37 and Hsc70, however, does not agree with the current belief that p50cdc3? 
is a component of the late Hsp90/kinase heterocomplex, because Hsp70 is thought to 
enter the Hsp90 chaperone cycle at the early stages. Nonetheless, given the fact that the 
current Hsp90 chaperone cycle is built primarily on studies of the steroid hormone 
170 
receptors, the chaperone cycle of Hsp90 with the kinase and/or other Hsp90 clients could 
be quite different. Alternatively, p50cdc3? may not be a true Hsp90-specific cohort. 
Instead, it may cooperate with other chaperones, such as Hsp70 as well, given the 
complexity and sometimes overlapping pathways of the different molecular chaperone 
machines in vivo. Moreover, considering the existence of a possible Bag domain-like 
binding surface for Hsp70 in p50cdc37, p50cdc3? may potentially regulate Hsp70 with 
regards to its ATP cycle upon binding to its ATPase domain. Thus, p50cdc37 may 
coordinate Hsp70 and Hsp90 functions in a manner that is similar to the proposed 
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